



















   






Phosphoinositide 3-kinases (PI3Ks) are signalling enzymes that play important roles in various cellular processes and in disease, such as cancer and auto-immunity. There are several isoforms of PI3K whose individual roles have been studied extensively, amongst other to understand whether any of the PI3K isoforms may represent a target for selective pharmacological intervention in disease. 
In this study, I aimed to identify the mechanisms that determine the sensitivity of cancer cell growth and proliferation to inhibition of the p110 isoform of PI3K. p110β is activated downstream G-protein coupled receptors (GPCRs), and occurs in complex with a regulatory subunit named p85 which links this PI3K to tyrosine kinase signalling pathways. The parameters that determine cellular sensitivity to p110 are unclear.
To characterize the role of p110β in signal transduction, its recruitment downstream a model receptor tyrosine kinase (PDGFR, platelet-derived growth factor receptor) and its binding to the different p85 isoforms was investigated. p110β was found to be recruited downstream active PDGFR alongside p110, the other PI3K isoform that acts as the main PI3K isoform downstream such receptor. I also document that there is no preferential association of p110β with p85α or p85β, the two main p85 isoforms. 
In a panel of human cancer cell lines, I discovered that cancer cell lines that showed sensitivity to p110β growth and cell signalling inhibition were deficient in expression or function of IRS-1 (insulin receptor substrate-1), although they expressed IRS-1 mRNA, and this molecular trait was further investigated. Using cell transfection and RNA interference (RNAi) techniques I tried to modulate p110β sensitivity in various cellular models. Overexpression of IRS-1 protein in p110β-sensitive cancer cells could not be achieved, likely due to the same inhibitory signalling networks that prevent expression of endogenous IRS-1. Unexpectedly, downregulation of IRS expression by RNAi resulted in a positive effect of p110β inhibition on cell growth and proliferation. Such a growth-stimulating effect of inhibition of p110 was also observed under other conditions. The molecular basis for this effect is not completely clear to date and possible explanations are discussed.
I conclude that p110 has a role as a signalling modulator that, upon specific circumstances, can determine both positive and negative responses in the cellular signalling circuitry and behaviour.
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Each living cell needs to continuously adapt its internal molecular landscape and its behaviour (i.e. growth, proliferation, cell division, differentiation) to the changing conditions of the environment, and through the evolution many different mechanisms have evolved to integrate the signals coming from outside with the intracellular machinery. 
During the evolution of pluricellular organisms, cells have also adapted to co-ordinate their behaviour to achieve the ability to build an organized response at the organismal level to variations of the internal omeostatic equilibrium. The complex network of signalling cascades that have been extensively studied in the last 40 years represents the core mechanism used by the cell to achieve this. 
Two important features characterize most (if not all) the cellular signalling pathways, that is signal modulation and amplification. Traditionally, the prototypical signalling cascade has been described as comprising several different components that activate one another in an ordinate and unidirectional way. The upstream components can activate many downstream substrates before being deactivated, thus generating “waves” of signals that amplify in intensity during their propagation within the cell. The simplified model of a linear signalling pathway has been proven not to fully describe the actual dynamics of signal transduction, as many positive and negative feedback mechanisms exist and have a crucial role in spatially and temporally modulate the activity of each signalling pathway. Furthermore, upon normal physiological conditions each signalling system needs to be terminated after the signal has been generated and transmitted, in order to keep it fully under the control of the cell. Therefore the reversibility of the active status of a signalling pathway back to its basal state is another crucial feature of the biological signalling systems.
Most of the signalling activity in the cell is generated at the plasma membrane level, due to the activation of cell surface receptors by their specific extracellular ligands. Furthermore ion channels and intracellular receptors, such as steroidal hormones receptors, are also known to elicit a signalling response in the cell. 
The two major cell surface receptor groups currently known to trigger many signalling pathways are the receptor tyrosine kinases (RTKs) and the G protein-coupled receptors (GPCRs). The main molecular actors to play downstream these receptors are the members of the Ras-MAPK pathway, the Janus kinases (JAK-STAT), phospholipase C (PLC) and the phosphoinositide 3-kinase (PI3K) enzymes (Shaw & Cantley, 2006). This work is focused on the study of the PI3K signalling pathway, which is therefore described in more detail below. 
The PI3K family comprises several distinct isoforms involved in a range of biological functions (Engelman, et al., 2006; Vanhaesebroeck, et al., 1997b). The PI3K family of lipid kinases has been also studied extensively as potentially one of the major targets in cancer therapy. In the context of cancer, the class IA PI3K isoforms (p110, p110 and p110) have attracted most attention, given that they are acutely stimulated by RTKs, GPCRs and Ras. A role for p110 in cancer has been recognized for a while, although recent publications have highlighted the importance of p110 and p110 in oncogenic signalling. The gene encoding p110 is very commonly amplified or mutated and activated in solid tumours  ADDIN EN.CITE (Engelman, et al., 2006; Zhang, et al., 2007b; Zhang, et al., 2008a). A role for the leukocyte-enriched p110 in haematological malignancies has also been reported  ADDIN EN.CITE (Billottet, et al., 2006; Sujobert, et al., 2005). The class IA PI3Ks occur in complex with a regulatory subunit of which there are 5 species (collectively called ‘p85s’). A detailed description of the main classes of PI3K and the catalytic and regulatory subunits that compose these enzymes family is described in the paragraphs below.

1.1	The PI3K enzymes and their lipid products
The enzymes classified in the PI3K family are known to regulate a wide array of biological functions mainly through the production of lipid second messengers.
These lipid derivatives are produced by phosphorylation on the 3’-OH position of the inositol head group of phosphatidylinositol (PtdIns) and phosphoinositide (PI) lipids, and they are therefore called 3’-phosphoinositides (3’-PI). The 3’-PIs known to be produced in mammalian cells are  PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3, also known as PIP3 (Vanhaesebroeck & Waterfield, 1999) (Figure 1‑1).
Many different cellular proteins can recognize the 3’-PI produced by active PI3K enzymes through the interaction of specific protein domains, leading to their recruitment to different cell membrane compartments and activation. Such domains include the PH (pleckstrin homology) domain, that is known to recognize PIP3 and the FYVE and PX domains that bind to PtdIns(3)P and are involved in vacuolar protein sorting and endosome function  ADDIN EN.CITE (Ellson, et al., 2002; Leevers, et al., 1999; Lemmon & Ferguson, 2000; Lindmo & Stenmark, 2006; Xu, et al., 2001). 


Figure 1‑1. Schematic structures of phosphatidylinositol (PtdIns) and phosphoinositide (PI) lipid products produced by PI3K
a. PtdIns is composed of two hydrophobic tails and an inositol headgroup. The two tails consist of fatty acid chains that reside within the inner leaflet of the membrane bilayer, whereas the hydrophilic headgroup is in contact with the cytosol.    
b. PI3Ks can phosphorylate the 3-position of the inositol ring using ATP producing different PI lipids. 
Figure adapted from Dr. G. Nock’s PhD thesis

To achieve specific and precise spatio-temporal regulation of the signal generated by active PI3K, the cell deploys phospholipide phosphatase enzymes that dephosphorylate different sites of the inositide ring of phosphoinositides.
In mammalians, the most studied phospholipide phosphatases are known as PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10), SHIP2 (SH2 domain-containing inositol 5-phosphatase), both expressed in a wide array of different tissues, and SHIP1, which is the predominant isoform in haematopoietic cells  ADDIN EN.CITE (Muraille, et al., 1999; Stephens, et al., 2005).
PTEN is an important tumour suppressor gene and its activity is frequently lost during cell transformation as a result of point mutation, gene silencing or gene deletion  ADDIN EN.CITE (Cully, et al., 2006; Harris, et al., 2008). PTEN can dephosphorylate the 3’-PI position of PIP3 to PtdIns(4,5)P2. This event counteracts the lipid kinase activity of PI3K. SHIP1 and SHIP2 dephosphorylate the 5’-PI position of PIP3 to convert it in PtdIns(3,4)P2  ADDIN EN.CITE (Freeburn, et al., 2002; Rohrschneider, et al., 2000).  Through this mechanism these three lipid phosphatases act as brakes on the growth stimulating, pro-mitogenic signals generated by active PI3K (Figure 1‑2).
Moreover, the phosphatase activity of SHIP isoforms can activate alternative downstream signalling pathways, that recognize PtdIns(3,4)P2 as the main molecular trigger, through the interaction with a different set of lipid-binding protein domains (Harris, et al., 2008). 






Figure 1‑2. Class I PI3Ks signal downstream of RTK and GPCR
Schematic representation of the role of class I PI3K downstream RTK and GPCR. The lipid kinase activity of PI3K is counterbalanced by the lipid phosphatase PTEN that dephosphorylates PIP3 at the plasma membrane, thus switching off the signal. Other cytoplasmic proteins, most importantly the serine/threonine members of the Akt/PKB family, are recruited and activated at the plasma membrane by the peak of PIP3 production and transduce the signal further downstream the pathway, thus stimulating different physiological responses in the cell such as cells survival, cell growth and proliferation and cell metabolism.

1.2	Classification of PI3Ks
The PI3K family consists of eight distinct catalytic and eight regulatory isoforms, which have been further subdivided into three classes. All the catalytic isoforms present an homology region comprising the catalytic core domain and a helical or PIK (PI kinase homology) domain (Figure 1‑3) (Vanhaesebroeck & Waterfield, 1999). The subdivision of the eight catalytic isoforms into the three classes is mainly based on their domain modular structure, on the in vitro lipid substrate specificity and on their regulation.  

1.2.1	Class I PI3K
All the PI3K included into class I are heterodimers, composed of a regulatory subunit and a catalytic subunit. In vitro, these enzymes show a marked preference for PtdIns(4,5)P2 as lipid substrate, although in vitro they can also phosphorylate PtdIns and PtdIns(4)P. Therefore, the main phosphoinositide product of class I PI3K enzymes is PIP3  (Hawkins, et al., 1992).
Class I is further divided into two subclasses, termed class IA and class IB, on the basis of which regulatory subunit is coupled to the catalytic subunit. Class IA PI3K contains p85/p55/p50 regulatory isoforms whereas class IB contains p101/p84 regulatory isoforms.

Class IA PI3K
 In mammalians, the class IA catalytic subunits are p110, p110 and p110, and they are encoded by three different genes. The class IA regulatory subunits are p85, p55 and p50, encoded by the PIK3R1 gene, p85 encoded by PIK3R2 gene and p55, encoded by PIK3R3 gene (Vanhaesebroeck, et al., 1997a) (Figure 1‑3).
The regulatory subunit interacts with the catalytic subunit through the inter-Src homology 2 (SH2) region that is located between two SH2 domains (Vanhaesebroeck & Waterfield, 1999). In vitro data suggest that all the regulatory subunits are able to bind all the catalytic subunits, and so far no preferential binding between specific regulatory and catalytic isoforms has been found, at least in cell culture-based experiments.
The p110α and p110β isoforms are ubiquitous and widely expressed in the different mammalian tissues, whereas p110 and p110δ are predominantly expressed in leukocytes  ADDIN EN.CITE (Chantry, et al., 1997; Vanhaesebroeck, et al., 1997b).The binding of p85 subunit to other cellular proteins contributes to the localization of PI3K in specific subcellular sites, such as the early endosome compartment through the interaction with Rab5  ADDIN EN.CITE (Chamberlain, et al., 2004). Moreover, p85 plays a regulatory role on Rab5 through its RabGAP activity, therefore promoting its inactivation  ADDIN EN.CITE (Chamberlain, et al., 2004). 




Figure 1‑3. Structural organization of the regulatory and catalytic subunits of the PI3K family
a. Five regulatory subunits are currently known, being encoded by three different genes. p85, p55 and p50 isoforms are encoded by PIK3R1 gene, p85 isoform is encoded by PIK3R2 gene and p55is encoded by PIK3R3 gene. All the class IA PI3K regulatory isoforms present structural similarities in the two SH2 domains and the inter-SH2 domain that mediate the binding with the catalytic subunits. p85α and p85β isoforms also contain a Bcl homology (BH) domain. Two regulatory isoforms are comprised into the class IB, namely p101 and p84. The binding with the class IB catalytic subunit p110 is mediated by the region at the N-terminus of p101, whereas the C-terminal region of p101 is involved in the interaction with GPCRs  ADDIN EN.CITE (Krugmann, et al., 1999; Voigt, et al., 2005). p150 is the only class III regulatory subunit that has been identified to date, presenting a high homology with yeast Vps15p protein kinase. 
 b. The eight PI3K catalytic isoforms are divided into three classes. Structural similarities are apparent among the eight isoforms, and they all present a phosphoinositide kinase (PIK) and a kinase core domain at the C-terminal containing both the ATP and PI binding sites, whereas a Ras binding domain (RBD) is present in all class I and class II catalytic subunits. p110α, p110β and p110δ isoforms are classified into the class IA, and they all couple with a p85 regulatory subunit through an adaptor binding domain. p110γ isoform does not bind the p85 adaptor and is therefore classified as the sole class IB catalytic isoform. The three catalytic subunits that constitute the class II present a C-terminal C2 domain that enables them to bind in vitro phospholipids in a Ca2+-independent manner. 
It has been reported that interaction of p110with the p85 regulatory subunit increases its protein stability but decreases its enzymatic activity (Yu, et al., 1998).
The SH2 domain of the PI3K regulatory subunit binds phosphorylated tyrosine residues in a specific pYxxM motif (pY is phospho-tyrosine, X stands for any amino acid and M is methionine (Songyang, et al., 1993)) on the intracellular portion of active receptor tyrosine kinases, such as the PDGF (pleckstrin-derived growth factor) receptor  or on receptor-associated scaffolding proteins or adaptors, such as IRS (insulin receptor substrate) (Hawkins, et al., 2006). This binding event triggers the relieving of the catalytic inhibition of class IA p110 isoforms and also results in the active PI3K enzyme now being in contact with its inositide substrates at the plasma membrane (Yu, et al., 1998) (Figure 1‑4a). 


Figure 1‑4. Recruitment and triggering of class I PI3K activity downstream RTK and GPCR
 (a) The binding of the extracellular ligand (e.g. IGF-1) to its specific receptor triggers its dimerisation and the stimulation of intrinsic kinase activity, leading to self-phosphorylation of the cytoplasmic portion of the receptor on specific tyrosine residues, some of these residing within the YxxM motif. The class IA PI3Ks are recruited and activated downstream receptor tyrosine kinase via the interaction of the p85 regulatory subunit (through its SH2 domains) with these phosphorylated tyrosine residues. This brings the p110 catalytic subunit close to the plasma membrane where it phosphorylates PtdIns(4,5)P2 to PIP3. 
(b) The stimulation of a GPCR by its specific ligand leads to downstream activation of the heterotrimeric G-protein. The GDP bound to the  subunit is exchanged with GTP leading to the release from both the membrane receptor and the  subunit. The free Gβγ subunit interacts with the p101/p84 regulatory subunits, thus bringing the catalytic subunits p110 to the plasma membrane and triggering its enzymatic activity. 
Class IA regulatory subunits
Five different class I PI3K regulatory subunits have been identified in mammals (Figure 1‑3a). p55 and p50 are generated by alternative initiation of transcription of the PIK3R1 gene  ADDIN EN.CITE (Abell, et al., 2005).
The regulatory subunits are involved in many types of protein-protein interactions. The core structure of all the regulatory subunit isoforms consists in a proline-rich region, which is known to interact with SH3 domains, followed by two SH2 domains separated by an inter-SH2 (iSH2) domain region. As already stated, the SH2 domains can interact with phosphotyrosine (pTyr) residues enclosed in the sequence context pYxxM. The iSH2 region interacts with the p110 moiety of the class IA PI3K holoenzyme dimer.
The N-terminal region presents substantial differences between the various isoforms, while the C-terminal region is more conserved. The N-terminal region of p85 and p85 presents an additional SH3 domain followed by a proline-rich domain and a BH domain, whereas the N-terminal region of the other class IA regulatory subunit isoforms (p55, p50 and p55) is shorter and does not have any homology with other known protein domains.
PIK3R1 
This gene encodes for p85, p55 and p50. These isoforms are expressed ubiquitously and apparently bind to p110, p110 and p110 with equal affinity. Nonetheless, it has been proposed that the regulatory subunits may differ in their ability to regulate the catalytic activity of the p110 subunit. As an example, it has been reported that the lipid kinase activity of p110 upon insulin stimulation is higher when it is coupled with p50 than when the regulatory subunit in the dimer is p55 or p85  ADDIN EN.CITE (Inukai, et al., 1997). 
To further understand the role of each regulatory subunit isoform, several KO murine models have been obtained. The phenotype observed in the PIK3R1 KO mice, though, is difficult to interprete because the abrogation of p85 alters the level of expression of the other non-targeted class IA PI3K subunits. Moreover, the deletion of one specific regulatory subunit might result in an increase of the recruitment of the other isoforms (even if their expression is unchanged) to active cell surface receptors, thus resulting in quantitative and qualitative alterations of the signalling activity of the cell.
The deletion of the last five coding exons of PIK3R1 gene results in the abrogation of all the three regulatory subunits encoded by this gene, namely p50, p55 and p85(i.e. full-PIK3R1 KO), and leads to the generation of KO mice that present elevated post-natal mortality. These mice show necrosis of the liver and of the brown fat tissue, plus they are hypoglycaemic with reduced secretion of insulin and increased glucose tolerance due to upregulated PI3K activity  ADDIN EN.CITE (Fruman, et al., 2000). Besides, PIP3 production and Akt/PKB phosphorylation in full-PIK3R1 MEFs is increased. Similar observations result from the analysis of full-PIK3R1 KO heterozygous mice, and in MEF cells obtained from these mice the response to IGF-1 stimulation is more sustained than in controls  ADDIN EN.CITE (Mauvais-Jarvis, et al., 2002; Ueki, et al., 2002a). These findings are surprising because PI3K has always been described as a positive regulator of insulin response in vitro. Moreover, in full-PIK3R1 KO mice p85 is upregulated while p110 and p110 are downregulated, and the production and maturation of mature B cells is impaired. KO mast-cells show a defective response to SCF, but no defect in signalling activity triggered by IgE, while T cells appear fully functional  ADDIN EN.CITE (Fruman, et al., 1999a; Fruman, et al., 1999b; Suzuki, et al., 1999). 
It is known that the activation of PI3K pathway downstream insulin and IGF-1 receptor ultimately leads to negative feedback regulation via increased IRS-1 phosphorylation and downregulation  ADDIN EN.CITE (Ozes, et al., 2001). Indeed, treatment of insulin-responsive mammalian cells with proteasome-inhibitors (e.g. lactacystin, MG-132), PI3K inhibitors or mTOR inhibitor rapamycin results in the blockade of insulin-dependent IRS-1 degradation  ADDIN EN.CITE (Haruta, et al., 2000), and deletion of p70S6K1 in mouse increases insulin sensitivity  ADDIN EN.CITE (Um, et al., 2004). One way to explain the unexpected insulin hypersensitivity in the full-PIK3R1 KO mice would be to hypothesize that the deletion of class IA regulatory subunits improves insulin signalling by preventing insulin-responsive tissues from reaching the threshold of PI3K activity that triggers the negative feedback loop. Mice with heterozygous loss of both p110 and p110 catalytic subunits, though, present glucose intolerance and hyperinsulinaemia upon fasting  ADDIN EN.CITE (Brachmann, et al., 2005), thus arguing against the idea that reduced PI3K activity increases the stability of IRS-1 and therefore improves the overall signalling activity. This finding led to propose that p85 subunits can have a negative role in insulin signalling mechanisms when they are not coupled to p110 catalytic subunits, and that the ratio of p85 to p110 subunits plays a critical role in regulating in vivo insulin response. This model implies the existence of a free pool of uncoupled p85 subunits (that has a faster turnover rate because it is not protected from degradation by binding to p110) in the cell, and that these proteins bind to active insulin and IGF-1 receptors without triggering any PI3K response (because they are not coupled to any catalytic subunit), thus reducing the amount of phosphotyrosine binding sites on the active receptor available for the fully functional PI3K p110-p85 dimer. The ratio between free (uncoupled) and p110-coupled p85 subunits would thus set the normal state of insulin sensitivity in a given cell type or tissue. In p85 KO tissues the free p85 pool would be preferentially lost given the lower stability of uncoupled p85 subunits, thus resulting in a net increase of signalling output mediated by the catalytically active p85-p110 dimers  ADDIN EN.CITE (Brachmann, et al., 2005) (Figure 1‑5). 


Figure 1‑5. Model of the regulation of insulin sensitivity by the ratio between unbound and p110-bound p85 subunits
This figure is taken from  ADDIN EN.CITE (Brachmann, et al., 2005) and depicts the proposed model suggesting that in the cell p85 regulatory subunits are normally present in excess of the p110 catalytic subunits, and that a pool of less stable, free p85 subunits exists and is responsible for the regulation of insulin sensitivity. This model proposes that the uncoupled p85 subunits are able to interact with active insulin and IGF-1 receptors thereby reducing the amount of fully functional p85-p110 PI3K dimers that are recruited to and activated by these receptors. In p85 KO cells the pool of uncoupled p85 subunits would be preferentially reduced, leading to increased recruitment of catalytically active p85-p110 dimers and therefore insulin hypersensitivity and increased response to cell stimulation.  Upon reduction of p110 subunits or overexpression of p85 subunits the outcome would be a decrease in insulin sensitivity resulting in insulin resistance.

This model, though, is in contrast with the data obtained by quantitative mass spectrometry analysis that do not support the existence of uncoupled p85 or p110 subunits, suggesting a 1:1 ratio between the p85 and p110 subunits in murine cell lines and primary tissues  ADDIN EN.CITE (Cutillas, et al., 2006; Geering, et al., 2007a). To explain the phenotype of PIK3R1 KO mice while taking into account these findings the following model has been proposed. It is known that p85 can interact with lipid phosphatases such as SHIP or PTEN  ADDIN EN.CITE (Bouscary, et al., 2003; Chagpar, et al.; Kotelevets, et al., 2005; Zhang & Broxmeyer, 1999), therefore loss of p85 expression may lead to reduced recruitment of phosphatases to receptor complexes (Geering, et al., 2007b). In agreement, mice with a liver-specific deletion of the PIK3R1 gene exhibit improved hepatic and peripheral insulin sensitivity despite having a reduced total PI3K activity, due to decreased lipid phosphatase activity (but not protein expression ) of PTEN (Taniguchi, et al., 2006). This mechanism is likely to function as an internal negative feedback in insulin (and, more generally, growth factor) signal transduction, aimed to keep under control this critical node of the cellular signalling network. 
Moreover, it is possible that upon reduced expression of p85 subunits the recruitment to IRS of certain proteins is increased. An example is JAK tyrosine kinase that has been shown to inactivate SHIP through phosphorylation (Habib, et al., 1998). The increased recruitment of JAK to IRS protein would thus result in the downregulation of SHIP lipid phosphatase activity and a net increase of PI3K signalling output (Figure 1‑6).  
The deletion of the first exon only of PIK3R1 gene leads to the generation of p85 KO mice, and as already mentioned in these mice p55 and p50 isoforms were found to be upregulated. The p85-only KO mice present a phenotype similar to that of full-PIK3R1 KO mice, but they are viable  ADDIN EN.CITE (Suzuki, et al., 1999; Terauchi, et al., 1999). 





Figure 1‑6. Hypothetical model explaining the increased signalling in p85 KO cells
In WT cells the tyrosine phosphorylation of IRS docking proteins downstream active insulin receptor leads to the recruitment and the activation of PI3K that produce PIP3 at the level of the plasma membrane. Phosphorylated IRS also recruits other proteins such as the lipid phosphatase SHIP that degrades PIP3, thus switching off the signal triggered by PI3K activation. 
In p85 KO cells less PI3K molecules are expected to be recruited by phosphorylated IRS, thus leaving more docking sites on IRS available for the binding of other proteins such as JAK. This protein can phosphorylate and inactivate SHIP, thus leading to a net increase in PIP3 levels.
This figure is taken from (Geering, et al., 2007b).

PIK3R2 
The product of this gene, the regulatory subunit p85, is expressed ubiquitously although in insulin-responsive tissues it seems to be present in lower quantities than p85
PIK3R2 KO mice present unvaried expression of the class IA PI3K isoforms, although they present hypoinsulinaemia, hypoglycaemia and enhanced insulin sensitivity  ADDIN EN.CITE (Ueki, et al., 2002b). The development of lymphocyte cells is unvaried in these mice, as well as the ex vivo propagation of B cells. 

PIK3R3
p55, that is encoded by this gene, is found in all tissues in adult mouse and it is early expressed during the embryonic stage  ADDIN EN.CITE (Inukai, et al., 1996). p55 was identified as a protein interacting with tyrosine-phosphorylated IRS-1 in an expression library screening analysis. Indeed, p55 interacts with phospho-IRS-1 through its N-terminal SH2 domain that is capable of binding to pYxxM motifs  ADDIN EN.CITE (Pons, et al., 1995). 
p55 has been found to play an important role in the transduction of proliferative signals arising from IGF-1R in a subset of highly proliferative human glioblastomas that lack EGFR amplification   ADDIN EN.CITE (Soroceanu, et al., 2007). No p55 KO mouse models have been published to date.   

Class IA catalytic subunits
p110 
p110 has been considered for long the most relevant class IA signalling isoform, due to its ubiquitous expression and its frequent mutation in cancer. 
In human, two alternative mRNA transcripts are known to be generated through alternative splicing of two 5’ untranslated exons placed just before the first coding exon. These two non-coding exons are found ~50 kb upstream of the translation start ATG codon  ADDIN EN.CITE (Astanehe, et al., 2008). The promoter of PIK3CA gene comprises binding sites of different transcription factors and regulators of gene expression, such as FOXO3a and NF-kB, both positively controlling p110 expression, and p53 that is known to inhibit p110 expression  ADDIN EN.CITE (Astanehe, et al., 2008; Hui, et al., 2008; Kok, et al., 2009) (Figure 1‑7).
Interestingly, FOXO3a activity is known to be negatively regulated by cytoplasmic sequestration when phosphorylated by active Akt/PKB downstream PI3K; in other words, p110 can inhibit its own gene expression through this negative feedback pathway  ADDIN EN.CITE (Hui, et al., 2008). 





Figure 1‑7. Scheme of the 5' UTR of the human PIK3CA gene
The figure schematically shows the structure of the 5’ UTR region of the human PIK3CA gene, with the two untranslated exons -1b and -1a placed upstream the first coding gene (in blue) that contains the first translated ATG codon. The arrows indicate the sites of binding of FOXO3a, NF-kB and p53 transcriptional factors. The positions of the transcription factors binding sites are expressed relative to the first nucleotide of exon -1b.
Figure adapted from (Kok, et al., 2009).

Similar early-stage lethality was observed in mice homozygous for a kinase-dead allele of p110, but heterozygous mice were viable and displayed growth retardation and insulin resistance  ADDIN EN.CITE (Foukas, et al., 2006). Further studies on mice models have also established for p110 a role in the embryonic development of blood vessels (angiogenesis), as both p110 KO and KI mice (or endothelial cells subjected to RNAi-induced depletion of p110) present early embryonic lethality and defective signalling downstream RTK that are crucial for angiogenesis initiation and progression such as VEGFR  ADDIN EN.CITE (Graupera, et al., 2008; Lelievre, et al., 2005).
p110 and cancer
PIK3CA gene is commonly amplified in many cancer types, thus leading to p110 overexpression  ADDIN EN.CITE (Perez-Tenorio, et al., 2007; Samuels, et al., 2004; Wu, et al., 2005). 
Somatic missense mutations have been found at relatively high frequency in PIK3CA, the gene encoding for p110, in tumours of the lung, ovary, liver, colon, stomach, brain and breast  ADDIN EN.CITE (Samuels, et al., 2004; Thomas, et al., 2007). These mutations are clustered around three hotspots in the kinase (H1047R) and helical (E542K, E545K) domain (Jia, et al., 2009). The mechanisms whereby these mutations cause the activation of p110 have recently begun to be elucidated through crystallography-based studies, suggesting that the helical domain mutations disrupt an inhibitory interaction with the p85 regulatory subunit and that, in general, these point mutations interfere with the inhibitory interactions occurring between different domains of p110 and between p110 and the regulatory subunits that compose the functional dimeric enzyme  ADDIN EN.CITE (Miled, et al., 2007). Studies of overexpression of these point mutations in mammalian and chicken cells have confirmed that they are oncogenic  ADDIN EN.CITE (Isakoff, et al., 2005; Zhao, et al., 2005) and that they promote the activation of p110 through different molecular mechanisms, as the helical domain mutations make p110 independent of binding to p85 but require the interaction with RAS-GTP, whereas the catalytic domain mutations result in the independence from RAS-GTP signalling but high dependence on the interaction with p85 for full activation (Zhao & Vogt, 2008). The H1047R kinase domain mutation has been found to increase IRS-1 phosphorylation, whereas the two most common helical domain mutations (E542K, E545K) do not cause such effect, suggesting again that these mutations represent different mechanisms of lipid kinase activation and therefore transforming activity in cancer cells  ADDIN EN.CITE (Carson, et al., 2008). Many of the PIK3CA mutants reported in the literature have been found to promote growth factor-independent colony formation and invasive growth in three-dimensional models of cell proliferation, and these effects can be contrasted by treatment with PI3K inhibitors, thus suggesting that a pharmacological approach to the treatment of p110-driven cancer is feasible (Zhang, et al., 2007b). 
  
p110
Traditionally, p110 was thought to be mainly localized in the cytoplasmic compartment, where it exerts its lipid-kinase enzymatic function at the level of the plasma membrane. Further investigation suggested that the PI3K enzymes and p110 in particular, could also reside and be active in other cellular compartments such as the perinuclear region in mouse neurons  ADDIN EN.CITE (Bartlett, et al., 1999). Furthermore, recent evidence indicates that p110 can be also found into the nucleus, where it activates the nuclear Akt/PKB pool and dynamically regulates DNA replication and cell cycle progression  ADDIN EN.CITE (Marques, et al., 2008; Marques, et al., 2009). More generally, the subcellular localization as well as main site of action of class I PI3K isoforms in in vitro cellular models has yet to be accurately described. p110 (and, to a lesser extent, p110) has been found to promote the pluripotency maintenance and self-renewal of mouse embryonic stem cells (mESC), whereas p110 is involved in the transduction of signals that induce cell growth and proliferation (such as insulin) and, ultimately, ESC differentiation (Kingham & Welham, 2009). 
The physiological role of p110 has been studied both using in vitro cell-based models and in vivo genetically engineered mouse strains. The first attempt of in vivo analysis of p110 role was performed through the generation of p110 KO mice but this approach did not lead to conclusive results due to the very early embryonic lethality that even prevented the generation of viable fibroblast cells. Further attempts were made by refining the genetic technique through the generation of p110 KI mice or p110 conditional KO  (i.e. the expression of p110 is ablated only in certain tissues/organs or in a time-regulated way after the completion of embryonic development). Indeed, homozygous knock-in of PIK3CB led to a decrease of 50% of viable adult mice compared to expected Mendelian ratios and these mice showed growth retardation and developed mild insulin resistance, while the insulin-evoked Akt/PKB signalling in liver showed unchanged magnitude compared to control but declined faster in p110 KI or in control animals treated with p110-selective inhibitor  ADDIN EN.CITE (Ciraolo, et al., 2008; Jia, et al., 2008). Thus, these findings are in line with the hypothesis that p110 plays a minor role in insulin signalling  ADDIN EN.CITE (Foukas, et al., 2006; Knight, et al., 2006). Interestingly, male p110 KO mice are sterile due to testicular hypotrophy and impaired spermatogenesis that leads to oligoazoospermia (i.e. lack of production of mature and functional sperm cells)  ADDIN EN.CITE (Ciraolo, et al.). This defect is caused by defective proliferation and survival of pre- and post-meiotic cells, and it has been suggested that this phenotype depends on the role of p110 downstream the tyrosine kinase receptor c-Kit, that is known to promote the production of functional sperm cells by triggering PI3K activity  ADDIN EN.CITE (Blume-Jensen, et al., 2000; Ciraolo, et al.; Kissel, et al., 2000). 
p110has been also found to play a role in platelet physiology and in thrombosis, thus opening a new field for therapeutic intervention through the use of isoform-specific inhibitors  ADDIN EN.CITE (Jackson, et al., 2005). In particular, p110 is involved in the molecular mechanisms that regulate the formation and the stability of the integrin-mediated intercellular bonds that occur between platelets following shear stress activation  ADDIN EN.CITE (Schoenwaelder, et al.). As a result, in vivo isoform-specific targeting of p110 through the use of small-molecule inhibitors eliminates occlusive thrombus formation, without prolonging bleeding time. In conclusion, these findings suggest that p110 is an important new potential target for antithrombotic therapy (Jackson & Schoenwaelder, 2006).

Classification of p110




Figure 1‑8. p110 is a class IA PI3K catalytic isoform but it is active mainly downstream GPCR
p110 was originally included in the class IA PI3Ks because of its binding with the p85 regulatory subunits and because of its structural homologies with the other class IA catalytic subunits, p110 and p110. However, recent evidence suggests that p110 exerts its role in cell signalling mainly downstream active GPCR, being activated by the interaction with G subunits. The presence of the p85 regulatory subunits, though, suggests that p110 can also be activated by the interaction with Tyr-phosphorylated residues on receptor tyrosine kinase (RTK), similar to p110 and p110 isoforms, thus not excluding a role in signal transduction downstream this class of cell membrane receptors.

These findings are supported by the fact that in a series of in vitro observations p110β, but not the other two class IA p110α or p110δ, was found to be activated by Gβγ subunits  ADDIN EN.CITE (Kurosu, et al., 1997; Maier, et al., 1999). Moreover it has been reported that dominant-negative p110β, but not p110γ, inhibits MAPK activation following stimulation with the GPCR ligand lysophosphatidic acid (LPA), a lipid derivative that acts as a potent mitogen and is found in the serum  ADDIN EN.CITE (Yart, et al., 2002). 
Nonetheless, evidence has been published that p110 can be recruited to, and phosphorylated by, active receptor tyrosine kinases such as PDGFR in NIH 3T3 immortalized fibroblasts, although microinjection of inactivating anti-p110 antibodies in these cells did not substantially reduce PDGF-induced cell proliferation or reorganization of intracellular actin filaments, but had an impact on insulin-induced mitogenic response and cytoskeleton remodeling  ADDIN EN.CITE (Hooshmand-Rad, et al., 2000; Roche, et al., 1998). 
Published data suggest that p110 can be synergistically activated by G subunit and phosphotyrosyl peptide synthesized according to the amino acid sequence of IRS-1  ADDIN EN.CITE (Kurosu, et al., 1997; Okada, et al., 1996). Despite the fact that p110 is thought to be the main class I PI3K isoform to be activated by insulin, being selectively recruited to IRS proteins downstream of the insulin receptor where it is activated  ADDIN EN.CITE (Foukas, et al., 2006; Knight, et al., 2006), it has been proposed that in the context of insulin signalling, p110β could play a role in maintaining a pool of PIP3 that is not required for Akt phosphorylation but which defines a threshold for the amount of p110α activity necessary to activate the pathway  ADDIN EN.CITE (Knight, et al., 2006). How this mechanism would exactly work is unclear. Moreover, p110 plays a role in insulin signalling in some in vitro cellular models, such as J774.2 macrophage cells  ADDIN EN.CITE (Chaussade, et al., 2007). MEF cells in which p110 is not expressed or is catalytically inactive are able to respond to growth factors that function through RTK, including insulin, further suggesting that p110 activity is dispensable for the response to RTK stimuli  ADDIN EN.CITE (Guillermet-Guibert, et al., 2008; Jia, et al., 2008). Finally, it is possible that the still unclear role of p110 downstream RTK can be explained by the relatively weak lipid kinase activity of p110 compared to p110 ADDIN EN.CITE (Beeton, et al., 2000). Signals deriving from abundant receptors such as PDGFR could be sufficiently intense to trigger the activation of Akt/PKB through p110 recruitment, even in the absence of p110  ADDIN EN.CITE (Zhao, et al., 2006).
p110 and cancer
The role of p110 in cancer has begun to be elucidated in the recent years, both through the study of mouse models or tumor samples derived from human patients and with large-scale in vitro experiments, aimed to identify a correlation between specific genetic traits and the response to the selective inhibition of PI3K isoforms.
So far no cancer–specific mutations in p110 have been identified in human cancer; however overexpression of wild-type p110 (or p110) is sufficient to induce transformation of chicken embryo fibroblasts, suggesting that p110 has an intrinsic oncogenic potential  ADDIN EN.CITE (Kang, et al., 2006). In accordance with this interpretation, p110 has been found to be overexpressed in about 15% of human invasive breast carcinomas, and its membrane expression has been associated with worse prognosis due to its link to HER2 overexpression, lower age of onset, higher aggressive grade, lymph node involvement and the presence of distant metastasis, and negatively associated with ER (estrogen receptor) status (Carvalho, et al.). Moreover, transformation and signalling by p110 is sensitive to loss of interaction with Ras, which acts as a membrane anchor  ADDIN EN.CITE (Denley, et al., 2008). Furthermore, the introduction of a myristoylated version of p110 (i.e. it is constitutively anchored to the plasma membrane) in non-transformed human mammary epithelial cells (HMEC) is sufficient to trigger high levels of Akt/PKB activation and to induce a tumorigenic and invasive behavior in these cells when implanted in nude mice  ADDIN EN.CITE (Zhao, et al., 2005).
Further evidence for a role of p110 in cancer comes from the study of mice homozygous for the K805R kinase-inactive mutation of PIK3CB gene that show partial protection from tumorigenesis in an ERBB2-induced model of breast cancer, plus they can survive to adulthood provided the expression of the catalytically inactive p110 is high  ADDIN EN.CITE (Ciraolo, et al., 2008). This observation, together with others, suggests that p110 could have non-enzymatic, dosage-dependent functions in development and growth. Moreover, in a prostate cancer model driven by loss of PTEN, ablation of p110 prevents tumor formation, whereas loss of p110 has no effect on tumorigenesis, and  in cell culture studies ablation of p110 prevents oncogenic transformation by activated RAS and other oncoproteins  ADDIN EN.CITE (Jia, et al., 2008). Interestingly, the transforming activity of RAS in these cells was fully restored upon re-expression of wild-type p110 but partially restored with the K805R kinase inactive form of p110again suggesting that both the kinase-dependent and kinase-independent functions of p110 could have a role in oncogene-induced transformation  ADDIN EN.CITE (Jia, et al., 2008). The central role of p110 in prostate cancer has been further confirmed by studies showing that targeted knockdown of p110, rather than p110 in human prostate cancer cell lines results in significantly reduced downstream signalling activation and increased cell cycle arrest and cell apoptosis (Hill, et al.). Moreover, p110 has been found to be responsible for androgen receptor (AR) transactivation and proper interaction with AR-responsive gene promoters in prostate cells and to be overexpressed in aggressive human prostate cancer, in correlation with poor prognostic factors  ADDIN EN.CITE (Zhu, et al., 2008).  
Further evidence has been published that loss-of-activity of the lipid phosphatase PTEN in human cancer cell lines leads to increased sensitivity to PI3K inhibition  ADDIN EN.CITE (DeGraffenried, et al., 2004) and in particular to dominance of p110 in cell signalling and regulation of growth, therefore conferring sensitivity to p110-selective, small-molecule inhibitors  ADDIN EN.CITE (Edgar, et al.; Torbett, et al., 2008; Wee, et al., 2008). It is important to note, though, that the correlation between the inactivation of PTEN and the increased sensitivity to p110 inhibition has been appreciated in large-scale screening of many different cancer cell lines, although it may not always occur at the level of the single cancer cell line. It is therefore likely that other factors contribute to the selective dependency on p110in the context of cancer.   









Figure 1‑9. Summary of the biological and pathological roles of p110
This scheme summarizes the information obtained to date on the role of p110 in physiology and cancer biology. Most of this information has been obtained through the study of genetically engineered murine models. Highlighted is the concept that p110 is mainly active downstream GPCR. 

p110
This isoform is highly expressed in leukocytes  ADDIN EN.CITE (Chantry, et al., 1997; Geering, et al., 2007a), can be also found in neurons  ADDIN EN.CITE (Eickholt, et al., 2007) but is expressed at low levels in most other cell types (Vanhaesebroeck, et al., 1997a). It has been proposed that p110 plays a role in the regulation of leukocyte transmigration through the endothelium in response to inflammatory signals, but it remains to be clarified whether the main site of activation of p110 is the endothelium itself, the leukocytes or both  ADDIN EN.CITE (Geng, et al., 2004). Interestingly, a selective role for p110 in the regulation of PTEN activity has been documented by our research group  ADDIN EN.CITE (Papakonstanti, et al., 2007; Papakonstanti, et al., 2008). Indeed, it has been proposed that p110 acts as a controller of PTEN activity, thus self-regulating its own signalling output and that of the other class I PI3K isoforms, possibly resulting in a mechanism of indirect cross-regulation between the PI3K isoforms (Figure 1‑10). 
Interestingly, the control of PI3K over PTEN activation in macrophages (both primary and immortalized) is performed by p110, as the increase of PTEN lipid phosphatase activity in macrophages was observed only upon selective p110 inhibition  ADDIN EN.CITE (Papakonstanti, et al., 2008). This finding supports the hypothesis that in leukocytic cells p110 plays a central role in PI3K signalling. Nonetheless, it does not exclude that in other cellular contexts (e.g. non-leukocytic cells) other p110 isoforms could play a regulatory role over PTEN activity.
Regarding the role of p110 in malignancies, its expression does not seem to change between untransformed and transformed leukocytes, and in acute myeloid leukemia (AML) cells p110 is the only isoform that is clearly detected, whereas the expression of the other class I isoforms is less consistent and can vary considerably  ADDIN EN.CITE (Billottet, et al., 2006; Sujobert, et al., 2005). Nonetheless, p110 is found to be expressed in some non-leukocyte cancers such as breast and colon carcinoma and melanoma, where it plays a role in the regulation of both the directionality and the speed of migration (Sawyer, et al., 2003).
The in vivo study of p110 has been carried out through the generation of genetically engineered KO mouse strains that lack the expression of PIK3CD gene (Clayton, et al., 2002; Jou, et al., 2002). These mice are viable but display a reduced production of mature lymphocyte B cells and smaller spleens and lymph nodes. Intracellular signalling downstream the B cell antigen receptor (BCR) was found to be reduced, and the proliferation of p110 KO B cells was also affected when cultured ex vivo. The abundance of the lymphocyte T cells in the p110 KO mice was found to be identical to control animals, thus indicating a B cell-specific role for p110. p110 KI mouse strains were also obtained, and their phenotype appeared more pronounced (Okkenhaug, et al., 2002). The signalling activity downstream BCR and the ex vivo proliferation capacity of the B cells derived from the p110 KI mice were greatly reduced. Similar results were obtained in a study where p110 was pharmacologically inhibited by treating WT mice with an isoform-selective inhibitor of p110 (Bilancio, et al., 2006). Moreover, p110δ KI mice showed a decreased number of T cells in the spleen and mast cell function was impaired, due to reduced signalling activity downstream IL3 and SCF receptor with consequent decreased DNA synthesis and degranulation capacity  ADDIN EN.CITE (Ali, et al., 2004). 


Figure 1‑10. Proposed model of the negative regulation of PTEN activity by active p110δ in macrophages
This scheme depicts the proposed model for the regulation of PTEN activity in macrophages by p110 through the regulation of RhoA small GTPase activity  ADDIN EN.CITE (Papakonstanti, et al., 2007). Upon activation by RTK stimuli (e.g. CSF-1R), p110 activity is triggered and leads to a surge in PIP3 production and the activation of several downstream signalling pathways, including Akt/PKB. This results in the positive modulation of a RhoA GAP, named p190, and in the inhibition of p27, a protein known to be a negative regulator of RhoA (p27 can bind to RhoA and block its activation by various RhoA guanoside exchange factors or GEF). Therefore, upon p110 inhibition the activation of RhoA by its GEFs is not prevented by p27 binding to RhoA. The impact of p190RhoA-GAP stimulation is weaker than the one generated by p27 inhibition, therefore the net output of p110 activation is the upregulation of RhoA (straight line versus dotted line) and, consequently, PTEN activity.
On the other hand, the inhibition of p110 results in increased PTEN activity due to the reduced signalling input of tyrosine kinase enzymes such as PYK2 and Src, thus leading to reduced p190 RhoA-GAP activity. 
Active RhoA can stimulate ROCK protein kinase activity, leading to PTEN upregulation. This mechanism therefore provides an effective negative feedback loop-based, self-regulatory system allowing the cell to keep p110-dependent signalling activity under control. Moreover, cross-regulation between the different class I PI3K isoforms is made possible since active PTEN can degrade the PIP3 produced by any p110 isoform. 
This figure has been taken from Papakonstanti et al., 2007.

Class IB PI3K
p110 binds the p101 and p84 regulatory subunits  ADDIN EN.CITE (Stephens, et al., 1997; Suire, et al., 2005). p110γ/p101/p84 heterodimers are activated by the Gβγ subunits of heterotrimeric GPCRs (Figure 1‑4b) and p110γ, like p110δ, is mainly expressed in leucocytes and is involved in both innate and adaptive immunity  ADDIN EN.CITE (Hirsch, et al., 2006; Laffargue, et al., 2002; Lemmon & Ferguson, 2000; Rommel, et al., 2007; Sasaki, et al., 2000). p110 is also expressed in other cell types such as cardiomyocytes  ADDIN EN.CITE (Alloatti, et al., 2005; Patrucco, et al., 2004), endothelial cells  ADDIN EN.CITE (Puri, et al., 2005) and smooth muscle cells  ADDIN EN.CITE (Vecchione, et al., 2005). Amplification of the PIK3CG gene has been reported in ovarian carcinoma  ADDIN EN.CITE (Zhang, et al., 2007c). 
The analysis of p110KO and KI mice, which are viable and fertile, has revealed that this isoform plays a role in the myeloid cells of the immune system, and that it is required for the migration of these cells towards inflammed tissues (Hirsch, et al., 2000; Li, et al., 2000; Patrucco, et al., 2004; Sasaki, et al., 2000). Moreover, p110 is involved in cytoskeleton reorganization following pro-inflammatory stimuli, ultimately leading to the chemotactic migration of the leukocytes  ADDIN EN.CITE (Barberis, et al., 2009). 
It is interesting to note that in some cases the phenotypes expressed by p110 KO and KI mice were different. In particular, while p110 KO mice showed alterations in cardiac contractility in response to chronic blood pressure increase (caused by experimental transverse aortic constriction), p110 KI did not present such phenotype  ADDIN EN.CITE (Crackower, et al., 2002; Patrucco, et al., 2004). To explain these differences it has been proposed that in cardiomyocytes p110 exerts its role in cell signalling through both scaffolding (i.e. via protein-protein interactions) and non-scaffolding (i.e. via its lipid-kinase activity) functions. Indeed, p110 can bind and control the cytoplasmic enzyme PDE3B through protein-protein interactions. Since PDE3B degrades cAMP, leading to decreased PKA activity and therefore decreased heart contractility, the deregulation of PDE3B due to the lack of p110 in cardiomyocytes could induce the opposite reaction, thus explaining the cardiac phenotype observed in p110 KO mice. In conclusion, these studies have highlighted how differences in PI3K targeting approaches (i.e. gene KO versus KI strategy) can have different signalling and functional outcomes, with implications for the interpretation of the phenotypes in light of potential clinical application of isoform-specific inhibitors (Vanhaesebroeck, et al., 2005).

1.2.2	Class II PI3K
Class II PI3Ks are larger than class I PI3Ks (170 – 210 kDa). Three catalytic subunits are included in class II PI3K, namely PI3K-C2α, PI3K-C2β and PI3K-C2γ, which occur in cells without regulatory or adaptor proteins. The three class II PI3K catalytic subunits present a 45-50% sequence homology with class I PI3K at the level of the lipid kinase domain and also contain a PIK domain, a kinase core domain and a Ras binding domain. Their main divergence is in the C-terminal portion, where they present an additional C2 domain that enables the three members of class II to bind phospholipids in vitro in the absence of Ca2+ ions. 
The activation of class II PI3Ks can be triggered by many different stimuli such as insulin, EGF, PDGF, interaction of integrins with extracellular matrix, chemokines, clathrin clustering and LPA  ADDIN EN.CITE (Domin, et al., 2005; Gaidarov, et al., 2001; Maffucci, et al., 2005; Vanhaesebroeck & Waterfield, 1999). Compared to the amount of information available on class I PI3K members, much less is known on the specific role of the class II PI3Ks and on their specific mechanisms of activation. This is partly due to the lack of small molecule, isoform-selective inhibitors and of genetically engineered mouse models. To date, progresses have been made by deploying the RNAi approach to artificially manipulate class II PI3K isoform expression, unveiling the role of specific isoforms in biological events such as cell survival and smooth muscle cell contraction  ADDIN EN.CITE (Elis, et al., 2008; Wang, et al., 2006).
The main in vitro substrate of the class II PI3Ks is PtdIns which is converted to PtdIns(3)P, although these enzymes can also phosphorylate PtdIns(4)P and PtdIns(4,5)P2. PtdIns(3)P is now considered as an important inositol phospholipid messenger having relevant functions in cell signalling in parallel with PIP3  ADDIN EN.CITE (Falasca & Maffucci, 2006). 
Class II PI3Ks are bound to different membrane components of the cell, such as the plasma membrane, the trans-Golgi network, the endoplasmic reticulum and the clathrin-coated vesicles  ADDIN EN.CITE (Domin, et al., 2000; Vanhaesebroeck & Waterfield, 1999), in contrast with the predominantly cytosolic localization of class I PI3Ks. The expression of PI3KC2γ isoform is mainly limited to the liver in mammalians, in contrast with the other two class II PI3K isoforms, PI3KC2α and PI3KC2β that show a wider expression pattern (Vanhaesebroeck & Waterfield, 1999). 

1.2.3	Class III PI3K
The only class III PI3K expressed in mammals, Vps34, is an ortologue of the vesicular sorting protein 34 (Vps34p) found in Saccharomyces cerevisiae. It can only utilize PtdIns as substrate, thus being able to generate PtdIns(3)P. Vps34 contains a PIK and a kinase core domain like the members of the other two classes of catalytic PI3K isoforms and it is found to be coupled with a Ser/Thr protein kinase regulatory subunit called Vps15p in yeast and p150 in mammals (Vanhaesebroeck & Waterfield, 1999).
Class III PI3K plays a role in the complex mechanisms of regulation of vesicular sorting and endosome turnover processes during endocytosis, and is mainly found associated with intracellular membranes (Foster, et al., 2003).
Furthermore, the enzymatic activity of class III PI3K is important for the regulation of autophagy in yeast (Kihara, et al., 2001) and possibly in mammalian cells, as well as the dynamic rearrangement of intracellular vesicular structures  ADDIN EN.CITE (Futter, et al., 2001), the fusion of the phagosomes with late endosomes/lysosomes  ADDIN EN.CITE (Itakura, et al., 2008; Vieira, et al., 2001) and the bidirectional intracellular trafficking between Golgi apparatus and endosome reticulum  ADDIN EN.CITE (Burda, et al., 2002).
Finally, the role of class III PI3Ks in autophagy is linked with the capacity of cells to sense the availability of nutrients in the surrounding environment and to tune their metabolic activity accordingly. Indeed, it has been shown that Vps34 is active when the cell is exposed to readily available amino acids and glucose and it can feed into mTOR and S6K1 signaling pathways that positively control protein synthesis and cell growth, whereas when nutrients are scarce this signalling activity is strongly reduced and Vps34 contributes to stimulate the autophagic response  ADDIN EN.CITE (Byfield, et al., 2005; Chang, et al., 2009). Overall, these apparently contrasting roles of Vps34 suggest for this PI3K enzyme the existence of distinct pools that are able to interact with different accessory proteins, to form separate functional complexes that are then regulated in opposite ways by nutrients.  

1.3	The Insulin/IGF-1 and the PDGF signalling pathways
The PI3K enzymes are active downstream PDGFR and the IR/IGFR, thereby playing a role in some of the most widely studied cellular pathways that share many signalling components and are implicated in a series of physiological mechanisms of fundamental importance to maintain the homeostatic equilibrium of complex organisms. 
PDGF is a potent extracellular growth factor, produced by a wide array of cell types, which stimulates cell growth and proliferation upon binding to its cognate receptor. PDGFR is a receptor formed by one - and one -chain that dimerize upon binding of PDGF. Three possible combinations of PDGFR subunits can occur, that is –, - and –. The extracellular region of the receptor consists of five immunoglobulin-like domains and contains the ligand-binding region while the intracellular part is a tyrosine kinase domain (Dibb, et al., 2004). Upon dimerization, the PDGFR undergoes a series of allosteric rearrangements that lead to the activation of the kinase domain. As for the IR/IGFR class of RTK receptors, active PDGFR goes through a series of tyrosine transphosphorylation events that fully activate the receptor and allow for the recruitment of a complex array of cytoplasmic molecules. Binding to these sites is mediated by SH-2 and PTB domain-containing proteins, of which the PI3K p85 regulatory subunit is one of the most studied.  
Insulin is the major hormone controlling the glucose and lipid metabolism, and elicits different responses in the target cells by stimulating glucose uptake, gene expression and alterations of cell morphology (Saltiel & Kahn, 2001). It is produced and secreted by the beta cells, which are part of the endocrine portion of the pancreas, in response to the increase in blood glucose level that usually follows the ingestion of food. Mayor organs that are insulin targets include the liver, fat and muscle tissues, although many other cell types in the body are able to sense and respond to insulin.
IGF-1 is part of a complex of growth factors collectively called the “IGF system” (Sachdev & Yee, 2001). The IGF system comprises at least two known IGF isoforms (IGF-1 and IGF-2), their receptors, IGF-binding proteins (IGFBPs) and IGFBP proteases. Both IGF isoforms are known to have a role in endocrine, paracrine and autocrine cell-to-cell communication mechanisms and stimulate cell growth, cell survival and proliferation, and are widely implicated in cancer biology as stimulators of cancer progression  ADDIN EN.CITE (Sachdev & Yee, 2001; Yee, 1998). 
The insulin (IR) and IGF (IGFR) receptors belong to a subfamily of RTKs that also includes the insulin receptor-related receptor (IRR). Some evidence has been gathered suggesting that hybrid receptors between IGFR and IR can exist, and they behave more like IGFR than IR  ADDIN EN.CITE (Federici, et al., 1997; Soos, et al., 1993). IR and IGFR present a high degree of homology, especially in the intracellular protein kinase domain (Figure 1‑11). These receptors function as allosteric enzymes and they are tetrameric proteins composed of two alpha and two beta subunits. Alpha and beta subunits are bound together through a series of disulfide bonds; the two alpha subunits compose the extracellular domain of the receptor and contain a cystein-rich region (L1-CR-L2 domains) that mediates the selective binding of the ligand, whereas the two beta subunits span the transmembrane and the intracellular region of the holoenzyme and contain the tyrosine kinase domain. The ligand selectivity of the IR/IGFR lies in the structural differences between the L1-CR-L2 regions between these two closely related receptors  ADDIN EN.CITE (Lou, et al., 2006). In the basal state the alpha subunits inhibit the tyrosine kinase activity of the beta subunits, and such inhibition is relieved upon ligand binding to the alpha subunits through allosteric activation of the beta subunits (Saltiel & Kahn, 2001). The activated receptor then undergoes a series of autophosphorylation and transphosphorylation events between the two beta subunits, essential for the full activation of the receptor. 


Figure 1‑11. Domain structure of the IR/IGFR
This scheme depicts the domain structure of the IR/IGFR. Two alpha and two beta proteins compose the receptor, bound together by disulphide bonds present in the extracellular region. A complex of fibronectin type III (FNIII) domains is present just before the trans/juxtamembrane region, followed by the kinase domain (that presents the highest degree of similarity between IR and IGFR) in the intracellular portion of the receptor. 
Image taken from Diabetes and carbohydrate metabolism; Chapter 2: Insulin signaling and action: glucose, lipids, protein. Authors: Cai Li, Ph.D., and Bei B. Zhang, Ph.D.
Editors: Ira D. Goldfine and Robert J. Rushakoff. 
Available at http://www.endotext.org/diabetes/index.htm
The active, phosphorylated receptor then recruits and activates a complex network of adaptor and effector proteins such as i) the IRS, the SHC and the GRB2 scaffolding proteins; ii) lipid kinases like PI3K; iii) small G-proteins like Rac and iv) serine, threonine and tyrosine kinases (Ogawa, et al., 1998) (Figure 1‑12). 


Figure 1‑12. The insulin/IGF-1 receptor and the downstream signalling pathways
This figure depicts the signalling pathways known to be active downstream the members of the IR/IGFR subfamily of RTK. Binding of the ligand to the extracellular moiety of the receptor triggers its allosteric activation, followed by autophosphorylation of the intracellular portion. Phosphorylated tyrosine residues act as docking sites for a range of adaptor molecules that relay the signal to downstream effectors molecules.  Overall, the IR/IGFR system controls different cellular functions such as glucose uptake and metabolism (mainly IR), regulation of gene expression, cell growth and proliferation and cell survival (both IR and IGFR). See the text for a more detailed description of the signalling pathways involved in the transduction downstream the IR/IGFR receptors. 
Figure taken from Saltiel & Kahn, 2001.

1.3.1	The IRS proteins 
The IRS docking proteins display various tyrosine residues on their surface that are known to be the substrate of IR and IGFR (White, 1998) (Figure 1‑13a). When phosphorylated, these tyrosine residues act as binding sites for many proteins involved in signal translation, with PI3K playing a major role. 










Figure 1‑13. Linear domain structure of IRS-1 and IRS-2 docking proteins and their interaction with other members of the Akt/PKB signalling pathway
a. IRS-1 and IRS-2 are the two best characterized members of the IRS family of adaptor/docking proteins. They present a high degree of homology and are formed by a PH domain at the N-terminus region that mediates the interaction with phosphorylated inositol lipids and therefore the recruitment to the plasma membrane, a PTB domain that recognizes phospho-tyrosine protein domains exposed by other proteins (e.g. active, Tyr-phosphorylated IR/IGFR intracellular domains) and many C-terminus tyrosine residues placed in consensus sequences that allow their phosphorylation by other protein kinases (e.g. active IR/IGFR) thus producing SH2 protein binding sites for effector proteins further downstream the signalling pathway (e.g. SH2 domain-containing p85 subunits of PI3K). IRS-2 also contains a KRLB domain that has been found to interact with the tyrosine kinase domain of the IR.
b. The IRS protein is recruited to active IR/IGFR through the interaction of its PH domain with the phosphoinositides at the plasma membrane and the phosphorylated tyrosine residues on the RTK by the recruitment of the PTB domain. The tyrosine residues displayed on the IRS surface are then phosphorylated by the active IR/IGFR and function as docking sites for a number of adaptor proteins and effectors such as PI3K (through the recruitment of the SH2 domains of the p85 regulatory subunit), which further transduce the signal generated at the plasma membrane. Active IRS proteins also recruit protein tyrosine phosphatases (e.g. SHP2) that switch off the signal, thus acting as a control over the activity of the signalling pathway.
Figures taken from White MF, 1998.

IRS-1 has been described as the most important isoform for the signal transduction downstream IR/IGFR (Saltiel & Kahn, 2001). IRS-2 protein presents a KRLB domain that has been found to limit the tyrosine phosphorylation of IRS-2, possibly functioning as a negative feedback mechanism that reduces IRS-2 involvement in signal transduction  ADDIN EN.CITE (Wu, et al., 2008). Overall, given the high degree of structure similarity between IRS-1 and IRS-2, their overlapping tissue expression and the similar type of extracellular stimuli to which they respond, it is not surprising that these two isoforms are largely complementary to each other. Nonetheless, the study of the KO murine models suggests that to a certain extent IRS-1 and IRS-2 play also non-redundant (i.e. isoform-specific) roles. Indeed, IRS-1 KO mice show growth retardation and hyperinsulinaemia, but did not progress to the stage of full insulin resistance or diabetes  ADDIN EN.CITE (Araki, et al., 1994). On the other hand, IRS-2 null mice do not show defects in body growth but display reduced fertility, insulin resistance and diabetes  ADDIN EN.CITE (Withers, et al., 1998). Other studies have also suggested that, in certain contexts, IRS-1 is relevant to relay mitogenic stimuli whereas IRS-2 plays a more relevant role in the control of cell metabolism (Dearth, et al., 2007). This partial separation between the roles of IRS-1 and IRS-2 may also be relevant in the context of cancer and is described in § 1.3.2. 









    Figure 1‑14. Regulation of human IRS-1 activity and/or protein stability by serine phosphorylation
This scheme shows the serine phosphorylation sites currently known for IRS-1 that concur to the negative regulation of IRS-1 activity and protein stability. On the left side are depicted the signalling inputs that trigger different signalling proteins, ultimately leading to serine phosphorylation of IRS-1. on the right side are described the outcomes of the serine phosphorylation events, that globally reduce IRS-1 signalling activity.
Image taken from Gibson et al., 2007.

PI3K-dependent signalling leads to downregulation of IRS-1 by the phosphorylation on five serine residues (in human: Ser636, Ser639, Ser662 Ser731, Ser1101) operated by Akt/PKB and S6K1  ADDIN EN.CITE (Zhang, et al., 2008b). Insulin/IGF-1-induced serine phosphorylation then primes IRS proteins for ubiquitin association followed by proteasome-mediated degradation (Lee, et al., 2000). Indeed, IRS-1 has been recently found as a proteolytic target of the CUL7 E3 ubiquitin ligase following activation of mTOR and S6K (Xu, et al., 2008). 

1.3.2	The role of IRS proteins in cancer 
A role for IRS-1 and IRS-2 in cancer onset and progression has been demonstrated by different studies. The first published evidence proved that IRS-1 overexpression can transform MEF and NIH 3T3 cells, the latter cell model showing upregulation of MAPK pathway, colony formation in soft agar, growth under reduced serum stimulation and, most importantly, tumor formation upon implantation in nude mice  ADDIN EN.CITE (D'Ambrosio, et al., 1995; Ito, et al., 1996). It has been proposed that IRS-1 and IRS-2 play different roles in cancer cell biology, as IRS-1 would be the main isoform to transduce pro-proliferative signals whereas IRS-2 would have a major role in the promotion of cell motility and metastasis formation  ADDIN EN.CITE (Byron, et al., 2006; Jackson, et al., 2001). 
Moreover, an important crosstalk exists between the IGFR/IR pathway and the steroid hormones system, as it has been showed exhaustively in highly hormone–dependent human cancers such as breast carcinoma. In vitro studies have shown that human cancer cell lines expressing estrogen receptor (ER+) are sensitive to IGF-1 stimulation whereas cancer cell lines that do not express ER (ER-) are only minimally responsive to IGF-1 (Dearth, et al., 2007). 





Figure 1‑15. The IRS proteins play a central role in cancer cell signalling
IRS docking proteins play a role downstream one of the most characterized cancer cell signalling pathways, namely the insulin/IGF-1 pathway. IRSs can be recruited downstream IGFr, IR and hybrid receptors and trigger the activation of several anti-apoptosis, cell motility and pro-mitogenic pathways, as well as being able to co-migrate to the nucleus when complexed with active estrogen receptor (ER), where they can co-operate in the upregulation of many components of the PI3K and the MAPK pathways, including IRS proteins.
Image taken from Sachdev & Yee, 2001. 

Numerous studies have analyzed the expression and phosphorylation levels of IRS-1 and IRS-2 in human cancer, both in ex vivo specimen (i.e. tumor samples derived from patients) and in human cancer cell lines. The evidence suggests that IRS overexpression is generally associated with tumor growth and the development of more aggressive forms of cancer, in line with the intuitive concept of an increased IRS-dependent signalling in transformed cells. Nonetheless, experimental data in human patients and murine models have been obtained suggesting that IRS proteins, and IRS-1 in particular, can be also downregulated in aggressive cancer, particularly in lung tumor. As an example, a subset of human squamous cell lung carcinomas has been found to have lost IRS-1 expression, correlating with a larger tumor size  ADDIN EN.CITE (Han, et al., 2006). Furthermore, a recently published research has showed that degradation of IRS-1 in non-small-cell lung cancer (NSCLC) promotes tumor growth and proliferation, with a profound impact on tumor-induced mortality in murine models of Ras-driven lung cancer  ADDIN EN.CITE (Houghton, et al.). The proposed mechanism whereby IRS-1 is degraded in lung cancer cells has never been described previously and involved a specific serine proteinase enzyme secreted by neutrophil leukocytes, called neutrophil elastase, that is internalized by the tumor cells upon infiltration of the lung cancer mass by the neutrophil cells during the inflammatory response. Indeed, it has been reported that tumor infiltration by neutrophil in patients with sustained inflammatory response correlates with poor clinical outcomes (Foekens, et al., 2003). Once within the lung cancer cell, this protease would accumulate in the endosomal compartment where it degrades IRS-1 protein. Interestingly, the downregulation of IRS-1 would force PI3K towards the PDGF/PDGFR signalling pathway (normally lung epithelium cells do not express neither PDGFR nor its ligand, but transformed lung cells acquire the capacity to do so), which does not require the IRS proteins to convey its signal further downstream the pathway, resulting in more sustained pro-growth and -proliferative drive and therefore more aggressive tumor. These findings may explain the PI3K pathway upregulation in NSCLC despite the low recurrence of inactivating PTEN mutations in human lung cancer. Moreover, the authors propose that the “switch” of PI3K to PDGFR has an impact on cancer growth because IRS-1-dependent signalling has a more “homeostatic” effect whereas PDGFR-directed stimulation is overall more potent and pro-growth. Indeed, PDGF is known as a very potent mitogenic stimulus. Concluding, Houghton et al. have shown that i) IRS-1 can be downregulated in lung cancer cells and this correlates with increased tumor growth and aggressivity and ii) PI3K can switch from one signalling pathway to another based on the availability of all the protein components required for the signal transduction, in this case IRS-1.   

1.3.3	The Akt/mTOR/S6K signalling pathway downstream PI3K
The class IA PI3Ks are recruited to phosphorylated IRS proteins via the SH2 domains in the p85 regulatory subunits, and can regulate the activity of three main classes of signalling molecules: the AGC family of serine/threonine protein kinases, guanine nucleotide-exchange proteins of the Rho family of GTPases and the Tec family of tyrosine kinases (Saltiel & Kahn, 2001). One of the most studied members of the AGC kinases family is PDK1. This protein constitutively resides at the plasma membrane and through phosphorylation activates the serine/threonine kinase Akt/PKB, that is recruited (thanks to its PH domain) and activated at the plasma membrane by the PIP3 produced by active PI3K. Once active, Akt/PKB acts as an important switch for the activation of different signalling pathways. 
Among the Akt/PKB substrates there are GSK3, FKHRL1 and CREB that are involved in the regulation of cell metabolism. 
Active Akt/PKB promotes cell survival by phosphorylating the BAD component of the BAD/BCLXL complex, that once active binds to 14-3-3 causing dissociation of the BAD/BCLXL complex and through the activation of IKK, which ultimately leads to NF-KappaB activation and cell survival. 
Finally, Akt/PKB activates the mTOR pathway, which ultimately results in the phosphorylation of ribosomal protein S6 kinase, p70S6K, on Thr389 (Figure 1‑16) (Sarbassov, et al., 2005a). The signal generated by active Akt/PKB is transmitted to mTOR through a series of intermediate protein switches, namely the TSC complex and the Rheb GTP-binding protein (a member of the Ras family of small GTPases). 
Active Akt/PKB phosphorylates (and inactivates) the TSC complex, which is formed by the two homologous proteins TSC1 (also named hamartin) and TSC2 (known also as tuberin). These are two tumor suppressing proteins that complex together and function as GAP for the small GTPase Rheb that switches from an inactive GDP-bound state when stimulated by the TSC complex to an active, GTP-bound state  ADDIN EN.CITE (Castro, et al., 2003). In its active state, Rheb triggers mTOR activation, thereby stimulating downstream transduction of the signal. Phosphorylation of TSC complex operated by active Akt/PKB inhibits a Rheb inhibitor, thus causing overall stimulation of mTOR activity.




Figure 1‑16. The Akt/mTOR/S6K pathway and its regulation by PI3K
mTOR plays a signalling role in two distinct branches of this pathway, according to which of two mTOR-binding molecules, raptor and rictor, it is complexed with (Cybulski & Hall, 2009). The raptor-mTOR complex, termed mTORC1, promotes protein expression and, ultimately, cell growth by phosphorylating S6K and 4E-BP1. It is able to sense and adapt to the abundance of nutrients in the cellular environment thanks to AMPK (among others) and it is sensitive to inhibition by the drug Rapamycin. This is a bacterial natural product that can inhibit mTOR through association with its intracellular receptor FKBP12, and the FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR (Huang, et al., 2003). mTOR can also exist as part of another complex called mTORC2, but when in this state it can not be inhibited by rapamycin  ADDIN EN.CITE (Sarbassov, et al., 2004). Sensitivity to Rapamycin has been therefore used as a discriminant factor to distinguish between mTORC1 and mTORC2-dependent functions. 
The rictor-mTOR complex, called mTORC2, is involved in the positive feedback regulation of Akt/PKB activity, as well as controlling PKC and Rho/Rac activity and, ultimately, cell proliferation and survival, cytoskeleton rearrangements and cell metabolism.
An important negative feedback loop has been established between active S6K and IRS-1 protein, whereby serine phosphorylation of IRS-1 triggers its inactivation and degradation.
Image taken from Sarbassov et al., 2005a.

It has been shown that active mTORC2 can phosphorylate Akt/PKB on Ser473 residue that is necessary for full activation of Akt/PKB signalling, thus providing an example of self-reinforcing positive feedback loop. For this reason, mTORC2 is also indicated as “PDK2”, as its function is complementary to PDK1 to achieve maximal Akt/PKB activation  ADDIN EN.CITE (Sarbassov, et al., 2005b).
Active S6K then phosphorylates S6 ribosomal protein, thus regulating the translation of a broad range of mRNAs produced by the cell and, more generally, the cellular protein expression machinery. Active mTOR also phosphorylates (and inactivates) the eIF4EBP protein, also known as PHAS, an inhibitor of the translation initiation factor eIF4E, and induces the dephosphorylation of eEF2 and the inactivation of EF2K. A complex feedback loop exists between S6K and mTORC2, as active S6K1 phosphorylates T1135 on Rictor thus negatively regulating mTOR activity, and directly phosphorylates mTOR on Ser2448  ADDIN EN.CITE (Dibble, et al., 2009; Rosner, et al.). Such phosphorylation has been shown to activate mTOR, but only when it is part of the mTORC1. Furthermore, S6K itself is negatively regulated by the phosphorylation on several serine and threonine residues followed by polyubiquitination and proteasome-mediated degradation, thus providing an effective means of S6K turnover regulation (Wang, et al., 2008).
In conclusion, the Akt/mTOR/S6K pathway has an ample control on cell growth and proliferation, cell survival and the expression of extracellular proteins, being therefore a crucial mechanism for the pleiotropic control of the cellular processes.
Akt/PKB (and possibly some PKC isoforms) is also known to play a major role in the stimulation of glucose intake of the cell following insulin stimulation. Such function is mediated by the translocation to the plasma membrane of GLUT4 protein (a glucose transporter) from an intracellular compartment (Figure 1‑12) (Cheatham, 2000). In parallel with Akt/PKB activation, active IR also triggers the phosphorylation of the CAP adaptor protein and its subsequent translocation to the plasma membrane and complex formation with the Cbl protein. Such complex is then phosphorylated and translocates to the lipid rafts in the plasma membrane, where Cbl can interact with the adaptor protein Crk that is associated with the Rho-family GEF C3G. Such protein activates a member of the small GTPases family, namely TC10, than finally promotes the translocation of GLUT4 to the plasma membrane (Saltiel & Kahn, 2001).
1.3.4	The Ras-MAPK signalling pathway 
Another relevant protein for the signal transduction downstream the IR is GRB10, which can directly interact with active IR (similarly to the IRSs) and interacts with Erk protein, which is part of the downstream MAPK pathway (Holt & Siddle, 2005).
This pathway is also triggered by the phosphorylation of IRS proteins and/or SHC, followed by the interaction with the adaptor protein GRB2, the recruitment of SOS to the cell membrane and finally the activation of Ras small GTPase. SHP2 is recruited downstream active IR/IGFR by the interaction with GAB1 or IRS-1/-2 and it contributes to the full activation of Ras by modulating the activity of Csk, a Tyrosine kinase that can phosphorylate a conserved residue in the C- terminal region of SFK thereby downregulating their kinase activity. Once the inhibitory effect of Csk is relieved, SFK can act as molecular switches that trigger Ras activity (Figure 1‑12)  ADDIN EN.CITE (Zhang, et al., 2004). Once active, Ras stimulates a small GTPase serine kinases cascade known as the MAPK pathway through the sequential activation of Raf, MEK and Erk. Active Erk can translocate to the nucleus where it phosphorylates a battery of transcription factors, thus triggering the expression of several genes involved in cellular proliferation and differentiation. 
Ras is also known to directly stimulate PI3K activity through direct interaction with the class I catalytic subunits (that possess a Ras binding domain) (Vanhaesebroeck & Waterfield, 1999). It has been shown that for p110 (and p110) the interaction with Ras is essential for its full activation and oncogenic signalling  ADDIN EN.CITE (Kang, et al., 2006). 
In conclusion, p110 plays a central role in the integration of signals arising from the GPCR and Ras, due to its capacity to integrate the signals arising from GPCR stimulation and EGFR transactivation, and may be crucial for the co-ordinate activation of both GPCR- and RTK-dependent cell signalling pathways.

1.3.5	Intracellular signalling of internalized receptors
The signalling activity of the IR/IGFR is not limited to the cell surface, but continues following the internalization of the active receptor. Active receptor endocytosis is part of a general physiological mechanism of the cell whereby cell surface receptors that have been activated by the binding of their specific ligands are withdrawn from the plasma membrane through a complex and highly regulated process (Murphy, et al., 2009). This internalization process is dependent on the tyrosine autophosphorylation of the receptor and involves the recruitment and activation of a complex array of accessory molecules, such as clathrin (that concurs in the formation of membrane invaginations containing the receptors that are targeted for internalization) and ubiquitine ligases (that ubiquitinate the active receptor thus priming it for internalization). Regarding the IR/IGFR system, it has been reported that IRS-1 proteins bound to the active receptor at the plasma membrane are internalized with the receptors itself and continue to transduce signals leading to the activation of the PI3K and MAPK enzymes (Li, et al., 2005).  
Interestingly, IR phosphorylation level has been found to be even higher when the receptor is internalized than when it is located at the plasma membrane, and both PI3K and MAPK activity seems to follow this dynamics by reaching a higher activity level downstream the internalized receptor (Murphy, et al., 2009). Furthermore, internalization events result in the concentration of the receptor protein kinase domains and their substrates (i.e. the receptor itself) in a more confined space than at the plasma membrane, thus contributing to the maintenance and amplification of receptor signalling activity. 
In conclusion, these findings suggest that the intracellular phase of receptor signalling, that has only recently begun to be analyzed in detail, may play an equally or even more relevant role in cell physiology than the “plasma membrane phase” that has so far been at the centre of the research efforts in the field. Moreover, it is by no means clear what (if any) role is played by the signalling molecules recruited to the internalized receptors in the regulation of the internalization process itself. As an example, little is known on the role of the PI3K enzymes, and in particular if any specific PI3K isoform may have a predominant regulatory function in the receptor endocytosis and signalling shutdown mechanisms. 
Nonetheless, receptor internalization is primarily a mechanism used by the cell to shut off signalling, thus being a crucial passage for the regulation of many signalling complexes including IR/IGFR. The acidification of the endosomes lumen, that is a mechanism used by the cell to degrade the endosomal content as is provoked by the activation of proton pumps residing on the endosomal membrane, causes the dissociation of the receptor-ligand complex, thus strongly attenuating the receptor protein kinase domain activity  (Bevan, et al., 2000). Furthermore, the phosphorylated intracellular portion of the IR/IGFR is attacked by a series of cytoplasmic PTPs. One of the most studied in the context of IR downregulation is the isoform PTP1B that dephosphorylates the tyrosine residues on the receptors or their associated accessory proteins (such as IRSs) (Figure 1‑12) (Saltiel & Kahn, 2001).  

1.4	GPCR signalling and cross-talk with RTK pathway

1.4.1	GPCRs and the G protein signalling machinery
The superfamily of G protein-coupled receptors (GPCRs) represents the majority of cell-surface receptors, and up to 1% of the mammalian genome (around 1000 different GPCR isoforms) encodes for this class of receptors  ADDIN EN.CITE (Clapham, 1996; Hur & Kim, 2002). GPCRs mediate the response of living cells to a wide array of external stimuli, ranging from odorants and taste ligands to hormones and lipids, thus participating in a series of complex and diverse physiological functions. About half of the known GPCRs recognize non-sensory ligands such as peptides and lipids. GPCRs such as receptors of chemokines and neurotransmitters have been implicated in cancer progression, cell motility and metastasis development, as in the case of 2-adrenergic receptor in the human breast cancer line MDA-MB-468  ADDIN EN.CITE (Bastian, et al., 2006; Entschladen, et al., 2002).
Classically, GPCRs have been described as cell-surface proteins comprising seven trans-membrane domains and coupling with trimeric small-GTPase cytoplasmic proteins, called G proteins (Wettschureck & Offermanns, 2005). A given G protein is formed by an  subunit, that contains the GTPase enzymatic activity and a dimeric complex formed by the  and  subunits. Several different isoforms of the ,  and  subunits have been cloned. The high number of possible combinations of ,  and  isoforms forming the functional trimeric G protein complex is likely to contribute to the hetereogeneity and flexibility of GPCR signalling, used by the cell to regulate a wide spectrum of physiological functions (Hamm, 1998).   
In resting conditions, the G subunit is coupled to the G moiety and it is bound to GDP. Upon binding of its specific extracellular ligand, the GPCR interacts with the G protein and decreases the intrinsic GTPase activity of the G subunit (thus acting as a G-GEF), thereby favouring the substitution of GDP with GTP. This event results in the dissociation of the GTP-bound G subunit from the G moiety and the activation of downstream signalling effectors by both the free G and G subunits. The G subunit is inherently capable of self-terminating the G protein signalling activity by hydrolyzing GTP to GDP, thus returning to its G-coupled inactive state. The G protein therefore represents a paradigmatic mechanism of self-controlling signalling switch (Clapham, 1996) (Figure 1‑17). 


Figure 1‑17. Cyclic functional activation of G protein downstream GPCR
This figure shows the activation/deactivation cycle of the G protein coupled to GPCR. The binding of specific extracellular agonists (Ag) to the seven-transmembrane domain GPCR enhances its interaction with cytoplasmic trimeric G protein. Such interaction results in the GPCR acting as a GEF for the G protein, in the substitution of GDP bound to the G subunit with GTP and the detachment from the G moiety. Once independent, both the G and the G subunits interact with a network of molecular effectors that propagate the signal further downstream.  Signal termination occurs when the G subunit hydrolyzes GTP to GDP, thus returning to its inactive state and recomposing the resting-state trimeric complex by interacting again with the G subunit. GTP hydrolysis is the therefore one of the limiting steps of signalling activity downstream GPCR, and is modulated by many regulators of G protein signalling (RGS) as well as some effectors of the G subunit.
This image has been taken from Wettschureck & Offermanns, 2005.

On the other hand, long-term GPCR signal termination occurs by means of different mechanisms, including receptor desensitization, internalization and degradation. These phenomena are regulated by multiple phosphorylation events of the GPCR intracellular region due to GRK proteins, following by -arrestin binding (that also prevents further interaction with G proteins) and finally clathrin-mediated receptor internalization (Pitcher, et al., 1998). 
Many G protein effectors have been identified, including calcium and potassium channels, PLC, adenylyl cyclase (a cytosolic enzyme that hydrolizes ATP to produce cyclic AMP, an important intracellular second messenger), components of the MAPK pathway and PI3K. The effect on some of these (in particular adenylyl cyclase and PLC), along with amino acid sequence similarities between the G subunits have been traditionally used to classify the different G proteins into four main subfamilies, namely Gs (that activate adenylyl cyclase), Gi (that inhibit it), Gq (that activate PLC) and G12/13 that regulate small-GTPase proteins (Hur & Kim, 2002).  
Regarding PI3K, as discussed above, the p110 and p110 (the latter being restricted to leukocytes) have been implicated in signal transduction downstream GPCR. p110 in particular is activated by the interaction with the G subunit of the Gi/Gq/G12/13 G proteins, which are active downstream several GPCRs such as the LPA receptor, of which three isoforms are currently known, namely LPA1, LPA2 and LPA3  ADDIN EN.CITE (Mills & Moolenaar, 2003; Okada, et al., 1996; Wettschureck & Offermanns, 2005). It has been shown that, upon GPCR activation, the G subunit recruits p110 and p110 to the membrane (acting as a membrane anchor) and allosterically stimulates their catalytic activity. The regulatory subunits coupled to the p110 proteins (i.e. p101 and p85) have been found in vitro to be dispensable to convey such stimulation, although in vivo experiments suggest that they are required for G-induced activation  ADDIN EN.CITE (Brock, et al., 2003; Krugmann, et al., 2002; Maier, et al., 1999).

1.4.2	GPCR-RTK transactivation 
GPCR and RTK (e.g. for growth factors such as insulin, EGF, PDGF) are co-expressed in cells, and extensive research efforts have revealed that these two classes of receptors can cross-talk to modulate the cellular responses to extracellular stimuli, thereby allowing the integration of different extracellular stimuli and the cellular response in complex physiological contexts. The research efforts in the field have initially focused on the transactivation of RTK-dependent pathways (including Ras-MAPK signalling network) operated by various GPCR ligands  ADDIN EN.CITE (Hur & Kim, 2002; Weiss, et al., 1997). 
The concept of GPCR-RTK transactivation was originally introduced to explain the induction of EGFR phosphorylation following stimulation of rat fibroblasts with GPCR ligands, including LPA  ADDIN EN.CITE (Daub, et al., 1996). There are many proposed mechanisms for this type of receptor cross-talk. One involves the GPCR-induced activation of cell membrane matrix metalloproteinases that release an EGFR ligand from its immature form proHB-EGF  ADDIN EN.CITE (Prenzel, et al., 1999) (Figure 1‑18). 


Figure 1‑18. A "triple-membrane-passing-signalling" model of GPCR-induced transactivation of EGFR
This scheme depicts one of the proposed models of EGFR transactivation by active GPCR. The graphic representation highlights the concept of cross-membrane or “serpentine” signalling flux that exists between the GPCR and EGFR. According to this model, the primary intracellular (outside-in) signal generated by the active GPCR is translated (through the action of several cytoplasmic mediators, depicted in the yellow box) into a new extracellular, inside-out (i.e. it begins inside the cell and goes towards the extracellular space) autocrine-paracrine signalling wave, originating from the matrix metalloproteinases (MP) at the plasma membrane. These enzymes promote the release of HB-EGF in the extracellular space, which can therefore bind to and activate the EGFR. Following this, an intracellular signalling cascade is activated downstream active EGFR (second “outside-in”), resulting in the upregulation of the Ras-MAPK pathway and others signalling cascades, including the PI3K.
Image taken from Wetzker & Bohmer, 2003.    

The metalloproteinases activation operated by the GPCR is mediated by several intracellular signalling proteins and second messengers, including PKC, Src and Ca2+ ions (Wetzker & Bohmer, 2003). proHB-EGF is an heparin-binding, immature precursor of an EGF-like growth factor that accumulates at the plasma membrane and binds to the portion of extracellular matrix composed of heparin sulphate proteoglycans  ADDIN EN.CITE (Raab & Klagsbrun, 1997). Once released, HB-EGF binds to the extracellular portion of EGFR receptor, thereby activating downstream cellular responses  ADDIN EN.CITE (Prenzel, et al., 1999). One interesting aspect of this transactivation model, termed “triple-membrane-passing-signalling”, is that the signalling generated by the active GPCR is further elaborated and modulated through an additional trans-membrane passage before generating an intracellular signalling downstream of EGFR, thus crossing the membrane for three times. Alternative transactivation mechanisms have also been described that do not involve the  metalloproteinases, but instead rely on the activation of cytoplasmic signalling molecules such as the Tyr kinases Src and Pyk2, or the generation of second messengers (e.g. H2O2) (Wetzker & Bohmer, 2003). In this case the active Tyr-kinases would directly phosphorylate (and activate) EGFR, whereas the generation of H2O2 would trigger the reversible inactivation of PTP, thus allowing the full phosphorylation of the intracellular domains of EGFR. These mechanisms are likely to play a role in contexts such as membrane microdomains or scaffolds where GPCR and RTK cluster in limited areas of the cell surface. 
Furthermore, it has emerged in the past few years that cross-talk between GPCR and RTK is not a unidirectional mechanism, but rather a reciprocal transactivation process. In other words, RTKs too can activate GPCRs to relay stimuli using different mechanisms (Delcourt, et al., 2007). These mechanisms resemble those described above for GPCR-RTK transactivation and can be divided in two distinct groups. One comprises the RTK-GPCR transactivation events occurring upon neo-synthesis and secretion of the GPCR ligand (thus acting in an autocrine-paracrine manner), as in the case of IGF-1- and PDGF-induced synthesis of sphingosine-1-phosphate (S1P), a bioactive signalling lipid (Delcourt, et al., 2007). The other group includes those transactivation events that do not require the neo-formation of GPCR ligands, but involve the direct physical interaction between the active RTK and the GPCR (e.g. NGFR-LPA1 transactivation) or the Src-mediated GPCR phosphorylation and its consequent activation even in the absence of the cognate ligand (as in IGF-1R-PAC1R transactivation) (Delcourt, et al., 2007).             
More recently, LPA-induced transactivation of PDGFR has been investigated in a model of human bronchial epithelial cells  ADDIN EN.CITE (Wang, et al., 2003). This study revealed that PDGFR phosphorylation induced by LPA was dose-dependent, it peaked 5 min post-LPA stimulus (lasting for up to 30 min) and was sensitive to PTX (an inhibitor of GPCR signalling) treatment. Moreover, it was resistant to treatment with broad-range inhibitors of matrix metalloproteinases, suggesting a different mechanism of action compared to EGFR transactivation. The authors proposed a role for phospholipase D (PLD) in PDGFR transactivation. PLD is an enzyme bound to the plasma membrane that generates intracellular signals by hydrolizing phosphatidylcholine, a phospholipid component of the cell membrane. The resulting phospholipid is phosphatidic acid, which acts as a secondary messenger by triggering the activation of a broad range of signalling enzymes that regulate several cellular events (Hodgkin, et al., 1998). One of these, PKC, has been reported to phosphorylate PDGFR and may therefore represent one of the effectors of GPCR-RTK cross-talk  ADDIN EN.CITE (Yang, et al., 2009). 











Figure 1‑19. A model of Ras/MAPK activation through parallel tracks
This figure describes the model of Ras/MAPK pathway triggering upon GPCR activation based on two mechanisms acting in parallel, i.e. the transactivation of RTK followed by direct Ras activation (track 1) and the involvement of a series of cytoplasmic signalling components that include PI3K (track 2). Here, only PI3Kisoform is indicated, but a role for p110 has been documented as well  ADDIN EN.CITE (Yart, et al., 2002). The relative prevalence of either mechanism can vary between different cell types, and their concurrent activity gives rise to a phenomenon that has been termed “multi-track signalling”.
This figure has been taken from Wetzker & Bohmer, 2003.  









2.1	Buffers, solutions, reagents and apparatusES
2.1.1	General buffers
PBS: 155.17 mM NaCl, 2.7 mM KCl, 2.71 mM Na2HPO4, 1.54 mM KH2PO4 (Invitrogen, cat. no. 20012-019).
TBE buffer: 89 mM Tris.Acetate, 2 mM EDTA, pH 8.0
PBS-T: 0.1% (v/v) TWEEN®20 (Sigma, cat. no. P1379) in PBS
TBS: 20 mMTris.HCl, 150 mMNaCl in ddH2O, pH7.6
TBS-T: 0.1% (v/v) TWEEN®20 in TBS
TE: 10 mM Tris.HCl pH 7.6, 1 mM Na2EDTA

2.1.2	Detergents for cell lysis
Igepal (Sigma, cat. no. I3021)
Triton X-100 (cat. no. T8787)
These two detergents are widely used non-ionic surfactant for recovery of membrane components under mild non-denaturing conditions.

2.1.3	General reagents
Bio-Rad Protein Assay Dye Reagent (BioRad, cat. no. 500-0006)
Trypsin-EDTA (GIBCO, cat. no. 25300)
Lysophosphatidic acid (LPA) (Sigma, cat. no. L7260); soluble in DMSO
Platelet-derived growth factor (PDGF)-BB (Peprotech, cat. no. 100-14B); soluble in water plus 0.1% BSA
Human recombinant insulin (Sigma, cat. no. 91077C); soluble in water
DMSO (Sigma cat. no. D8418)
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) (Promega cat. no.  G5430)

Transfection reagents:
Dharmafect 1 transfection reagent (Thermo Scientific Dharmacon, T-2001-02)  
siRNA tools:
1.	on-Target Plus set of four siRNA, targeting human IRS-1 mRNA (Thermo Scientific Dharmacon, J-003015-09 to J-003015-12). These four siRNAs are further indicated in this report as IRS-1 siRNA #1 to #4.
2.	on-Target Plus set of four siRNA targeting human IRS-2 mRNA (Thermo Scientific Dharmacon, J-003554-08 to J-003554-11). These four siRNA are further indicated in this report as IRS-2 siRNA #1 to #4.
3.	on-Target Plus siRNA targeting human GAPDH mRNA (Thermo Scientific Dharmacon, D-001830-01-05)




	1% Triton X-100 (for immunoprecipitation and Western Blot);
	1% Igepal (for co-immunoprecipitation)
Salts and protease/phosphatase inhibitors
50 mM Tris.HCl pH 7.4 (for immunoprecipitation and Western blot) ;50 mM HEPES pH 7.4 (for co-immunoprecipitation)	50 mM NaF [phosphatase inhibitor (BDH, cat. no. 102464T)]
150 mM NaCl	1 mM EDTA		1 mM Na3VO4 [tyrosine phosphatase inhibitor (Sigma, cat. no. S6508)]
0.7 mM pepstatin A [acid protease inhibitor (Sigma, cat. no. P4265)]	10 μM leupeptin [serine and cysteine protease inhibitor (SIGMA, cat. no. L2884]
40 mM β-glycerophosphate		27 μM TLCK [serine protease inhibitor (Sigma, cat. no. T7254)]
10 mM sodium pyrophosphate	1 mM PMSF [serine protease inhibitor, dissolved in isopropanol (Sigma, cat. no. F1428)]
1 μg/ml aprotinin [trypsin inhibitor (Sigma, cat. no. A6103)]	1 μM okadaic acid [phosphatase inhibitor (Calbiochem, cat. no. 495604)]
2.1.5	Buffers and reagents for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and protein blotting analysis (Western blotting)
Polyacrylamide running and stacking gels:
	1 x large gel system (Hoefer)	2 x small gel system (BioRad)
	8% Running gel	Stacking gel	8% Running gel	Stacking gel
1.5 M Tris.HCl pH 8.8	7.5 ml	-	3.75 ml	-
1 M Tris.HCl pH 6.8	-	1.25 ml	-	0.625 ml
H20	13.9 ml	6.8 ml	6.9-ml	3.4 ml
30% Acrylamide solution	8.0ml	1.7 ml	4.0 ml	0.85 ml
10% SDS	0.3 ml	0.1 ml	0.15 ml	0.05 ml
10% APS	0.3 ml	0.1 ml	0.15 ml	0.05 ml
TEMED	0.018 ml	0.01 ml	0.01 ml	0.005 ml
(TEMED = Tetramethylethylenediamine; APS = ammonium persulfate)

Running buffer: 0.25 M Tris pH 8.5, 0.192 M glycine, 0.1% w/v SDS

Transfer buffer: 0.25 M Tris.HCl pH 8.5, 0.192 M glycine, 0.1% SDS, 20% methanol

5x SDS sample buffer (Laemmli buffer, final volume 12 ml): 




100 mg Bromophenol Blue

Home-made ECL:
Solution A: 20 mM Tris-HCl pH 8.5, 0.02% H2O2
Solution B: 20 mM Tris-HCl pH 8.6, 13.2 mg coumaric acid (Sigma, cat. no. C9008), 0.868 mg luminal (Sigma, cat. no. A8511).
Upon use, identical volumes of solution A and solution B were mixed and poured over the PVDF membranes.

Stripping buffer:
Guanidine hydrochloride 8 M (Sigma, cat. no. G4505).
Guanidine hydrochloride is a very strong denaturing agent and completely dissociates the complexes between PVDF-membrane bound proteins and primary antibodies. It also detaches proteins loosely bound to the membrane, typically milk proteins used to saturate the membrane. Therefore, after guanidine hydrochloride treatment the membrane needs to be re-saturated with 5% milk solution in TBS-T before further reblotting.

2.1.6	PI3K inhibitors
	LY294002: Pan-PI3K inhibitor (Calbiochem, cat. no.  440202)
	TGX-221: p110β-selective PI3K inhibitor (Cayman Chemical, cat. no.  663619-89-4)
	TGX-115: p110-selective PI3K inhibitor (from Piramed, Slough)
	TGX-155: p110-selective PI3K inhibitor (from Merck/Serono, Geneva)  

All PI3K inhibitors stocks were prepared dissolving the compound in DMSO at 10 mM concentration.







Table 2‑1. IC50 values of PI3K inhibitors
References: 
LY294002 and TGX-155  ADDIN EN.CITE (Ali, et al., 2008);
TGX-221  ADDIN EN.CITE (Knight, et al., 2006)
TGX-115  ADDIN EN.CITE (Knight, et al., 2004) 
The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a compound at inhibiting an enzyme, and is expressed as the concentration of compound that gives half the maximal inhibitory effect.

2.1.7	Other inhibitors
	MG-132: proteasome inhibitor (Calbiochem, cat. no. 474790). Soluble in DMSO.
	Rapamycin: inhibitor of mTOR (Calbiochem, cat. no. 553210). Soluble in DMSO.
	FPT: inhibitor of Ras family small GTPases (Calbiochem, cat. no. 344150). Soluble in water. Inhibits the farnesylation of Ras thus preventing its functioning at the plasma membrane level. 
	Gallein: (Tocris biosciences, cat. no. 3090). Blocks PI3K activation by GPCR through sterical inhibition of the G subunit.  ADDIN EN.CITE (Lehmann, et al., 2008). Soluble in DMSO




Name	Specificity	Source and  cat. no. 	Secondary	Concentration/ dilution
IGF-1R	IGF-1 Receptor Beta (C-20)	Santa Cruz, sc-713	Rabbit, pAb	1:500 (WB)
Akt	Akt/PKB, PH domain, clone SKB1	Upstate, 05-591	Mouse, mAb	1:1000 (WB)
Erk	Total Erk	CST, 9102	Rabbit, pAb	1:1000 (WB)
GAPDH	GAPDH	Abcam, ab8245	Mouse, mAb	1:1000 (WB)
INSR	Insulin receptor,  subunit	Santa Cruz, sc-711	Rabbit, pAb	1:500 (WB)
IRS-1	IRS-1 pre-CT (antigenic specificity: pre-C-terminus region of IRS-1) 	Upstate, 06-526	Rabbit,  pAb	1:1000 (WB)
IRS-1 mono	IRS-1	Gift from Prof. Withers, Imperial College London	Mouse, pAb	1:200 (IP)
P-IRS-1	Phospho IRS-1 (Serine 1101)	CST, 2385	Rabbit, pAb	1:1000 (WB)
IRS-2	IRS-2	Upstate, 06-506	Rabbit, pAb	1:1000 (WB)
p110	p110(immunogen aa 101-300)	Transduction Labs, P94520-150	Mouse, mAb	1:500 (WB)1:20 (IP)
p110	p110	Santa Cruz, sc-602	Rabbit, pAb	1:50 (WB)
p110	p110	In house	Rabbit, pAb	1:10 (IP)
p110	p110	Abcam, ab1678	Rabbit, pAb	1:300 (IP)
p110	p110	Epitomics	Rabbit, mAb	1:1000 (WB)
p85	p85	Upstate, 06-497	Rabbit, pAb	1:1000 (WB)1:200 (IP)
p85	p85clone U10	In house (also commercially available: Cell Sciences, CMP021)	Mouse, mAb	1:200 (WB)1:10 (IP)
p85	p85clone T15	In house (also commercially available:Abcam, ab28356)	Mouse, mAb	1:500 (WB)1:10 (IP)
P-Akt308	Phospho-Akt (threonine 308)	CST, 9275	Rabbit, pAb	1:1000 (WB)
P-Akt473	Phospho-Akt (serine 473)	CST, 9271	Rabbit, pAb	1:1000 (WB)
PDGFR	PDGFR	Santa Cruz, sc-80991	Mouse, mAb	1:50 (IP)
PDGFR	PDGFR	Santa Cruz, sc-432	Rabbit, pAb	1:1000 (WB)
P-Erk	Phospho-Erk	CST, 9106	Mouse, mAb	1:2000 (WB)
P-PTEN	Phospho PTEN (Ser380/Trh382/383)	CST, 9554	Rabbit, pAb	1:1000 (WB)
P-S6K1	Phospho S6K1 (threonine 389)	CST, 9205	Rabbit, pAb	1:1000 (WB)
PTEN	PTEN	CST, 9552	Rabbit, pAb	1:1000 (IP)
S6K1	Total S6K1	NEB/Cell signalling, 9202	Rabbit, pAb	1:1000 (WB)
Tubulin	Tubulin	Sigma, T6074	Mouse, mAb	1:10000 (WB)
Vinculin	Vinculin	Sigma, V9131	Mouse, mAb	1:5000 (WB)

Secondary antibodies
Secondary	Source	Source and cat. no. 	Dilution
HRP-anti-rabbit IgG	Donkey	Amersham, NA934-1ML	1:5000 (WB)
HRP-anti-mouse IgG	Sheep	Amersham, NXA931	1:5000 (WB)

2.1.9	Protein-coupled sepharose beads used for immunoprecipitation
Beads	Used to bind:	Source and cat. no. 
Protein A sepharose	Rabbit antibodies	Amersham, 17-5280-01
Protein G sepharose	Mouse or rabbit antibodies	Amersham, 17-0618-01
 
2.1.10	Buffers and reagents for agarose-gel electrophoresis of DNA products
Agarose (Helena Biosciences, cat. no.  8201-03)
Ethidium Bromide (Sigma, cat. no.  E8751)
FastRuler™ Low Range DNA Ladder (Fermentas, cat. no.  SM1103)
The agarose gels used for the electrophoresis of DNA were prepared and run using an Anachem Scotlab SL-H3 set (Anachem Scotlab) comprising gel casting trays, combs and gel running tanks with electrical wiring. The gel running tank was used in conjunction with a Hoefer PS500X power supplier (Amersham Pharmacia Biotech).

DNA loading buffer:  50% Glycerol; 1 mM EDTA ; 0.4% Bromophenol blue




2.2.1	Cell lines and culture media
Cell line	Species	Type of cell line
MCF-7	Homo sapiens	Breast adenocarcinoma cell line
MDA-MB-468	Homo sapiens	Breast adenocarcinoma cell line
NCI-H2085	Homo sapiens	Lung adenocarcinoma cell line
NIH:OVCAR-3	Homo sapiens	Ovary adenocarcinoma cell line
HCT-116	Homo sapiens	Colon adenocarcinoma cell line
U87-MG	Homo sapiens	Malignant glioma cell line
A2058	Homo sapiens	Metastatic melanoma cell line
PC-3	Homo sapiens	Prostate adenocarcinoma cell line
MCF-10A	Homo sapiens	Immortalized breast epithelium cell line
NIH-3T3	Mus musculus	Immortalized embryonic fibroblastic cell line
WT MEF	Mus musculus	Immortalized embryonic fibroblastic cell line
IRS-1 KO MEF	Mus musculus	Immortalized embryonic fibroblastic cell line
IRS-2 KO MEF	Mus musculus	Immortalized embryonic fibroblastic cell line

Human cancer cell lines:
All the human cancer cell lines, the MCF10-A and the NIH 3T3 cell lines described in this report were purchased from American Tissue Culture Collection (ATCC) and maintained in culture using standard procedures.
The tissue culture media used for these cell lines were:
- Complete RPMI with L-Glutamine, 25 mM HEPES (Sigma; cat. no.  52400-025)
- DMEM with L-Glutamine, 4500 mg/L D-Glucose, 110 mg/L Sodium Pyruvate (Invitrogen, cat. no.  41966-029)
- DMEM/F12
Media were supplemented with foetal calf serum (FCS) (Invitrogen, cat. no. 10500-064) or foetal horse serum (Invitrogen, cat. no. 16050-122)
All cell culture media were supplemented with 1% penicillin/streptomycin (Invitrogen, cat. no.  15140-122)
The cell lines described in this report were grown in different media, according to instruction from the ATCC:
MCF-7, U87-MG and PC-3: 
RPMI 1640 supplemented with 10% FCS. 

NIH:OVCAR-3:
RPMI 1640 supplemented with 20% FCS.

MDA-MB-468, NCI-H2085, A2058, HCT-116, NIH-3T3 and MEFs:
DMEM supplemented with 10% FCS. 

MCF-10A
DMEM/F12 supplemented with 5% fetal horse serum, 20 ng/ml EGF, 0.5 g/ml hydrocortisone, 100 ng/ml cholera toxin, 10 g/ml insulin.

2.2.2	Culture and maintenance of cell lines  
The culture media listed above were used for cell culture, and a humidified incubator with constant temperature (37oC) and CO2 concentration (5%) was used for propagation. The cells were sub-confluent and passaged on cell culture-treated plastic flasks and dishes of different size according to the experimental procedures adopted. To detach and split the cells, they were first briefly washed in PBS solution and then treated with trypsin-EDTA followed by the addition of pre-warmed fresh media.

2.2.3	Cryopreservation of cells
For long-term storage of the cell lines, stocks of frozen cells were kept in liquid nitrogen. Briefly, on the day of the freezing the cells were harvested following the procedure described above and the trypsin was removed by centrifugation at 700xg for 5 min, then the cells were resuspended in complete culture media in a volume sufficient to give a final density of 1x108 cells/ml. Sterile DMSO was added to the cell suspension to obtain a 10% DMSO dilution, and the suspension was quickly aliquoted (1 ml per vial) into sterile cryovials. The aliquoted cells were placed into a suitable plastic rack placed in a tank containing pure isopropanol, then frozen at -200C for 2 h and finally transferred at -800C for at least 24 h. The cells were subsequently moved into a liquid nitrogen tank for indefinite storage. 
To re-start the culture of a cell line, a cryovial containing the correct cells was removed from the liquid nitrogen tank and thawed quickly at 370C in a water bath, then the appropriate complete culture media was used to dilute the content of the cryovial and to transfer it into a suitable cell culture flask. 

2.3	CELL GROWTH AND PROLIFERATION ASSAY
2.3.1	Cell plating and drugs addition
5000 cells/well were seeded in 96-well plates treated for cell culture and left to adhere for 18-24 h. Multichannel pipettes were used throughout. A total of 20 wells per each cell line were seeded, and divided into four groups of five wells each. After this time, media was aspirated from all the wells and replaced with media containing no serum or 5% FCS plus a different drug or different concentration of the same drug. The drugs used were the pan-PI3K inhibitor LY294002 at 5 M, the PI3K p110-specific inhibitor TGX-221 at 0.05 M or 0.01M and pertussis toxin at 100 ng/ml. The control group of cells received DMSO only at 0.05% v/v. DMSO was also added to cells treated with drugs in variable quantities, in order to achieve the same final DMSO concentration in every cells-seeded plate used for a given experiment. Where indicated, PTX was boiled for 5 min at 95oC to inactivate it and used as a negative control. Final volume of media in each well was 100 l. DMEM or RPMI media (depending on the cell line) without FCS or containing 5% FCS was also added as a control to a quintuplet of wells where no cells had been plated, to account for inherent media absorbance. The cells were then incubated at 37o C in 5% CO2, and after 48, 72 or 96 h the number and the metabolic activity of the cells in each well was assayed by MTS assay.
2.3.2	Cell growth and proliferation assay 
To measure the cellular growth and proliferation rate the CellTiter 96® Aqueous non-radioactive cell proliferation assay kit (MTS assay) was used. This assay is based on a colorimetric reaction that takes place when an organic tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) is added to the cell culture. The MTS compound is yellow in solution but when metabolized in the cells’ mitochondria a soluble, red-brownish formazan compound is formed at a rate proportional to the metabolic activity of the cells. The native MTS compound has a light absorbance peak at 382 nm, whereas the bioreduced formazan molecule has an absorbance spectrum with a peak between 480 nm and 510 nm. The production of formazan is assayed by measuring the light absorbance of this compound in each well at the peak absorbance wavelength of 490 nm using a microplate reader (Tecan Sunrise). The MTS assay reagent kit was stored at -20oC and was thawed shortly before use. Once liquid, 20 l of MTS reagent protected from direct light to avoid degradation, was added in each well including the group of wells where no cells were plated, to account for the basal optical absorption of the MTS compound dissolved in either DMEM or RPMI. Once the MTS reagent was added, plates were kept in incubator for 2 h to allow cells metabolize it and then the formation of formazan was quantified using the microplate reader, reading the absorption at 492 nm wavelength.




A pcDNA3 vector containing the cDNA encoding human IRS-1 (called IRS-1/pcDNA3) was kindly provided by Dr. Giorgetti-Peraldi (Nice, France). Alongside this vector, an empty pcDNA3 was used as a negative control (Invitrogen, cat. no. V795-20). The two vectors were introduced into a competent strain of E. coli bacterial cells using the following protocol. A map of the pcDNA3 vector is shown in Figure 2‑1.
DNA concentration of the vectors was quantified using a Nanodrop-1000 spectrophotometer. 










Figure 2‑1. DNA map of the pcDNA3 vector and of its multiple cloning site region
The plasmid presents a gene expression promoter taken from the Cytomegalovirus (CMV) just upstream the multiple cloning site (MCS). The MCS features different restriction sites that can be used to clone exogenous DNA sequences in the vector itself. 
pcDNA3 vector confers the resistance to the antibiotic ampicillin and to the drug G418 thanks to two resistance-conferring genes that are included in the construct, indicated respectively as “Ampicillin” and “Neomycin” in this vector map.

2.4.2	Plasmid isolation from bacteria through Maxi Prep
The Qiagen Plasmid Maxi Prep kit (Qiagen, cat. no. 12263) was used. The kit provides several buffers and plasticware that are written in bold in the text below.

The protocol is the following:
1.	The bacterial suspension was poured into a plastic centrifuge bottle and spun down for 15 min at 6000xg at 40C.
2.	The supernatant was discarded and the bacterial pellet was resuspended in 4 ml of Buffer P1 (containing RNAase), then 4 ml of Buffer P2 were added, the suspension was vigorously mixed and incubated at room temperature for 5 min. 
3.	4 ml of cold Buffer P3 were added, followed by gently mixing by inversion and incubating on ice for 15 min.
4.	The suspension was then centrifuged for 30 min at 20000xg at 40C. Afterwards, the supernatant containing the plasmid DNA was removed promptly, placed into a new tube and centrifuged again at the same speed but for only 15 min.
5.	The supernatant was then transferred into a Qiagen-tip 500 column (previously equilibrated with 4 ml of Buffer QBT that was allowed to drain by gravity flow) and allowed to enter the column by gravity flow.
6.	The column was then washed twice with 10 ml of Buffer QC.
7.	Finally, the vector DNA was eluted from the column by adding 5 ml of Buffer QF. The flow through containing the DNA was harvested into a clean plastic tube. 
8.	The DNA was then precipitated by adding 3.5 ml of room-temperature isopropanol, mixing and centrifuging promptly at 15000xg for 30 min at 40C. 
9.	The DNA pellet was washed with 2 ml of 70% ethanol and centrifuged at 15000xg for 10 min, the supernatant was then carefully removed without disturbing the pellet.
10.	The pellet was left to air-dry for 10 min and then dissolved in 20 l of TE buffer by carefully rinsing the plastic tube walls to minimize DNA loss. The DNA yield was determined by reading the nucleotide concentration in the Nanodrop-1000 spectrophotometer.

2.4.3	Stable cell transfection 
Empty pcDNA3 and pcDNA3 containing the human IRS-1 cDNA were stably transfected into NCI-H2085 and NIH:OVCAR-3 cancer cell lines. 
Two 6-well plates were plated with both cell lines, each well with 2x105 cells. The cells were left to grow in complete media for 24 h. The wells containing the cells were then divided into three groups, each composed of three wells: one group receiving the empty pcDNA3 vector, one group receiving the IRS-1/pcDNA3 vector and one control group.
The FuGENE 6 transfection reagent (Roche, cat. no. 11 815 091 001) was used to prepare a FuGENE/vector DNA complex at a ratio of 3:2 (i.e. for each well to transfect, 3 l of FuGENE 6 were mixed with 2 g of vector DNA or 2 g of TE buffer 1X for the controls) diluted into 97 l of serum-free culture media (not containing antibiotics), to reach a final volume of 100 l. The culture media was added first into an Eppendorf tube followed by the FuGENE 6 reagent (avoiding contact between the tip containing the reagent and the Eppendorf walls before the tip was immersed into the culture media, as suggested by the protocol because FuGENE 6 reagent has high affinity with plastic materials) and then the DNA. The mix was quickly vortexed and then left to incubate at room temperature for 15 min.  
100 l of mix were then added to each well containing the cells in a drop-wise manner, by swirling the plates to ensure and even distribution over the entire well surface. 
The cells were then left to incubate for 48 h, followed by detachment and transfer into a separate medium-size cell culture flask containing complete culture media plus antibiotics and 0.8 mg/ml of the selection agent G418 (known also as Geneticin; Invitrogen, cat. no. 11811-031). The cells were kept in culture using complete culture media complemented with G418 for 45 days. The culture media was changed regularly and fresh G418 was added each time. At the end of this selection period, the flask were expected to contain only the cells that had stably incorporated the empty pcDNA3 or the IRS-1/pcDNA3 into their genomic DNA, whereas all the mock-transfected control cells should be killed.




The standard RNA interference (RNAi) technique relies on the use of artificially produced long double strands of RNA (dsRNA) with sections complementary to a specific mRNA, termed target mRNA. When these double-stranded RNA sequences are introduced into cells, these can be processed by cellular virus infection defence mechanisms and cleaved into shorter portions (Hannon, 2002) (Figure 2‑2). 
Tailor-made artificial short interfering RNA (siRNA) can also be synthesized and directly introduced into living cells (Dorsett & Tuschl, 2004). Using this mechanism, a drastic decrease in the expression of a targeted gene is achievable. Studying the effects of this decrease can show the physiological role of the gene product. Since RNAi may not totally abolish expression of the gene, this technique is sometimes referred as a "knockdown", to distinguish it from "knockout" procedures in which expression of a gene is entirely eliminated (Voorhoeve & Agami, 2003). The knockdown of the target gene achievable with the use of siRNA is always transient and depends on many factors such as siRNA stability, target mRNA turnover rate, transfection efficacy and others. It is possible though, with optimization of the transfection protocol, to obtain stable knockdown for up to 3-6 days without causing unspecific toxicity side effects on cellular proliferation.

Figure 2‑2. Schematic view of mechanism of RNAi for gene expression silencing
RNAi or post-transcriptional gene silencing is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes (Hannon, 2002). RNAi can be exploited to experimentally manipulate gene expression in living cells.
When dsRNA is introduced into a cell, it is recognized by the cellular anti-viral defence system comprising Dicer enzyme as a potential viral infection. A complex molecular splicing machinery then assembles and processes the dsRNA into shorter interference RNA (siRNA). These shorter double stranded RNA molecules can be synthesized and introduced directly into a cell by means of viral vectors or transfection of the cell. siRNAs are then separated into the two RNA single strands and the RNA sequence bearing the antisense nucleotide sequence (i.e. complementary to the sequence of the target mRNA) is integrated into the multimolecular RNA Induced Silencing Complex (RISC). This enzymatic complex recognizes and cleaves the mRNA target molecule, thereby transiently inhibiting its translation and eventually the target gene expression. Eventually, siRNA sequences are degraded through different cellular catabolic pathways, leading to progressive recovery of target mRNA and protein level in the cell.
Image taken from http://en.wikiversity.org/wiki/RNA_interference (​http:​/​​/​en.wikiversity.org​/​wiki​/​RNA_interference​).
2.5.2	Preparation of cells
Cells were seeded in 6- or 96-well plates depending on the aim of the experiment. To evaluate the RNA interference efficacy through Western blot analysis of target protein expression a sufficient amount of cell protein extract was needed. In this case, 105 cells were seeded on each well of a 6-well plate. To measure the target protein knockdown effects on cell phenotypes such as cell proliferation rate or response to drug treatment using the MTS assay method, 5x103 cells were seeded in each well of a 96-well plate. In both cases cells were left to adhere in complete media for 18-24 h. The supernatant was then removed and replaced with either serum-free or serum-containing fresh media plus diluted transfection reagents. 
2.5.3	Preparation of RNA interference reagents 
RNA transfection reagent Dharmafect 1 (DF1) and siRNAs were diluted separately in antibiotic- and serum-free media prior to be mixed together and left for 20 min at room temperature protected from direct light. Serum-free or serum-containing media was then added to reach the final concentration solution. In general the final concentration of siRNA was 100 nM unless otherwise stated whereas final DF1 concentration was between 0.05-0.2 % of total volume (0.05-2 l/ml), based on the optimization of the preliminary experiments (data not shown).  
2.5.4	Preparation of inhibitors
The effect of several inhibitors on cells targeted with RNA interference was assayed. These inhibitors were included in the serum-free or serum-containing media used to dilute the DF1-siRNAs complexes. 

2.6	CELL STIMULATION WITH GROWTH FACTORS AND TREATMENT WITH INHIBITORS
2.6.1	Stimulation of NIH 3T3 cells with PDGF and LPA alone or in combination (§ 5.1.3)
3x106 of NIH 3T3 cells were plated on cell culture plates (15 cm diameter) and left to adhere and grow for 24 h. Following this period, the cells were serum-starved (i.e. in 0% FCS) for 16 h and treated with PDGF (final concentration: 20 ng/ml) or LPA (final concentration of LPA: 1 M), alone or in combination. DMSO was added to cells treated with PDGF (since LPA was diluted in DMSO) in order to reach the same final concentration of DMSO in all the plates. DMSO was also added as control (without any other growth factor) in one of the plates. The cells were then harvested and lysed according to the co-IP protocol described in § 2.7.3. A co-IP reaction was then performed by immunoprecipitating PDGFR, and the immunoprecipitate samples were then analyzed by Western blotting (using a big SDS-PAGE apparatus) as described in § 2.8. 

2.6.2	Pre-treatment of NIH 3T3 cells with GPCR and Ras inhibitors and stimulation with PDGF (§ 5.1.4) 
NIH 3T3 cells were incubated with different inhibitors before being stimulated with PDGF.  Briefly, 3x106 NIH 3T3 cells were plated on each of 10 plates (15 cm diameter) and left to adhere and grow for 24 h. Following this period, the cells were grown for 16 h in media supplemented with 0.5% FCS and containing one of the tested drugs (i.e. PTX, FPT or Gallein) or control-treated with DMSO-only. DMSO was also added to cells treated with FPT (that was dissolved in water) in order to reach the same final concentration of DMSO in all the plates. The final concentration of the inhibitors was the following: PTX= 100 ng/ml; FPT= 5 mM and Gallein= 10 mM.
Following this passage the cells were stimulated with PDGF (final concentration: 20 ng/ml) for either 10 min or 30 min. The cells were then harvested and lysed according to the co-IP protocol described in § 2.7.3 and the recruitment of p110α, p110β p85α and p85β was measured by Western blotting.

2.6.3	Acute stimulation of MCF-7, NIH:OVCAR-3 and PC-3 cancer cell lines with FCS (§ 5.2.4)
1x106 cells of each cell line were plated on four cell culture plates (10 cm diameter), and left to adhere for 6 h. The cells were then serum-starved overnight, followed by 2 h incubation with DMSO, LY294002 (5 mM) or TGX-221 (0.1 mM) and then 15 min stimulation with FCS (5% final concentration). The cells were then harvested and lysed and the cell lysates processed for Western blotting analysis. 

2.6.4	Acute stimulation of MCF-7, MDA-MB-468, NCI-H2085 and NIH:OVCAR-3 cancer cell lines with FCS (§ 5.4.2) 
3x106 cells of each cell line were plated on two cell culture plates (15 cm diameter), and left to grow for 24 h. Following this the cells were serum-starved for 16 h, and then half of the plates (one for each cell line) were stimulated with 5% FCS for 15 min, then harvested and lysed. The total protein extracts were quantified and used to prepare the samples for the Western blotting analysis.

2.6.5	Treatment of the cancer cells with Rapamycin and MG-132 (§ 5.4.2) 
The cancer cells were plated on 10 cm diameter plates (1x106/plate) and left to grow for 24 h in complete culture media. For the Rapamycin experiment, four plates in total of PC-3 cells were prepared for this experiment. Rapamycin was then added to each plate (final concentration: 10 nM), and the cells were left in the presence of Rapamycin for the indicated amount of time before being harvested and lysed. DMSO was used as a negative control. The total protein extracts were then quantified and used to prepare samples for Western blot analysis. The resulting membrane was incubated with antibodies recognizing the indicated proteins. The bands corresponding to IRS-1 were quantified through computer-assisted methods and normalized with tubulin, to account for mistakes in the gel loading procedure.
For the MG-132 experiment, MCF-7, MDA-MB-468, NCI-H2085, PC-3 and NIH:OVCAR-3 were used. Each cell line was plated on two plates (10 cm diameter; 1x106 cells/plate). The cells were left to grow for 24 h in complete culture media, then MG-132 (10 mM) was added to one of the two plates of each cell line, whereas the other received DMSO. The cells were left in incubation for 16 h and then they were harvested and lysed, following the procedure already described. The total protein extracts were processed for the Western blot analysis, and the resulting membranes were incubated with antibodies recognizing IRS-1 and vinculin. 

2.7	Cell lysis and immunoprecipitation 
2.7.1	Cell lysis
DMEM or RPMI media were removed and the cells were rinsed twice with ice-cold PBS. Complete cold lysis buffer (0.3 ml/107 cells) containing protease and phosphatase inhibitors was then added onto the cells and these were harvested using a cell scraper and incubated for 10 min on a rotating wheel at 4°C (placed in a refrigerator). The cell suspension was then centrifuged at 13000 rpm for 12 min using a refrigerated centrifuge. Afterwards, the supernatant was moved to a new Eppendorf tube and its protein concentration was quantified using the Bio-Rad protein concentration assay (§ 2.8.1).   
2.7.2	Immunoprecipitation
For each sample 1 mg of total protein extract was used to perform an immunoprecipitation experiment. Briefly, 30 μl of protein A- or protein G-coupled sepharose beads prewashed in lysis buffer were used to preclear each sample by incubation for 2 h at 4oC to eliminate proteins binding aspecifically to the sepharose beads. Subsequently, samples were briefly spun down at 3500 rpm for 2 min and supernatants were transferred into a new set of Eppendorf tube containing either fresh protein A or protein G sepharose beads and the primary antibody or beads only (negative control). Incubation was performed for 4 h on a rotating wheel at 4°C. Samples were spun down at 2000 rpm and briefly washed three times with lysis buffer with spinning down at 2000 rpm. Finally, 20 μl of Laemmli buffer was added to the washed beads which were then boiled for 5 min at 95oC, to denaturate the proteins and detach them from the sepharose beads and to disrupt the interaction between the immunoprecipitated protein and other cellular proteins. The samples were then run on a SDS-PAGE gel as described in § 2.8.2 below.

2.7.3	Co-immunoprecipitation
1 mg of total protein extract was used for each sample analyzed. The general protocol followed for co-immunoprecipitation (co-IP) studies is similar to the protocol described in § 2.7.2, but with a series of noteworthy exceptions. In particular, to preserve the integrity of the multiprotein complexes, a different lysis buffer (termed co-IP buffer) was used. The composition of the IP and the co-IP buffers is described in § 2.1.4. The components that are peculiar to the co-IP buffer are the detergent Igepal (instead of Triton X-100) and the 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), that is a zwitterionic pH-buffering agent. The choice to use Igepal as non-ionic detergent and HEPES (compared to Tris.HCl) to maintain the optimal pH during cell lysis and the co-IP process was based on a series of preliminary experiments made to optimize the whole procedure (data not shown).
The cell lysis protocol used for the co-IP experiments is also different from the one described in the previous sections. 
When cell lysis was performed prior to co-IP, the cells were washed with ice-cold PBS buffer and then directly harvested in ice-cold PBS using a cell scraper. The cell suspension was then centrifuged for 2 min at 1500 rpm and washed again with ice-cold PBS. The supernatant PBS was aspirated and the cold co-IP lysis buffer was added to the cells. 100 l of lysis buffer were added on 106 cells. The cells were resuspended in lysis buffer and transferred into a new set of Eppendorf tubes, and then they were left in ice for 30 min (without agitation). The cell suspension was then centrifuged for 10 min at 10000 rpm in a refrigerated centrifuge. The supernatant was transferred in a new set of Eppendorf tubes and processed for immunoprecipitation, as described in § 2.7.2 above.

2.8	protein analysis procedures
2.8.1	Quantification of protein extracts
 The protein concentration of the lysate samples was quantified through a colorimetric assay using the Bradford protein assay dye reagent, which is based on the differential change of color of the reagent itself in relation to the protein concentration of the samples tested. 2 μl of lysate was added to 1 ml of Bradford dye reagent, the samples were briefly mixed and their absorbance was measured at 595 nm using a spectrophotometer Cary 50 Bio (Varian Inc., cat. no.  0010068900). The instrument was calibrated using serial dilutions of albumin. To obtain a blank reading necessary to account for the basic absorbance of the reagents and the solutions used, the optical density of 2 μl of lysis buffer mixed with 1 ml of Bio-Rad dye reagent was read at 595 nm, and the value obtained was then automatically subtracted from the reading of each protein sample. To account for the dilution of the protein lysate samples, the value of each reading was finally multiplied by the dilution factor (500) to obtain the protein concentration in mg/ml.
2.8.2	SDS-PAGE
The stacking and the running gels were prepared as follows. The running gel was prepared first and left to solidify. After that, the stacking gel was poured over and a specific plastic comb was used to cast the wells for the loading of the samples. For small gel casting and running the BioRad Mini Protean®3 System apparatus (BioRad, cat. no.  165-3301) was used. Large gels were prepared and run using a Hoefer SE-400 vertical SDS-PAGE apparatus system (Amersham Pharmacia Biotech).
Both the SDS-PAGE systems were used in conjunction with a Hoefer PS500X power supplier (Amersham Pharmacia Biotech).
To monitor the electrophoretic separation of the protein samples loaded on the polyacrylamide gels a protein molecular weight ladder was used. The marker used was the Prestained All-Blue Precision Plus Standard Molecular Weight (Bio-Rad, cat. no.  161-0373). 
The protein samples containing lysis buffer and Laemmli buffer were boiled for 5 min at 95°C and then each sample was loaded into one of the wells of the stacking gel. For large gels 100 μg of sample was loaded per well whereas on small gels the maximum amount loaded per well was 60 μg. 16 l of protein molecular weight marker were also loaded into a well to allow for the monitoring of the electrophoresis progression. Both the large and the small gel systems were run at room temperature. For large gels the voltage used was 60 V and run overnight, whereas the small gel system was run at 100 V for 2 h.
2.8.3	Electroblotting
Following SDS-PAGE, proteins were transferred by electroblotting from the poly-acrylamide gel onto a PVDF membrane (ImmobilonTM-P, Millipore). The PVDF membrane was first briefly washed with ethanol and then rinsed with ddH20. Both the gel and the membrane were soaked in transfer buffer and placed between two layers of Whatman 3M paper and two sponges, which had also been washed briefly in transfer buffer. The stacked layers of the sponges, the Whatman paper, the poly-acrylamide gel and the PVDF membrane was finally placed into the plastic grid of the electroblotting apparatus, then placed into a blotting tank containing sufficient transfer buffer to make sure that the entire contact surface between the poly-acrylamide gel and the PVDF membrane was constantly below the liquid level. The plastic grid was placed into the blotting tank so that the membrane was on the anode (positively charged) side of the electric circuit. For small gels the BioRad wet electroblotting system was used, and the voltage used was 100 V for 75 min keeping the transfer buffer cold by putting a plastic tank containing an ice block into the blotting tank. For large gels the Hoefer apparatus was used, and in this case the protein transfer procedure occurred at 60 V for 4 h at 4oC. 

2.8.4	Incubation of blot with secondary antibodies, protein visualization and band quantification
Once the electroblotting of the protein was complete, the resulting PVDF membrane was incubated for 1 h in a solution of 5% powder milk dissolved in TBS-T. The membrane was then rinsed with TBS-T to remove the excess milk and incubated overnight at 4°C on a rocking platform with the primary antibody diluted in a TBS-T solution containing 3% BSA and 0.05% sodium azide. The following day, the membrane was washed three times for 10 min with TBS-T and incubated for 1 h with the horseradish peroxidase (HRP)-conjugated secondary antibody diluted in TBS-T 5% milk at room temperature. The membrane was then washed three times for 10 min with TBS-T and finally incubated with ECLTM Western Blotting Detection Reagents (Amersham Biosciences) or home-made ECL for 2-3 min To conclude the procedure, the membrane was placed between two layers of cling film (Saran, UK) and exposed to super RX Fuji medical X-ray films (Fuji) in a dark room using a Konica Minolta SRX-101A film processor. 
Where indicated, the bands shown on developed films were quantified to perform statistical analysis. The developed films were scanned using a BioRad PowerLook scanner and related software (BioRad, 2100XL-USB), obtaining the optical density (OD) value for each band under analysis. Furthermore, the optical volume (OV) of each band was calculated by multiplying each OD for the band area expressed in mm2, and the optical volume values were then used for subsequent data manipulation and statistical analysis, by calculating the standard error of the mean (SEM), where indicated, or the standard deviation (SD) in the other cases.   

2.8.5	Stripping of blotted PVDF membrane
The PVDF membrane was washed twice for 5 min in ddH20 and then soaked in guanidine hydrochloride stripping buffer, prepared as described in § 2.1.5. The membrane was left in contact with guanidine hydrochloride until the membrane had become transparent (requiring about 10-20 sec). Membranes were then thoroughly washed twice for 5 min in ddH20 and three times for 5 min in TBS-T until no traces of stripping buffer were left and the PVDF membrane had ceased being transparent.  Membranes were saturated again in TBS-T solution containing 5% milk before a new incubation with a different primary antibody.

2.9	REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (RT-PCR) ANALYSIS 
2.9.1	Isolation of total RNA 
All the procedures adopted for the isolation, handling and storage of total cellular RNA extract were performed following strict good laboratory practice (GLP) rules, to minimize the degradation of RNA due to the contamination of ribonuclease (RNAse) enzymes that are commonly found in the environment. All the centrifuges, pipettes and bench surfaces were wiped clean using RNAseZap (Sigma) cleaning agent. The total RNA from the cell lines was extracted using RNeasy Plus RNA Extraction Kit (Qiagen). This kit provides several buffers and plasticware that are written in bold in the following text.
Briefly, 3x106 cells were seeded onto 6 cm diameter plates and maintained in complete culture media for 16 h. The growing medium was then aspirated and the cells were washed twice with ice-cold FCS. 350 l of RLT Plus lysis buffer, to which -mercaptoethanol (-ME) was added before commencing the procedure (10 l of -ME per 1 ml of Buffer RLT Plus), was added to each 6 cm plate, and the plates were manually agitated to make sure that all the cells adhering to the plate surface were in contact with the lysis buffer. This procedure was sufficient to provoke the detaching of the cells from the plates, and the resulting suspension of cells was harvested and transferred into a QIAshredder spin column placed in a 2 ml collection tube. The spin column was then centrifuged for 2 min at maximum speed at room temperature using a bench centrifuge, and the homogenized lysate was transferred to a gDNA Eliminator spin column. The column was placed in a 2 ml collection tube and centrifuged for 30 sec at 8000xg. The flow through was added with 350 l of 70% ethanol and mixed by pipetting. The solution was then transferred to an RNeasy spin column placed in a 2 ml collection tube and centrifuged for 15 sec at 8000xg. The flow through was discarded and 700 l of Buffer RW1 were added to the RNeasy spin column and it was again centrifuged for 15 sec at 8000xg. After discarding the flow through, 500 ml of Buffer RPE were added to the column and again centrifuged for 15 sec at 8000xg. The same procedure was repeated another time but with a centrifugation of 2 min at 8000xg to wash the spin column membrane. The RNeasy column was finally placed in an Eppendorf tube and 40 l of RNase-free water were added onto the column, followed by a centrifugation for 1min at 8000xg to elute the RNA from the column.
The total RNA yield and purity was assessed using a Nanodrop-1000 spectrophotometer (Thermo Scientific). To assess the quality of the isolated DNA, two analytical parameters are commonly used, that is the absorbance ratios 260 nm/280 nm and 260 nm/230 nm, that are automatically measured by the machine following each concentration reading. Nucleotides, RNA and DNA all absorb at 260 nm and contribute to the total absorbance.
The ratio of absorbance at 260 nm and 280 nm is used to assess the purity of DNA and RNA. A ratio of ~1.8 is generally accepted as “pure” for DNA; a ratio of ~2.0 is generally accepted as “pure” for RNA. If the ratio is appreciably lower in either case, it may indicate the presence of protein, phenol or other contaminants that absorb strongly at or near 280 nm.
The 260 nm/230 nm is a secondary measure of nucleic acid purity, and its value for “pure” nucleic acids is often higher than the respective 260/280 value. Expected 260/230 ratios are commonly in the range of 2.0-2.2. A much lower value could indicate the presence of organic contaminants that have not been properly removed following the nucleic acid isolation procedure.
The total RNA was kept at -200C for long-term storage.
 
2.9.2	Reverse Transcriptase reaction
Total RNA was used to derive complementary DNA (cDNA) from the messenger RNA (mRNA) pool. 2 g of total RNA was used for each sample analyzed. The RNA was incubated for 5 min at 65oC with 1 l of oligo(dT) oligonucleotides (500 g/ml, Invitrogen), 1 l of dNTP mix (each dNTP at 10 mM concentration, Promega) and RNAse-free sterile water to reach the volume of 13 l. After this passage the mix was immediately placed on ice, then 4 l of First-Strand Buffer (250 mM Tris-HCl, pH 8.3 at room temperature; 375 mM KCl; 15 mM MgCl2, Invitrogen) and 2 l of dithiothreitol (DTT) (1 mM, Invitrogen) were added and the mix was incubated for 2 min at 420C. Afterwards, 1 l of Superscript II Reverse Transcriptase (RT) enzyme (Invitrogen) was added to each sample and incubated for 50 min at 420C.
Finally the reverse transcriptase reaction was stopped by incubating the mix for 15 min at 700C. The cDNA obtained was kept at -200C for long-term storage.
2.9.3	Polymerase Chain Reaction





dNTP Mix (2 mM each dNTP)(Fermentas, cat. no.  R0241)	5 l
PCR Reaction Buffer 10x(Clontech, cat. no.  639142)	5 l
Taq polymerase enzyme(Clontech, cat. no.  639142)	0.25 l
Primer 1 (10 M)(Eurofins MWG Operon, see below)	2 l
Primer 2 (10 M)(Eurofins MWG Operon, see below)	2 l

For analysis of human IRS-1 cDNA, the following set of oligonucleotide primers was used (the nucleotide base sequence of all the oligonucleotides described below is given following 5’ to 3’ direction):
huIRS-1F1 (forward): CTTCTGTCAGGTGTCCATCC
huIRS-1R1 (reverse): CTCTGCAGCAATGCCTGTTC
Both the primer sequences and the PCR reaction protocol used to identify the human IRS-1 cDNA (see below PCR program 2) were taken and adapted from  ADDIN EN.CITE (Huang, et al., 2002). 
IRS1-F2 (forward): GTGGGGCTGCTGGGGGTTTG
IRS1-R1 (reverse): CGGTGGTGGGCACATCAGCTC
These two primers were designed using primerBLAST software available at the following Web address:
http://www.ncbi.nlm.nih.gov/tools/primer-blast/ (​http:​/​​/​www.ncbi.nlm.nih.gov​/​tools​/​primer-blast​/​​)
The primers were designed so that the amplificated sequence would span the junction region between exon 1 and exon 2 of human IRS-1 mRNA, in order to avoid any possible unspecific amplification of the non-matured (i.e. before the splicing process takes place) human IRS-1 primary transcript or the equivalent genomic region of the human IRS-1 gene.     
To assess the presence and the quality of the cDNA obtained from each sample a PCR reaction for the detection of human actin cDNA (a housekeeping gene which is commonly expressed in most cell types) was performed in parallel with any other PCR reaction. The following primers were used:
huActinFor: ACCACTGGCATCGTGATGGAC
huActinRev: AGGTAGTTTCGTGGATGCCACA
All these oligonucleotide primers were purchased from Eurofins MWG Operon. 
Once the PCR reaction mix was prepared and the cDNA was added, the reaction tubes were placed in a 96-well Peltier Thermocycler PTC-200 PCR machine (MJ Research) and the following PCR programs were used:
1.	human Actin cDNA PCR
940C    1 min
940C    30 sec
620C    30 sec       35 cycles
720C    30sec
720C    7 min
The expected size of the amplicon is 420 bp.

2.	human IRS-1 cDNA PCR with the primer couple huIRS-1F1/ huIRS-1R1
940C    30 sec
940C    30 sec
560C    30 sec       35 cycles
720C    30 sec
720C    7 min
The expected size of the amplicon is 311 bp.

3.	human IRS-1 cDNA PCR with the primer couple IRS1-F2/IRS1-R1
940C    1 min
940C    30 sec
620C    30 sec        35 cycles
720C    30 sec 
720C    7 min
The expected size of the amplicon is 552 bp.
To identify the amplified target the PCR products were loaded on a 2% agarose gel and subjected to an electrophoretic separation of the DNA amplicons contained in the post-PCR reaction mix. Briefly, 3 g of agarose powder were poured in 150 ml of TE buffer and the suspension was placed in an Erlenmeyer flask. The agarose powder in the TE buffer was heated in a microwave oven and occasionally stirred by agitation. Once the agarose powder was completely dissolved and no particle suspension was visible the solution was left to cool down for about 5 min, then 50 l of ethidium bromide (undiluted stock) were added to the solution that was then poured into a suitable plastic gel tray containing one or two plastic combs. The solidified agarose gel was removed from the casting tray and placed into a suitable gel electrophoresis tank. 
Before loading the DNA samples into the agarose gel, 8 l of DNA loading buffer were added to each DNA sample, then 20 l of each sample were loaded into a well. Along with the DNA samples, 18 l of DNA ladder molecular weight marker were loaded in a well onto the same gel, to facilitate the monitoring of the electrophoresis progression as well as to allow the broad recognition of the double-stranded DNA amplicons basing on their molecular weight.
The agarose gel was periodically observed under UV light using a Dual Intensity Ultraviolet Transilluminator (UVP, model no. GDS 7500). When the distance between the bands of the molecular weight ladder was judged sufficient to allow a sufficiently precise detection of the expected amplicon, a photograph was taken using the camera built into the transilluminator apparatus. 

2.9.4	Isolation of PCR products, sequencing and sequence analysis
To confirm the identity of the PCR products detected upon electrophoresis analysis on agarose gels, the DNA corresponding to the bands observed at the expected molecular size was isolated and subjected to nucleotide sequencing. The sequences obtained through this process were then compared to the target sequences described in on-line databases. 
Briefly, the PCR reactions were loaded onto a 2% agarose gel and electrophoretic separation was performed as described before. Once the target band, corresponding to the expected molecular weight, was sufficiently separated from the rest of the background bands, the agarose gel was placed onto an UV/visible transilluminator (UVP; model M20) and visually observed by protecting the eyes with an UV filter (Bolle’; model EN 166 9B). Using a scalpel the target band was accurately excised from the agarose gel and placed into an Eppendorf tube, aiming to minimize the total amount of agarose gel containing the DNA band. The agarose gel fragment containing the target DNA amplicon was then weighed and subjected to DNA extraction process through the use of a QIAquick Gel Extraction Kit (Qiagen, cat. no. 28704). Briefly, the agarose gel fragment was incubated at 50oC for 10 min upon continuous agitation in the buffer QG provided in the Qiaquick Kit. Three volumes of QG buffer were added to one volume of gel, considering 100 mg of gel ~100 l volume. Once the gel fragment was completely solubilized, one volume of isopropanol was added and the mixture was loaded onto a QIAquick spin column provided in the Kit. The column was centrifuged using a benchtop microcentrifuge for 1 min at maximum speed and the flow through was discarded. The DNA content of the solubilized agarose gel fragment was bound to the column and it was washed by adding 0.75 ml of Buffer PE (provided in the Kit) and centrifuging the column for 1 min at maximum speed. Finally, the DNA was eluted from the column by adding 50 l of Buffer EB (provided by the Kit, containing 10 mM Tris.HCl, pH 8.5) to the column and centrifuging for 1min at maximum speed. 
The concentration of the eluted DNA was measured by using a Nanodrop-1000 spectrophotometer (Thermo Scientific). 
A sample of the huIRS-1F1 PCR product was then sequenced by Eurofins MWG Operon (Company Website: http://www.eurofinsdna.com/products-services/custom-dna-sequencing/value-read-tube.html (​http:​/​​/​www.eurofinsdna.com​/​products-services​/​custom-dna-sequencing​/​value-read-tube.html​)).





The aim of this study was to investigate the role of the p110 isoform of PI3K in cell signalling using in vitro models of human and murine cell lines. To achieve this objective, the study focused on three aspects of p110 signalling, namely the molecular determinants of the sensitivity to p110 inhibition in human cancer cell lines, the characteristics of p110 recruitment and activation downstream of the PDGFR and the interaction between the p85 and the p110 PI3K subunits. The relevant literature that provided the background information as well as the conceptual framework for this research has been presented in the introductory section of this work. 
This project is part of a collaboration with AstraZeneca (AZ) Oncology, UK, and stems from a series of preliminary observations made by this company. Collaborators at AZ screened a large (>100) panel of human cancer cell lines using high-throughput techniques, aiming to find cell lines whose proliferation was blocked by three p110 inhibitors (early development stage compounds) derived from diverse chemical series and with an IC50 (enzyme) in the low nanomolar range. 





4	CONCEPTUAL BACKGROUND AND HYPOTHESIS
4.1 Analysis of the recruitment of p110 downstream RTK
An important role for p110 downstream GPCR has been recently reported (Guillermet-Guibert, et al., 2008), but the possibility that p110 can also be active downstream RTKs can not be excluded. Indeed, it has been suggested that p110 is recruited and activated by the PDGFR although it is not the main PI3K isoform responsible for the functional downstream signal transduction, as this role is covered by p110in the model system where this has been investigated, such as endothelial porcine cells and NIH 3T3 cells  ADDIN EN.CITE (Hooshmand-Rad, et al., 2000; Roche, et al., 1998). 
The recruitment of p110 to the activated PDGFR is not surprising, given that this receptor recruits PI3K through direct interaction between its tyrosine-phosphorylated intracellular domain and the p85 regulatory subunit. An interesting hypothesis is that such interaction could be modulated by the input deriving from the GPCR network. In turn, the activation of p110 may influence the recruitment of other PI3K isoforms, particularly p110, to the active PDGFR, and effect the signalling output downstream this receptor. In this sense, although not the main PI3K isoform to transduce downstream RTKs, p110 may still have a role as a regulator of the signalling activity downstream this class of cellular receptors. In other words, p110 may help to co-ordinate GPCR and RTK signalling. Indeed, published data suggest that p110 can be synergistically activated by G subunit and phosphotyrosyl peptide based on the IRS-1 amino acid sequence  ADDIN EN.CITE (Kurosu, et al., 1997; Okada, et al., 1996). I have investigated the role of p110 downstream PDGFR at different time points following the stimulation of with PDGF, to explore whether:
1.	p110 can be recruited to active PDGFR;
2.	p110 recruitment to PDGFR is influenced by GPCR signalling
3.	p110 activity can regulate the signalling output of p110 downstream active PDGFR.

4.2 Analysis of the binding between the class I PI3K regulatory and catalytic subunits 
It has been shown that the regulatory and the catalytic subunits of PI3K mainly exist in a heterodimer (Geering, et al., 2007a). Cell-based overexpression studies have suggested that each p85 isoform can bind each p110 isoform (Vanhaesebroeck, et al., 1997b), but the relative preference of the p85 isoforms for the different p110s in physiological systems has not been investigated in detail. It is not known whether the binding between the p85 and p110 isoforms in a physiological context occurs randomly (i.e. the likelihood of each regulatory subunit isoform to couple to any catalytic subunit is similar and the abundance of a given couple only depends on the relative expression of the subunit isoforms) or if there is any preferential interaction. In other words, if this binding was random, the proportion of a given regulatory isoform that is bound to each catalytic subunit should reflect its relative amount in the total cellular pool of regulatory subunits. I have therefore measured the relative p85 and p110 isoform distribution in p85/p110 complexes in a panel of human cancer cell lines by co-immunoprecipitating the class IA catalytic (p110, p110 and p110) and regulatory (p85 and p85) subunits. 
The data obtained have been also analyzed in the context of p110 sensitivity of cancer cell lines. In other words, I sought to verify whether there was a relation between the sensitivity to p110 inhibition and the relative binding of p85 to p110.   
I hypothesized that the p110-sensitive and the p110-resistant cancer cell lines could differ in terms of the relative binding between p110 and the two regulatory isoforms p85 and p85, and that the response to p110 inhibition could be (at least in part) due to a selective binding of p110 with either p85 subunit when forming the dimeric holoenzyme. As an example, it has been shown that the phosphorylation dynamics of p85 and p85uponinsulin stimulation in immortalized murine brown adipocytes is different, as p85 becomes more phosphorylated than p85  ADDIN EN.CITE (Kruger, et al., 2008). The phosphorylation of p85 proteins is thought to positively stimulate PI3K activity by relieving the inhibitory effect of the p85 subunit on the catalytic moiety  ADDIN EN.CITE (Cuevas, et al., 2001). Based on this background information, one could expect that in the p110-sensitive cancer cell lines p110 be preferentially coupled to p85, the more active p85 isoform, as this would explain the increased dependence on p110-generated signalling. On the contrary, in the p110-resistant cells p85 may be found preferentially coupled to p110, thus dispensing these cells from the inhibitory effects of p110 inhibitors (but not pan-PI3K ones).   

4.3	Analysis of the molecular determinants of the response to p110 inhibition in a panel of human cancer cell lines

4.3.1	Background information and conceptual framework
The preliminary screening of AZ was performed on cells cultured in complete culture media, and the ability of such inhibitors to downregulate PI3K pathway activation (by monitoring phosphorylation of specific downstream targets of PI3K such as Akt/PKB, GSK3 and S6) was also screened in a small subset of these cell lines. This led to the identification of nine cancer cell lines that displayed sensitivity to p110 inhibition. Six of these cell lines have been used for the work described in this thesis, namely MDA-MB-468 (breast cancer), NIH:OVCAR-3 (ovarian cancer), NCI-H2085 (lung cancer), PC-3 (prostate cancer), A2058 (melanoma) and HCC70 (breast cancer), along with a panel of four p110-resistant cell lines that were used as controls. Three of these resistant (according to AZ) cell lines were used for most of the experiments: MCF-7 (breast cancer), HCT-116 (colon cancer) and U87-MG (brain cancer). A fourth resistant cell line, BT474, was also included in the experiments on p85/p110 binding (presented in § 5.3). 
The published work related to all these human cancer cell lines was reviewed to identify any useful connection with the possible roles of p110 isoform in cancer biology. This literature has been discussed in the introduction but it is summarized here again. This information was combined with recent results published by our Centre to put forward the following project framework.
1.	A link between PTEN deficiency and sensitivity to p110 inhibition has been found in human cancer cell lines and in murine models of prostate and breast cancer  ADDIN EN.CITE (Edgar, et al.; Jia, et al., 2008; Torbett, et al., 2008; Wee, et al., 2008). For this reason, by performing literature research and through personal communications from collaborators I grouped together the available data on the mutational and amplification status of the PTEN, PIK3CA and PIK3CB genes to obtain a view of the genetic traits of the cancer cell lines. This information is presented in Table 4‑1.
It is important to note that the published data and the AZ findings suggest that the correlation between the lack of PTEN function and the sensitivity to p110 inhibition was not absolute. In other words, there were cases of PTEN-negative, p110-resistant cancer cell lines and vice versa, although the PTEN-negative cell lines were clearly more represented in the p110-sensitive category. Indeed, six out of nine (67%) p110-sensitive cancer cell lines were PTEN negative while only nine out of 60 (15%) p110-resistant cancer cell lines were PTEN negative.   











Table 4‑1. Summary of the human cancer cell lines identified by AstraZeneca as resistant or sensitive to p110 inhibition
The human cancer cell lines that were identified as resistant to p110 inhibition are indicated in yellow, whereas the cancer cell lines that showed sensitivity to p110 inhibition are in blue. The histological origin and the mutation status of PTEN PIK3CA and PIK3CB genes are also indicated. 
For each PTEN-null cancer cell line the known inactivating point mutation or genetic rearrangement is indicated (AZ, personal communication). 
Note that the NCI-H2085 lung cancer cell line does not present mutations in the PTEN gene but PTEN protein expression could not be revealed by Western blotting by our AZ collaborators. Therefore this cell line has been catalogued as “PTEN null”. 
Legend: p110-R= resistant to p110 inhibition; p110-S= sensitive to p110 inhibition; HM= homozygous mutation; HT= heterozygous mutation; del= gene deletion; [long]= a mutation that is related to the longer splicing variant of a gene. 

2.	Our laboratory has recently found that p110mainly signals downstream of GPCRs (Guillermet-Guibert, et al., 2008), whereas p110 is mainly activated by tyrosine kinase pathways, and is selectively recruited to IRS proteins downstream of the insulin receptor where it is activated  ADDIN EN.CITE (Foukas, et al., 2006; Knight, et al., 2006). 
3.	A negative feedback loop exists between the active S6K1 and S6K2 proteins and IRS docking proteins, leading to downregulation of expression and activity of IRS-1 and possibly of IRS-2, although the latter point is still debated  ADDIN EN.CITE (Harrington, et al., 2004; Shah & Hunter, 2006; Shah, et al., 2004) (Figure 4‑1). S6K1 is phosphorylated and activated by the mTORC1 complex, which comprises mTOR, regulatory associated protein of mTOR (Raptor), mammalian LST8/G-protein β-subunit like protein (mLST8/GβL) and PRAS40  ADDIN EN.CITE (Kim, et al., 2002).  
IRS-1 has been recently established as a proteolytic target of the CUL7 E3 ubiquitin ligase following activation of mTOR and S6K (Xu, et al., 2008). IRS-1 is the main IRS isoform to relay proliferative signals from extracellular stimuli such as insulin and IGF-1 via their tyrosine kinase receptors through binding of the p85 regulatory subunit of class IA PI3Ks  ADDIN EN.CITE (Byron, et al., 2006; Jackson, et al., 1998; White, 1997), and a reduction in its expression and functionality can attenuate the downstream signalling pathways. 
Furthermore, it has been shown that the loss of PTEN in human cancer cell lines (including U87-MG, MDA-MB-468 and PC-3 cell lines, comprised in AZ screening and used for the work described here) blocks IR/IGFR-dependent signalling by reducing the expression, the stability or the functionality of several components of this signalling pathway, including IR, IGFR and IRS-1 (Lackey, et al., 2007).

4.3.2	Hypothesis




Figure 4‑1. A model of negative feedback loop signalling downstream RTK in cell lines lacking functional PTEN
(A) Current understanding of signalling activity downstream insulin and IGF-1 receptor involving recruitment of PI3K to phosphorylated IRS-1 and production of PIP3, with consequent activation of Akt. Downstream activation of S6K1 leads to functional downregulation and degradation of IRS-1 through a negative feedback loop. S6K phosphorylates IRS-1 committing it to ubiquitin-dependent degradation via proteasome processing.
(B) Proposed model of “signalling switch” between p110 and p110 PI3K isoforms in cancer cell lines lacking functional PTEN. Chronic activation of Akt/mTOR/S6K signalling pathway, caused by the accumulation of PIP3 in the cell membrane, leads to downregulation of IRS-1 and p110 signalling. The cell becomes more dependent on GPCR-triggered p110 activity, and therefore is more sensitive to inhibition of p110. 

Based on the data above, several scenarios - not mutually exclusive - can be envisaged to determine cellular sensitivity to p110 inhibitors.
	1. Incapacity to use IRS/p110 signalling 
a.	IRS-1 downregulation can result from many different conditions such as increased negative feedback loop signalling due to chronic Akt/S6K activity (e.g. when PTEN is inactive). The lack of PTEN activity, which leads to activation of the PI3K pathway, could result in chronic upregulation of the mTOR/S6K1 signalling pathway and induce the negative feedback loop described above, thus causing IRS downregulation and a specific decrease of p110 signalling activity. Cells would therefore have to switch to GPCR stimuli for transducing pro-survival and growth signals, with p110 becoming the key PI3K isoform in these cells (Figure 4‑1B). 
However, as already discussed, not all cancer cell lines with defects in PTEN were sensitive to p110 inhibition and therefore other parameters are likely to be equally or more important. Some of these are mentioned below. 
b.	Lack of IRS expression could make cells a priori sensitive to p110 inhibitors, given that these cells are not capable of signalling through the insulin-IGF/IRS/p110 pathway, and therefore rely on p110. This may apply to the p110-sensitive cell line MDA-MB-468, which has been reported not to express IRS-1, and be caused by chromosomal rearrangements of the IRS-1 gene locus due to genomic instability in cancer cells  ADDIN EN.CITE (Jackson & Yee, 1999). 
c.	Chronic impairment of IRS docking function could lead to reduction of signalling pathway activation downstream RTK, even if the protein itself is properly expressed. Such event could result from mutational inactivation or phosphorylation of multiple serine residues known to downregulate IRS activity without affecting its expression  ADDIN EN.CITE (Boura-Halfon & Zick, 2009; Tremblay, et al., 2007). 

2.	High expression levels of p110






























5.1	ANALYSIS OF THE RECRUITMENT OF p110 AND p110 TO THE ACTIVATED PDGFR
5.1.1	Introduction
p110β has been included in the class IA PI3K subgroup based on the fact that it is bound to p85 regulatory subunits. Class IA PI3Ks have been considered the isoforms responsive to Tyrosine kinase-dependent stimuli (e.g. originating from active RTK or Src-like family Tyrosine kinases), and it is known that p85s are widely recruited to phosphorylated tyrosine residues on these kinases. To the contrary p110γ, the only class IB PI3K, is sensitive to GPCR-driven activation  ADDIN EN.CITE (Stephens, et al., 1994; Stoyanov, et al., 1995). Regarding p110 convincing evidence suggesting that this isoform can also be stimulated by G subunits released by activated GPCRs has been reported  ADDIN EN.CITE (Guillermet-Guibert, et al., 2008; Kurosu & Katada, 2001; Maier, et al., 1999). These findings have therefore raised the question whether p110 has a dual role downstream both categories of signalling pathways (i.e. Tyr-kinase and GPCR). In other words, p110 may require both Tyr-kinase and GPCR-dependent stimulatory signals to achieve full activation, thereby representing an example of cross-sensitivity to signalling inputs generated by different signalling pathways.    
To further investigate the role of p110β in this context, I analyzed the impact of its selective inhibition in the context of PDGF signalling. I chose to investigate the role of p110β downstream PDGFR in NIH 3T3 fibroblastic cells that express p110α and p110β and are known to be responsive to PDGF stimulation (Yu, et al., 2001).

5.1.2	Selection of a p110-selective inhibitor
I first carried out a preliminary screening of the three p110-specific small molecule inhibitors that are available in our laboratory. The inhibition of Akt phosphorylation upon LPA stimulation in NIH-3T3 cells was used as readout for p110 inhibition, as LPA is known to stimulate p110 activity  ADDIN EN.CITE (Guillermet-Guibert, et al., 2008; Yart, et al., 2002). The three molecules tested were TGX-221, TGX-115 and TGX-155, which are chemically-related morpholine compounds derived from LY294002  ADDIN EN.CITE (Jackson, et al., 2005; Knight, et al., 2004). The results obtained (Figure 5.1‑1 and data not shown) suggested that all three compounds tested were equally able to abolish the induction of P-Akt. It was decided to use only TGX-221 in subsequent experiments because this compound is commercially available and it has been used in several published studies, thus allowing for a comparison with the results obtained by other authors.  

Figure 5.1‑1. Inhibition of P-Akt generation upon LPA stimulation using a panel of p110β inhibitors
A panel of three p110inhibitors (TGX-115, TGX-221 and TGX-155) was tested on NIH-3T3 cells growing in DMEM media supplemented with 10% FCS. The inhibitors were used at the indicated concentration. The PI3K inhibitor LY294002 (LY in the figure) was used as a positive control, whereas cells treated with DMSO only represented the negative control. Cells were serum-starved for 16 h followed by addition of the inhibitors. One hour later, LPA (1 M) was added for 5 min followed by cell lysis, SDS-PAGE and Western blotting for the indicated proteins or their phosphorylated version.

5.1.3	p110β is recruited to the active PDGFR - co-stimulation with LPA does not impact on recruitment of p110 or p110 to the PDGF-stimulated PDGFR
The first question was whether p110β can be recruited to the active PDGFR and to evaluate the impact of concomitant stimulation with PDGF and LPA on the recruitment of p110α and p110β. I carried out a series of time courses of cell stimulation, followed by immunoprecipitation of the PDGFR and immunoblotting for p110α and p110β. 
The results in Figure 5.1‑2 show that p110β can be effectively recruited to the active PDGFR, in line with published evidence  ADDIN EN.CITE (Roche, et al., 1998). As expected, p110α was also recruited to PDGFR. A peak of recruitment of the two p110 isoforms was reached around 5-10 min post-stimulus.
As can be seen from the summary figure 5.1.2B, the level of recruitment of p110α to the PDGFR at 30 min appeared to be significantly enhanced upon co-stimulation of PDGF with LPA, compared to stimulation with PDGF alone, but the overall recruitment profile was not significantly affected over the 60 min period (Figure 5.1‑2B). No significant differences were observed for p110 under those conditions.
Stimulation with LPA alone did not induce significantly recruitment of p110 or p110 to active PDGFR compared to control cells stimulated with DMSO. 
In conclusion, these data show that (1) p110 can become effectively recruited to the active PDGFR, and (2) that the profile of p110 and p110 recruitment to the active PDGFR is not significantly altered upon combined PDGF plus LPA stimulation of the cells.











Figure 5.1‑2. p110 can be recruited to the active PDGFR. Co-stimulation of NIH 3T3 cells with PDGF and LPA does not have a major impact on the recruitment p110 or p110 to the active PDGFR.




B. Top panel: mean and SEM values (i.e. the error bars) calculated from the three independent experiments presented in A. above. An unpaired t-test statistical test was performed to compare the mean values obtained upon the different treatments of the cells. The difference measured in the recruitment of p110 to PDGFR upon 30 min stimulation (i.e. between the recruitment upon PDGF plus LPA stimulation and PDGF alone) was the only data point found to be statistically significant. Bottom panel: Alternative representation of the data in top panel, in order to allow a better comparison of the recruitment of p110 and p110 upon stimulation with PDGF alone or upon co-stimulation with PDGF plus LPA.
This experiment has been performed three times. *= p<0.05 

To expand this analysis I also screened the recruitment of p110α and p110β upon a longer time course of stimulation, i.e. up to 6 h. I based this choice on some literature evidence reporting that, in human hepatoma cell line HepG2, an early (30 min) and late (4-6 h) wave of PIP3 production can be revealed upon continuous PDGF stimulation (Jones, et al., 1999). Moreover, it has also been reported that the activity profile of p110α and p110in transfected NIH 3T3 cellsoscillates (i.e. they present several peaks of activation at different time points) upon long-term serum stimulation  ADDIN EN.CITE (Marques, et al., 2008). In particular, p110β has been found to show an early (up to 1 h), intermediate (4 h) and late (7-8 h) activity peak post-serum stimulation, and the authors have claimed that such dynamic temporal regulation of p110α and p110β activity occurs to regulate cell cycle progression and proliferation. Based on this notion, I chose to co-stimulate NIH 3T3 cells with PDGF and LPA for up to 6 h, and then immunoprecipitate PDGFR and quantify the amount of the different PI3K isoforms (p110α, p110β, p85α and p85β) (Figure 5.1‑3).














Figure 5.1‑3. Time-course analysis of class I PI3K recruitment to active PDGFR
NIH 3T3 cells were co-stimulated with PDGF and LPA for the indicated amount of time, following by evaluation of the recruitment of the various p110 and p85 isoforms to PDGFR by co-IP. Control cells were treated with DMSO only.
A graphical representation of the results is shown. The values corresponding to the p110 and the p85 isoforms were normalized to the control (i.e. cells treated with DMSO).
This experiment has been performed twice.

5.1.4	Inhibition of GPCR- or Ras-mediated signalling in NIH 3T3 cells reduces the recruitment of p110β to the PDGF-stimulated PDGFR
Because p110β is the only class IA PI3K isoform activated by G subunits, I sought to investigate the impact of inhibition of GPCR-dependent signalling on p110β recruitment to the active PDGFR. I therefore pre-treated NIH 3T3 cells with two inhibitors of GPCR signalling, namely PTX and Gallein. I also included a Ras inhibitor (FPT), as it has been suggested that active Ras can stimulate PI3K signalling  ADDIN EN.CITE (Jimenez, et al., 2002; Rodriguez-Viciana, et al., 1996a; Rodriguez-Viciana, et al., 1996b). This experiment was performed in the presence of 0.5% FCS. Figure 5.1‑4 shows the results of a co-immunoprecipitation experiment similar to the one described in § 5.1.3. Cells were stimulated with PDGF for 10 min or 30 min and the recruitment of p110α and p110β to the PDGFR was evaluated. 
Pre-treatment of the cells with PTX or Gallein significantly reduced the recruitment of p110β to the active PDGFR, suggesting that GPCR signalling input is important for its recruitment. The recruitment of both p85α and p85β was also similarly affected, in line with the observation on the recruitment of p110 (data not shown). 
Also pre-treatment with FPT had a significant impact on the recruitment of both p110 isoforms, although the statistical significance of the reduction of p110 recruitment was more limited (p<0.05). 
















Figure 5.1‑4. Inhibition of GPCR or Ras decreases the recruitment of p110 to the active PDGFR
The recruitment of p110 to the active PDGFR is partially dependent on signalling input from GPCRs and Ras. A. Following pre-treatment with the indicated inhibitors in the presence of 0.5% FCS, NIH 3T3 cells were stimulated with PDGF for 10 or 30 min, and the recruitment of p110 and p110 to the PDGFR was evaluated by co-IP with the PDGFR, followed by western blotting for p110 or p110. The blots obtained were quantified and, for each time point of each of the three independent experiments (labeled I-III), the optical density of each p110 orp110 band was normalized to the corresponding PDGFR band. The signals corresponding to pre-treatment with each inhibitor were then normalized to the corresponding control (i.e. pre-treatment with DMSO), and graphed accordingly.
B. Graphs combining the results obtained from the three independent experiments. The graphs shown in A. were combined to calculate the mean and SEM values (expressed with the error bars). To evaluate the statistical significance of the observed variations in the recruitment of p110 and p110 to the active PDGFR, an unpaired t-test statistical test was performed. The reduction of p110 recruitment induced by pre-treatment with any of the inhibitors tested upon 30 min stimulation with PDGF was found to be significant. The reduction of p110 recruitment was significant only upon pre-treatment with FPT and 30 min PDGF stimulation. This experiment was performed three times. *= p<0.05; ***= p<0.001.
5.1.5	Isoform-selective inhibition of p110β does not have a significant impact on the recruitment of p110α and p110 to the active PDGFR 
Despite being recruited to the active PDGFR, p110β is not the main PI3K isoform to relay signals generated by this receptor, because such role is most likely played by p110α  ADDIN EN.CITE (Guillermet-Guibert, et al., 2008; Hooshmand-Rad, et al., 2000; Roche, et al., 1998). Nonetheless, I investigated whether the isoform-selective inhibition of p110β may have an impact on the recruitment of p110 to PDGFR upon PDGF stimulation. I therefore first examined whether pre-treatment of NIH 3T3 cells with the p110-selective inhibitor TGX-221 affected the recruitment of p110 and p110 to the active PDGFR (Figure 5.1‑5).
NIH 3T3 cells were starved overnight in 0.5% FCS, pre-treated with TGX-221 or DMSO in 0.5% FCS for 1 h, followed by stimulation with LPA, PDGF or a combination of the two ligands, as indicated. As can be seen from the summary in B of Figure 5.1-5, a tendency for reduced recruitment of p110 to PDGFR (upon 30 min activation with PDGF only or PDGF plus LPA) was observed following TGX-221 pre-treatment, although this effect failed to reach statistical significance. Moreover, no evidence of an impact of TGX-221 on p110 recruitment to the active PDGFR was obtained (Figure 5.1‑5 B). We concluded that pharmacological inhibition of p110 kinase activity does not significantly influence the recruitment of p11 or p110 to the PDGF-stimulated PDGFR. 
Interestingly, in this experiment, stimulation with LPA alone induced the recruitment of p110 and p110 to the PDGFR (lanes 2 and 8 in Figure 5.1‑5 A). This could be due to transactivation of the PDGFR by the LPA receptor (a GPCR), as discussed in §1.4.2. This result was unexpected and discordant with the findings presented in Figure 5.1‑2. It should be noted, however, that the experimental set up was not identical in these two experiments, as the cells used for the experiment shown in Figure 5.1‑2 were fully serum-starved (i.e. 0% serum), whereas the cells in Figure 5.1‑5 were starved in 0.5% serum and stimulated in the presence of 0.5% FCS. This small amount of FCS may have amplified the transactivation of PDGFR upon stimulation with LPA, effectively resulting in enhanced recruitment of p110 and p110 (Figure 5.1‑5). Pre-treatment with TGX-221 did not influence the LPA-induced recruitment of the p110s to PDGFR (lanes 3 and 9 in Figure 5.1‑5).
I next assessed whether p110 inhibition had repercussions on downstream signalling by PDGF and/or LPA. This was done by pre-treating NIH 3T3 cells with TGX-221 and then stimulating them with PDGF and LPA, either separately or together. The experiment was performed on NIH 3T3 cells starved in 0.5% FCS or in 0% FCS (Figure 5.1‑6).

 
Figure 5.1‑5. Inhibition of p110 kinase activity does not significantly reduce the recruitment of p110 or p110to the PDGF-stimulated PDGFR
A. Three independent replicate experiments were performed. NIH 3T3 cells were starved overnight in 0.5% FCS before being pre-treated for 1 h with TGX-221 (0.1 M) or DMSO, followed by stimulation (in 0.5% FCS) for 5 and 30 min with LPA (1 M), PDGF (20 ng/ml) or a combination of the two stimuli. The cells were then harvested and lysed and PDGFR was immunoprecipitated. The amounts of (co)immunoprecipitated PDGFR, p110 and p110werequantified by measuring the density of the p110 and p110 signals on the Western blot films. The values of each p110 isoform were then normalized to the corresponding PDGFR bands for each corresponding time point in each replicate experiment. The graphs shown on the right document the impact of pre-treatment with TGX-221 on the recruitment of p110 and p110 (expressed as the percentage of protein that is recruited upon TGX-221 pre-treatment compared to DMSO controls) induced by LPA and PDGF, either alone or in combination, for the indicated time points. Each data point has been calculated as the % of the corresponding control (i.e. cells pre-treated with DMSO), and the horizontal line is set at 100 to represent the expected value when TGX-221 pre-treatment would not affect the recruitment of p110 or p110(null hypothesis).














Figure 5.1‑6. Inhibition of p110 reduces LPA-induced Akt/S6K1 phosphorylation but its impact on PDGF-dependent signalling is less marked
NIH 3T3 cells were starved overnight either in 0% FCS (upper panel) or in 0.5% FCS (lower panel) before being incubated for 1 h with TGX-221 (0.1 M) or DMSO. They were then stimulated either with LPA (1 M) and/or PDGF (20 ng/ml) for the indicated amount of time. During this procedure the culture media used for the overnight starvation (containing either 0% FCS or 0.5% FCS) was left unchanged. The cells were harvested and lysed and the protein extracts were used to evaluate the signalling activity downstream PI3K through Western blotting for the indicated proteins. It was not possible to obtain a clear result for P-Akt (308) in the cells starved in 0% FCS upon 5 min of stimulation with LPA and/or PDGF.
This experiment has been performed once for 0% FCS starving condition and twice for 0.5% FCS-starved cells.

These results confirm that the phosphorylation of Akt/PKB and S6K1 upon LPA treatment (a GPCR stimulus) is primarily dependent on p110β lipid kinase activity, because in all starving conditions TGX-221 pre-treatment completely blocked the phosphorylation of Ser473 on Akt/PKB and of Thr389 on S6K1 (LPA-induced Akt phosphorylation on Thr308 could not be revealed in any of the conditions tested, likely due to technical issues with the antibody used for this work, as it has also been sporadically observed in other experiments, data not shown). 
In the cells starved in 0% FCS, TGX-221 treatment did not have any impact on Akt/PKB phosphorylation induced by PDGF alone or in combination with LPA. This result supports the hypothesis that p110 does not play a mayor role in RTK-mediated signalling and is in line with the findings published by Guillermet-Guibert, et al., 2008, which were obtained in NIH 3T3 cells starved in 0% FCS. On the contrary, a limited impact of TGX-221 on PDGF- and PDGF plus LPA-induced Akt/PKB phosphorylation (but not on P-S6K1) was evident in the cells starved in 0.5% FCS. This could be due to the portion of Akt/PKB phosphorylation generated (possibly through transactivation) by the residual GPCR-dependent growth factors that were present in the culture media used for cell starvation (containing 0.5% FCS). A strong reduction of PDGFR protein level was apparent in the cells starved in 0.5% FCS and co-stimulated with LPA and PDGF, confirming the co-IP data shown in Fig. 5.1.5 A. The observation of increased PDGFR degradation upon LPA plus PDGF stimulation, compared to PDGF alone, is in line with the LPA receptor-PDGFR transactivation hypothesis, as in response to enhanced PDGFR activation (due to GPCR-RTK cross-talk) its downregulation would be more marked.      
In conclusion, the experiments described here support the concept that p110β can be recruited to active PDGFR (despite being recently described as mainly responsive to GPCR activation) and that this event may be partially dependent on the input of Ras- and GPCR-dependent signalling 
To summarize, the experiments described so far (Figs. 5.1-2 to 5.1-6) were aimed at the investigation in NIH 3T3 cells of 
(i)	the recruitment of p110α and p110β to the PDGFR upon stimulation with PDGF and/or LPA
(ii)	the impact of GPCR and p110β activity on downstream signalling upon stimulation with PDGF and/or LPA. 
These experiments have now been performed two or three independent times with consistent results, allowing statistical analysis resulting in reliable mean and SEM values. 

Our data show that:
	p110β can be effectively recruited, alongside p110, to the PDGF-stimulated PDGFR; 
	pre-treatment with inhibitors of GPCR and Ras signalling significantly reduced the recruitment of p110β to PGDF-stimulated PDGFR in the presence of 0.5% FCS; 
	pre-treatment with the p110 inhibitor TGX-221 did not affect the recruitment of p110 to PDGFR in cells stimulated with PDGF, suggesting that p110 lipid kinase activity is not required for its recruitment to PDGFR. The inhibitory effect observed on the recruitment of p110α was statistically not significant. Pre-treatment with TGX-221 reduced Akt signalling downstream the PDGFR under these conditions (0.5% serum – see below). An identical outcome was observed upon stimulation of cells with PDGF + LPA.
	The results shown above indicate that inhibition of p110 can in some instances block PDGF-induced pAkt. This contrasts with our previously published work (Guillermet-Guibert, et al., 2008) that p110β does not signal downstream of the PDGFR. An important difference between the published work and the studies reported here is the concentration of FCS serum used in these experiments, namely 0% and 0.5% FCS, respectively. I therefore carried out an experiment in 0% serum, and found – in line with our published work - no impact of p110β inhibition on PDGF-induced Akt phosphorylation, but complete suppression of LPA-dependent signalling. As a co-author of the above paper, I had already performed similar experiments on serum-starved NIH 3T3 cells (not included in this thesis), and therefore carried out this experiment in this thesis only once, as it was in full agreement with our published data.
	Finally, an exploratory experiment was carried out to investigate the dynamics of p110 and p110 recruitment to the PDGFR upon long-term (up to 6 h) stimulation with PDGF (20 ng/ml). Published studies had reported that PDGF stimulation of serum-starved cells induces a biphasic synthesis of PIP3 production  ADDIN EN.CITE (Marques, et al., 2008). A first peak of PI3K activity is observed 30-60 min after the addition of PDGF or serum, and with a second peak of activity 4-8 h after stimulation. These authors did not investigate whether this correlated with a biphasic recruitment of p110α and p110β to the active PDGFR. I carried out such an experiment, in 0% FCS and in the continuous presence of LPA (1M), with a view to provide a defined RTK and GPCR stimulus, similar to Jones et al. (who used PDGF only, at a concentration of 50 ng/ml and in the presence of 0.1% FCS), but also to mirror the use of 10% serum in Marques et al.. The data obtained showed that:
o	as expected, the total amount of PDGFR that could be immunoprecipitated from cells decreased over time, most likely due to internalization and degradation of the PDGFR, with the corresponding reduced amount of co-immunoprecipitated p110 and p85. The observation that the recruitment of p110 and p110 mirrored the expression levels of total PDGFR, suggests that the variation of PGDFR levels and not a varying recruitment of p110 and p110may underlie the fluctuation of PI3K activity reported in literature. Given the very consistent negative result in two experiments, this experiment was not further repeated;
o	a major drop in PDGFR expression was observed upon 60 min stimulation, with some evidence for a low level of PDGFR re-expression around 4 h of stimulation. This is in line with the data presented in the original version of my thesis, apart from the fact that in this case, the amount of p85 bound to the PDGFR within 60 min of stimulation was directly related to the amount of p110 bound (unlike in the previous experiment where the amount of co-immunoprecipitated p85 was more variable); 
o	the recruitment of p110 to the active PDGFR peaked at an earlier time point than that of p110.
The biphasic PDGFR expression, and the fact that the recruitment of p110 and p110 mirrored the expression levels of total PDGFR, suggests that the variation of PGDFR levels may underlie the fluctuation of PI3K activity reported in literature, and not a variation of p110 and p110recruitment. Given the very consistent negative result, this experiment was only performed twice.

5.2	ANALYSIS OF THE FACTORS THAT DETERMINE THE SENSITIVITY TO p110 INHIBITION
5.2.1	Analysis of the sensitivity of cell growth and proliferation to p110β inhibition
As described in Chapter 2, some preliminary data were available from AZ when this thesis was started. These data showed that a subset of human cancer cell lines showed sensitivity to p110 inhibition. This was tested in presence of serum and upon 48 h of p110 inhibition. I first tested p110 sensitivity under a broader series of conditions. Cells were analyzed both in the presence of serum or serum starvation, upon 48, 72 and 96 h of incubation. The metabolic activity and proliferation of all eight available cancer cell lines was first assessed using the MTS approach. The pan-PI3K inhibitor LY294002 was included as a positive control and to determine the “maximum inhibitory effect” of cellular metabolism/proliferation achievable through inhibition of overall PI3K activity. Thus, the effect of TGX-221 treatment was benchmarked against LY294002 to draw a conclusion on its inhibitory potency. In other words, the eight cell lines were classified as “resistant” or “sensitive” to p110 inhibition based on the capacity of TGX-221 to reduce cellular proliferation to an extent comparable to LY294002.  










 Figure 5.2‑1. MTS cell growth and proliferation assay of human cancer cell lines
A. MTS signal of the indicated cell lines following incubation with the indicated doses of drugs, in the presence or absence of serum. Shown are two cancer cell lines which are representative of the p110-resistant (MCF-7) and -sensitive (NCI-H2085) cell lines. The cellular metabolic and proliferative activity was assessed after 48, 72 and 96 h of culture in presence of DMSO alone (control), pan-PI3K inhibitor LY294002 (5 M) or p110β inhibitor TGX-221 (0.05 M or 0.1 M). The experiment was performed either upon serum starvation (upper panels) or in the presence of 5% FCS. The MTS signal of the drug-treated cells is expressed as related to that of DMSO-treated (control) cells.
This experiment has been performed three times (both in the presence of serum and upon serum starvation) for each cancer cell line. Representative results are shown. 






Table 5.2‑1. Summary of the maximal inhibitory effect of LY294002 and TGX-221 on the eight cancer cell lines tested
The table shows the maximum cell growth and proliferation inhibitory effect observed upon LY294002 or TGX-221 treatment within the 48 to 96 h time range tested, both in presence or absence of serum. The values listed express the highest percentage of reduction in the MTS assay readout, related to control cells treated with vehicle (DMSO) only. Cell lines resistant to TGX-221 (TGX-R) are shown in yellow, whereas sensitive cell lines are shown in blue. The U87-MG cell line expressed an intermediate response to TGX-221 and is shown in green. The A2058 cell line (shown in red) was resistant to both TGX-221 and LY294002 and is therefore indicated as a “PI3K-resistant” (PI3K-R).
Legend. TGX-R: TGX-221-resistant. TGX-S: TGX-221-sensitive. LY-R: LY294002-resistant. LY-S: LY294002-sensitive. PI3K-R: resistant to both TGX-221 and LY294002.
Overall, the reduction of growth and proliferation of the p110-sensitive cell lines (labelled in blue in Table 5.2‑1) induced by TGX-221 was between 20-60% compared to 5-20% in the p110-resistant cell lines (yellow in Table 5.2‑1). On the other hand, all the cancer cell lines (excluding A2058) showed a reduction of cell growth and proliferation in the presence of LY294002 equivalent to 20-70% of control-treated cells. Taking into account the different combinations of serum concentration in media and the different time points at which MTS was performed, the cancer cell lines classified as “p110-sensitive” showed a maximum of 30-60% reduction of MTS signal upon serum starvation and 20-40% in presence of serum when treated with TGX-221, often at the lower dose (0.05 M) tested, and these values were not dissimilar to those obtained using LY294002 (Table 5.2‑1). 
It is interesting to note that the inhibitory effect of TGX-221 on the cell lines was milder in the presence of 5% serum compared to cells that were pre-starved of serum. The reason for this is not clear at the moment. It is possible that the presence of serum makes the cells intrinsically less dependent on p110 activity. Alternatively, serum may aspecifically reduce the amount of TGX-221 available to achieve full p110 inhibition, by binding and sequestering TGX-221, thus lowering its effective concentration. 








Figure 5.2‑2. A2058 is resistant to both LY294002 and TGX-221
This figure shows the results of the MTS assay of A2058 human melanoma cell line. The resistance to both LY294002 and TGX-221 was particularly evident in the cells growing in culture media complemented with 5% FCS.  This experiment has been performed twice.

The glioma cancer U87-MG was described as p110-resistant in AZ screening (Table 4‑1), but my experiments (Figure 5.2‑3) suggested an intermediate response to TGX-221 compared to LY294002. For this reason, U87-MG could not be clearly labelled as p110β-resistant or –sensitive cell line but rather “borderline” (Table 5.2‑1).


Figure 5.2‑3. U87-MG shows a mild sensitivity to p110 inhibition in MTS cell growth and proliferation assay
MTS signal in U87-MG cells upon the indicated period of treatment with LY294002 and TGX-221 at the indicated concentration. The protocol followed to perform such experiment is the same as for the experiment shown in Figure 5.2‑1. The MTS signal of the cells treated with the inhibitors was normalized to that of the control (i.e. treated with DMSO) cells. 
This experiment has been performed twice. 
5.2.2	Effects of long term inhibition of p110 in human cancer cell lines 
The analysis of the cell growth and proliferation of the cancer cell lines to PI3K inhibition was also extended to a longer drug treatment time point, i.e. 7 days, with replenishment of fresh drug after 4 days of growth (Figure 5.2‑4). 
For some cancer cell lines these results were different from those described in § 5.2.1 (Table 5.2‑2). In the presence of serum, long-term (168 h) TGX-221 treatment of NIH:OVCAR-3 (which showed sensitivity to TGX-221 in the shorter time experiment) increased the cell growth and proliferation. In the presence of 5% serum, the p110β-sensitive (according to the 48-96 h experiment) cells NCI-H2085 continued to show sensitivity to p110β inhibition, whereas when the experiment was performed upon serum starvation this cell line showed very low or no sensitivity to p110β inhibition. In other words, upon specific experimental conditions in some cases p110 inhibition had a positive effect on cell growth and proliferation. 













Figure 5.2‑4. Treatment of six human cancer cell lines for 7 days with LY294002 or TGX-221
The graphs show the representative results of the impact of continuous treatment of the indicated cell lines for 7 days (168 h) with LY294002 (5 M) and TGX-221 (0.05-0.1 M). The general experimental protocol followed were the same as for the experiments described elsewhere in the text, with the major difference that the culture media and the drugs were replenished after 96 h of growth. The experiment was performed either upon serum deprivation (upper panel) or in the presence of 5% FCS (lower panel). The cell growth and proliferation rates were measured by MTS assay. The MTS signal for each cell line is expressed as related to the DMSO-treated (control) cells.
This experiment has been performed three times for MDA-MB-468 and NIH:OVCAR-3 cells and twice for the remaining cell lines.


Table 5.2‑2. Summary of the effect of the different duration of TGX-221 treatment on the cell growth and proliferation of cancer cell lines
This table summarizes and compares the results of TGX-221 treatment of different duration (48-96 h versus 168 h) on cancer cell line growth and proliferation discussed in § 5.2.1 and § 5.2.2. The cell lines are colour-labelled as shown in Table 5.2‑1, according to their response to 48-96 h TGX-221 treatment. The cell lines resistant to TGX-221 are labelled in yellow, the cell lines sensitive to TGX-221 are labelled in blue and the A2058 cell line, that is resistant to both TGX-221 and LY294002 treatment, is labelled in red.  
Legend. R: resistant to TGX-221; S: sensitive to TGX-221 (the number in brackets indicates the % of reduction of cell growth and proliferation compared to control); low S: low sensitivity to TGX-221; ↑: increased cell growth and proliferation upon TGX-221 treatment (the number in brackets indicates the % of increase compared to control); PI3K-R: resistant to both TGX-221 and LY294002.

The observation of positive effects upon TGX-221 treatment on cell growth and proliferation was sporadically made throughout the experimental work reported here, and in some cases was clearly identifiable as a specific consequence of the inhibition of p110β. As an example, Figure 5.2‑5 shows the results obtained using MDA-MB-231, a human breast carcinoma cell line.  A strong increase (up to 50% compared to control-treated cells) in cell growth and proliferation was observed upon 4 days of TGX-221 treatment, particularly at lower doses (i.e. 0.05-0.1 M). These unexpected observations, as well as the potential implications in the understanding of the role of p110β in cell signalling, are discussed in § 6.5.  
The response of MDA-MB-231 cells to TGX-221 and LY294002 treatment was evaluated during the preliminary phases of this work and this cancer cell line was not further used. 


Figure 5.2‑5. Cell growth and proliferation analysis of MDA-MB-231 cells treated with various doses of TGX-221
MDA-MB-231 cells were characterized as described for the other cancer cell lines described so far. The cells were treated for 96 h with DMSO, LY294002 (5 M) or TGX-221 (0.05-0.3 M). The experiment was performed in the presence of 5% FCS and the cell growth and proliferation rates were measured by MTS assay. The MTS signals of the cells treated with the drugs were normalized to that of the cells that received DMSO only (controls).
This experiment has been performed twice.

5.2.3	 Analysis of the effect of pertussis toxin on growth and proliferation of cells 
Following the experiments described above, the available cancer cell lines were tested for their sensitivity to PTX, a drug widely used to interfere with GPCR signalling. PTX catalyzes the ADP-ribosylation of the α subunits of the heterotrimeric G proteins Gi, Go, and Gt. This prevents the G proteins from interacting with GPCR at the cell membrane, thus interfering with intracellular communication (Ribeiro-Neto & Rodbell, 1989). Since p110β is thought to relay signalling stimuli downstream GPCR, I predicted that the cancer cell lines sensitive to TGX-221 would show some sensitivity to PTX as well. Indeed, the results shown in Figure 5.2‑6 suggest that three cancer cell lines sensitive to TGX-221 were also inhibited by PTX, although to a lower extent, and an additive effect was observed when both TGX-221 and PTX were used. 
Overall, the data obtained from the treatment of the various cancer cell lines with TGX-221 and PTX broadly confirmed the data obtained by AZ (with some exceptions, described elsewhere in this work) and permit a classification of such cell lines on the basis of their sensitivity to p110 inhibition, as shown in Table 5.2‑3. 


Figure 5.2‑6. MTS cell growth and proliferation assay analysis of response to TGX-221 and PTX treatment of six different cancer cell lines
The indicated cancer cell lines were tested for their sensitivity to TGX-221 or PTX treatment through MTS assay. The results for each cell line are expressed related to DMSO-treated (control) cells.
The upper panel shows results obtained with TGX-221-resistant cell lines, whereas the lower panel relates to the TGX-221-sensitive cells. TGX-221 was used at a concentration of 0.1 M and PTX at 100 ng/ml. The results shown here are representative of two independent experiments performed for each cell line.
Statistical significance: **p<0.01; ***p<0.001.


Table 5.2‑3. Summary of the maximal inhibitory effect of LY294002, TGX-221 and PTX on eight cancer cell lines (% of reduction in cell growth and proliferation compared to vehicle-treated cells)
The numbers in this table express the maximal reduction (in percentage) of the cell growth and proliferation observed in the MTS assay experiments described earlier in the text.
The cell lines shown in yellow where found to be resistant to p110 inhibition, whereas those shown in blue were sensitive to p110 inhibition. The U87-MG cell line had an intermediate response to p110 inhibition and is shown in green. The A2058 cell line (shown in red) was resistant to both TGX-221 and LY294002 and is therefore indicated as a “PI3K-resistant” (PI3K-R).
Legend. N/D: not determined. TGX-R: TGX-221-resistant. TGX-S: TGX-221-sensitive. LY-R: LY294002-resistant. LY-S: LY294002-sensitive. PI3K-R: resistant to both TGX-221 and LY294002.

5.2.4	Akt/S6K1 pathway signalling analysis in MCF-7, NIH:OVCAR-3 and PC-3 cancer cell lines
To further investigate the effect of p110 inhibition on cell growth and proliferation, I performed a series of experiments to assess the impact of p110 inhibition on intracellular signalling in p110-sensitive cancer cell lines (tested in the MTS assay). I chose two sensitive cells lines NIH:OVCAR-3 and PC-3 and the resistant MCF-7 as a control. Given the crucial role of Akt/S6K1 pathway as a transducer of pro-growth and proliferative signals, it can be expected that the sensitivity to TGX-221 treatment at the cell growth and proliferation level is accompanied by an equal sensitivity at the level of intracellular cell signalling.
FCS was chosen to acutely stimulate the cell lines, as it is a complex mixture of Tyr-kinase- and GPCR-dependent extracellular stimuli (thus allowing a global appreciation of the impact of p110 inhibition) and that it better reflects the experimental conditions that were used for the MTS assay experiments (conducted either in presence of serum in the culture media or upon serum deprivation).
The cells were serum-starved overnight and then stimulated with 5% FCS. The results are shown in Figure 5.2‑7.  
In line with p110 sensitivity determined by MTS assay, FCS-induced P-Akt/PKB signalling in NIH:OVCAR-3 and PC-3 was strongly inhibited by TGX-221, whereas MCF-7 was resistant (but responded to LY294002). A similar pattern was observed for P-S6K1. Erk phosphorylation was not affected by inhibitor treatment. Note that it was not possible to detect Erk phosphorylation in PC-3 cells, possibly due to an intrinsic difficulty of these cells to activate Erk in response to extracellular stimuli. It has indeed been reported that P-Erk response in PC-3 cells is defective upon stimulation with insulin, IGF-1 and PDGF, although cells respond to EGF (Lackey, et al., 2007).
Therefore, the observed reduction in cell growth and proliferation as assessed in MTS assay is likely to be caused by the inhibition of Akt/S6K signalling upon isoform-selective p110 inhibition.


Figure 5.2‑7. Correlation between p110β sensitivity defined on the basis of inhibition of cell growth and proliferation (Table 5.2‑1) and p110β sensitivity to inhibition of acute signalling
MCF-7, NIH:OVCAR-3 and PC-3 cells were used for this experiment. The cells were serum-starved overnight, pre-treated with the indicated drugs and then stimulated with FCS. 
This experiment has been performed three times.
5.2.5	Screening of the expression of various signalling components in the cancer cell lines
To begin the analysis of the molecular determinants of the sensitivity to p110β inhibition, I chose to perform a general screening of the eight available cancer cell lines by immunoblotting for different components of the PI3K pathway. I evaluated the expression of all class I PI3K catalytic isoforms as well as p85α, p85β, IRS-1 and IRS-2 and PTEN (Figure 5.2‑8).
The results on PTEN (and its phosphorylated version) confirmed the preliminary data shown in Table 4‑1. The only cell lines that were found to express PTEN at detectable levels were the p110β-resistant MCF-7 and HCT-116 and the p110-sensitive NIH:OVCAR-3. These findings further highlighted the strong (but not perfect) correlation between p110-sensitivity and the lack of PTEN expression. The data related to PTEN expression in the p110β-sensitive NCI-H2085 confirmed the preliminary information shown in Table 4‑1, as this cell line was found to lack PTEN protein expression despite presenting a WT PTEN gene. Therefore, NCI-H2085 functionally is a PTEN-negative cancer cell line. 
The expression of the four class I PI3K catalytic isoforms was variable among the cell panel, and did not reveal any clear correlation with the p110 sensitivity. This result was unexpected since preliminary information obtained by AZ suggested that the PIK3CB gene is amplificated (e.g. up to seven gene copies in NCI-H2085) in most of the p110β-sensitive cancer cell lines (Table 4‑1). Therefore, the data on p110β protein expression do not support the intuitive hypothesis that p110 sensitivity correlates with a high level of p110 protein expression. 
The expression of p85α and p85β was quite variable and suggested that the p110β-sensitive cell lines expressed comparatively less p85α than the control cell lines. For this reason I hypothesized that the relative expression of the two main p85 isoforms (p85α and p85β) and, more importantly, their binding with p110β may have a role in the determination of the p110β-sensitivity in the cancer cell lines analyzed. This line of investigation is described in §5.3.
Interestingly, the blotting of IRS-1 and IRS-2 documented that the p110β-sensitive cancer cell lines lack (or have a greatly reduced) IRS-1 expression, although they express IRS-2 to level comparable to the control cell lines. This striking correlation between defective IRS-1 expression and p110β sensitivity was further investigated as described in § 5.4 to 5.6.







Figure 5.2‑8. Western blot screening of PI3K pathway components in eight cancer cell lines






5.3	ANALYSIS OF THE ASSOCIATION BETWEEN THE CLASS IA p110 PI3K AND THE p85 ISOFORMS
5.3.1	Introduction
To further analyze the molecular determinants of the sensitivity to p110β inhibition observed in a subset of cancer cell lines, I investigated the association between the regulatory and the catalytic subunits of the functional dimeric PI3K holoenzyme. In particular, I analyzed the association between the three class IA catalytic isoforms (p110, p110 and p110) and the two most abundant class IA regulatory isoforms, namely p85 and p85. Whether there is any selective association between different p85 species and different p110 isoforms has thus far not been comprehensively addressed.
If the binding between the p110 and the p85 isoforms occurs randomly, the relative abundance of any specific p85-p110 dimer is expected to be determined by the relative abundance of each component in the cell, therefore a more abundant p85 or p110 isoform should be more represented in the total pool of the PI3K dimeric holoenzymes. Alternatively, it is possible that the binding between p85 and p110 is not random. 

5.3.2	Analysis of the binding between the p85 and the p110 subunits in human cancer cell lines
Seven human cancer cell lines were used for the experiments described below, three p110β-resistant (MCF-7, HCT-116, BT474) and four p110β-sensitive (MDA-MB-468, NIH:OVCAR-3, PC-3 and HCC70). The two cell lines BT474 and HCC70 have not been used in other sections of my work, but were included here because they were part of the preliminary screening performed by collaborators at AZ (Table 4‑1).  






Figure 5.3‑1. Experimental strategy used to investigate the binding between the p85 and the p110 subunits
The model of random binding between the p85 and the p110 subunits (shown in the upper panel) predicts that the ratio of p85 and p85 coupled to the p110 catalytic subunits is simply based on their relative abundance in the cell (measurable in the TCL), and therefore a similar p85/p85 ratio should be observed in TCL and the p110 IPs.
The model of non-random binding (lower panel), to the contrary, predicts that the ratio of the p85 isoforms coupled to the p110 catalytic subunits does not reflect their relative abundance in the cell.    

I reasoned that, by comparing the abundance of p85 and p85 in p110, p110 and p110 immunoprecipitates to their abundance in the TCL of each cell line, it was possible to investigate whether the binding between p85 and p110 subunits is random or selective across the panel of selected cancer cell lines. In the latter case, one would expect the p85/p85 ratio in the IP experiment to be significantly different from the equivalent ratio in the TCL.
TCLs were obtained from each cell line, and separate IPs were performed for p110, p110 and p110. The amount of p85 and p85 proteins bound to each p110 isoform was then measured by Western blot and quantified. In parallel, TCL samples were loaded on the same gel alongside the co-IP samples. For each cell line, all samples were loaded twice on the same gel and in the same order, and separately blotted for p85 and p85Figure 5.3‑2). By adopting this procedure it was possible to compare the ratio of p85 and p85 in the p110 immunoprecipitates and in the TCL. All the blots shown in Figure 5.3‑2 were then analyzed by optical scanning to produce a numerical value of the optical density of each band. Given that it was not possible to observe p85 recruitment to p110, a comprehensive analysis was only performed for p110 and p110. The p85/p85 ratio for TCL, IPp110 and IPp110 was then calculated for each cell line. Finally, the average and the standard deviation for TCL, IPp110 and IPp110 were derived, and the averages were cross-compared by a paired t-test (using GraphPad software). 
The results are shown in Figure 5.3‑3; the differences between the average ratios of IPp110x and the TCL were not statistically significant (p>0.05), thus arguing in favour of the random p85-p110 binding hypothesis. Moreover, there was no statistically significant difference between the p110-resistant and the p110-sensitive cancer cell lines, thus not supporting the hypothesis of a correlation between the relative p85/p110 binding and p110 sensitivity. A Pearson correlation test (using GraphPad software) performed on the whole panel of cell lines evidenced a significant correlation between the TCL and IPp110 (r=0.81; p=0.026) or IPp110r=0.81; p=0.028) values, suggesting that the p85/p85 ratios vary across the panel of cell lines in a concordant way. In other words, this statistical analysis suggested that high p85/p85 ratios in the TCL significantly correlated with high ratios in IPp110 and IPp110 and vice versaIn conclusion, the data presented here support the hypothesis that the binding between p85 and p110 subunits is a random process and based on the relative expression of the p85 and the p110 isoforms. Nonetheless some cancer cell lines, in particular HCT-116, MDA-MB-468 and PC-3, may present significant differences between the TCL and the IP ratios, although the experiment should be repeated with these cell lines to confirm. In retrospect, it would therefore have been better to choose a sigle cell line (i.e. HCT-116) and perform the experiment several times in order to reach statistical significance. Nonetheless, the approach I followed allowed the investigation of p85/p110 binding as well as the possible differences between the p110-resistant and p110-sensitive cancer cells.


Figure 5.3‑2. Analysis of the recruitment of p85 and p85 to the class IA PI3K catalytic subunit isoforms
Seven different cancer cell lines were included in the analysis. TCLs from cells exponentially growing in complete culture media were immunoprecipitated using antibodies to the indicated p110 catalytic subunit isoforms. Negative control samples were prepared by not including antibody in the IP reaction, and are indicated as beads only. The TCLs, together with the IP samples were then loaded twice on the same SDS-PAGE gel, and the resulting membrane was then divided in two and immunoblotted with antibodies to p85 or p85. Thus, no membrane stripping was performed. The membranes were then sequentially incubated with antibodies recognizing the three p110 isoforms to assess the isoform-selective immunoprecipitation event (lower left representative blot).




Figure 5.3‑3. The recruitment of p85 and p85 to p and p110 is based on the relative abundance of each isoform and does not correlate with p110 sensitivity
A. This table summarizes the values of the p85p85 ratio in the TCL and the IPp110x (based on the experiments shown in Figure 5.3‑2) in the seven cancer cell lines. These values were obtained by quantifying the Western blot bands for each cell line. The average and the standard deviation for each column of the table was then calculated and are indicated at the bottom of the table. The differences between the three average values were not statistically significant (p>0.05). The p110-resistant cell lines are shown in yellow, whereas the p110-sensitive ones (p110-S) are in blue.
B. Graphical representation of the p85/p ratios listed in A for each cell line. These values were used to determine the corresponding averages and standard deviations listed at the bottom of the table shown in A. The p110-resistant (p110-R) cell lines are labelled in black, whereas the p110-sensitive ones (p110-S) are in blue. The black dots indicate the results for the TCL, the red squares represent the data for IPp110 and the blue triangles the data for IPp110b. 
5.4	IRS-1 PROTEIN EXPRESSION AND INTERACTION WITH THE p85 SUBUNIT OF CLASS I PI3K
5.4.1	IRS-1/p85 co-IP analysis  
Following the proposed conceptual framework described in § 4.3.1, I chose to focus on the analysis of IRS-1 (and IRS-2) proteins in the cancer cell lines. The proposed model predicts that in the p110β-sensitive cells, the functionality of the RTK/IRS/p110 signalling pathway is compromised and the cell could compensate by switching to the GPCR-triggered p110 activity to maintain sufficient PI3K activity. I therefore wanted to further test if p110β sensitivity correlated with reduced or no expression of either one or both IRS isoforms, or a defect in IRS recruitment of PI3K. 
Reduced expression of IRS-1 in the TGX-221-sensitive cells was evident in the analysis of the total cellular lysates (Figure 5.4‑1 A; TCL lanes). The expression of p85, tested by blotting for this protein the total cellular lysates, showed comparable levels between the four cell lines but co-IP experiments revealed strongly reduced or no interaction between IRS-1 docking protein and p85.
The expression of the IRS-2 isoform was also measured using the same approach, as well as its interaction with p85 protein. IRS-2 expression in total lysates and immunoprecipitates was comparable between the four cell lines, but p85 recruitment to IRS-2 was low in all the four cell lines (Figure 5.4‑1 B). These data suggest that IRS-1 is the main isoform which recruits p85, whereas IRS-2 does not seem to be able to compensate in the cell lines described here. Indeed, it has been suggested that IRS-1, but not IRS-2, is the crucial isoform for proliferation and growth signals in breast cancer cell lines, whereas the latter is more important for regulation of breast cancer cell adhesion and motility  ADDIN EN.CITE (Jackson, et al., 2001). 
In summary, these results documented that three out of four p110-sensitive cell lines, namely MDA-MB-468, NCI-H2085 and NIH:OVCAR-3 have a defect in IRS-1 expression, suggesting that the defect of p85 recruitment to IRS-1 protein is a contributor to the observed phenotype of the p110-sensitive cancer cell lines. This defect seems to be due to reduced or absent expression of IRS-1 protein in these cell lines. 
The analysis of IRS-1, IRS-2 and p85 expression as well as recruitment of p85 subunit to the two docking proteins was also performed on HCT-116, A2058, U87-MG and PC-3 cell lines, in some cases upon insulin stimulation, to obtain broader evidence supporting the proposed hypothesis (Figure 5.4‑2, Figure 5.4‑3). The p110β-sensitive PC-3 cells, although expressing IRS-1, showed defective IRS-1/p85 interaction, similarly to the other p110β-sensitive cell lines. Results observed in U87-MG cells (that are partially p110-sensitive or “borderline”; see Figure 5.2‑3) were similar to those of the p110β-sensitive cell lines, as IRS-1 expression and IRS-p85 interaction were undetectable. IRS-1/p85 interaction was detectable in the p110β-resistant HCT-116 cells. A2058 was the only p110β-resistant cell line (Table 5.2‑3) that did not show expression of IRS isoforms and recruitment of p85 (Figure 5.4‑2A). Nonetheless, as already stated before, this cell line shows a resistance to overall PI3K inhibition. 
In conclusion, the results shown in Figure 5.4‑2 and Figure 5.4‑3 support the hypothesis that the sensitivity to TGX-221 correlated with defective expression of IRS-1 and recruitment of p85 and this was also evident upon acute insulin stimulation. 
















Figure 5.4‑1 IRS-1 and IRS-2 expression and p85 recruitment in cancer cell lines
A. Western blot showing co-immunoprecipitation of IRS-1 and p85 proteins in four cancer cell lines. Cells were harvested upon exponential growth (70% confluence) in complete (10% FCS) media. Cell protein extracts were used to perform a IRS-1 immunoprecipitation.  Total cell lysates samples from the same cell lines were also loaded on the same gel, along with the immunoprecipitation reactions performed without any antibody (as negative control).  Following SDS-PAGE, immunoblotting was performed using anti-IRS-1 and anti-p85 antibodies. Anti-tubulin antibody was used to assess equal loading of the TCL.






        
Figure 5.4‑2. Recruitment of p85 to IRS-1 upon insulin stimulation




Figure 5.4‑3. IRS-1 and IRS-2 expression in U87-MG and PC-3 cell lines and recruitment of p85
A. Western blot analysis of IRS-1 expression and p85 recruitment in U87-MG and PC-3 human cancer cell lines. Cell extracts were obtained and processed as described in the legend to Figure 5.4‑1. IRS-1, IRS-2 and p85 were blotted using the same antibodies, although this time it was not possible to reveal IRS-1 expression in total cellular lysates. This problem appeared from time to time using anti-IRS-1 antibody for immunodetection on total cell extracts.
B. Western blot showing the results related to the IRS-2 isoform.


Table 5.4‑1. Summary of data on IRS-1/p85 recruitment, PTEN function and TGX-221 sensitivity
The maximal observed values of cell growth and proliferation reduction upon LY294002 treatment in the cancer cell lines are expressed as a percentage of the controls (see Table 5.2‑3). Also shown are the data on PTEN expression, IRS-1 binding with p85 and the response p110β inhibition as determined in my investigation.

5.4.2	Analysis of the activity of the Akt/S6K1/IRS-1 negative feedback loop in the cancer cell lines
The results shown so far are in line with the hypothesis that the sensitivity to p110β inhibition in some human cancer cell lines is linked to a deficit of IRS-1 expression or function. 
As discussed earlier, one of the factors that can explain reduced expression or functionality of IRS-1 is the chronic activation of the Akt/S6K1 negative feedback signalling loop that negatively regulates IRS-1. Such feedback-signalling pathway can be chronically active (i.e. it is switched on even in the absence of extracellular stimuli) in the cancer cell lines where the lipid phosphatase activity of PTEN is reduced or absent. To assess if this scenario could be plausible to explain the observations described to this point, I analyzed the activity of Akt/PKB and S6K1 proteins in a panel of cancer cell lines either under proliferating condition in complete culture media or upon serum deprivation (Figure 5.4‑4). 
As the graph in Figure 5.4‑4B suggests, basal (i.e. upon serum deprivation) phosphorylation of S6K1 in three out of four p110β-sensitive cancer cell lines examined (MDA-MB-468, NIH:OVCAR-3 and PC-3) is higher (about 50% of the phosphorylation level in 5% FCS in PC-3, over 90% in MDA-MB-468 and NIH:OVCAR-3) than the equivalent value in the control cell line MCF-7 (19% of the phosphorylation level in presence of serum), suggesting that in these cancer cell lines Akt/PKB and S6K1 are chronically more active. In other words, S6K1 is more phosphorylated in these cells than in MCF-7 cells in the absence of extracellular stimuli. Such chronic activity may cause the downregulation of IRS-1 that has been observed in these cell lines. This concept was found not to be valid in the p110-sensitive NCI-H2085, as S6K phosphorylation was found to be comparatively lower upon serum deprivation and not dissimilar from the control p110-resistant MCF-7. Finally, to validate the generality of this conclusion one could check other p110-resistant cell lines such as HCT-116.  


Figure 5.4‑4. Cell signalling analysis in MCF-7, MDA-MB-468, NCI-H2085, NIH:OVCAR-3 and PC-3 cancer cell lines
A. The protein samples were blotted for the indicated proteins. A black arrow indicates the bands corresponding to P-Akt473. Four separate experiments (two for PC-3 cell line) to measure the level of P-S6K in the two culture conditions examined were performed. The rest of the blots (Akt, Erk and tubulin) were performed once.
B. Graph summarising the data on the ratio between the Western blotting signals of P-S6K upon 5% serum or serum deprivation growing conditions, measured by optical quantification of the bands corresponding to P-S6K as shown in A. 
To further verify the negative feedback loop hypothesis, I experimentally interfered with the signalling activity of S6K1 by treating the p110β-sensitive cell lines with Rapamycin, an inhibitor of mTOR signalling. By inhibiting S6K1 activation I sought to assess if expression of IRS-1 could be restored in the cancer cell lines sensitive to p110β inhibition. Only in PC-3 cells a modest increase of IRS-1 (up to a maximum of 1.5 folds) upon Rapamycin treatment was observed (Figure 5.4‑5), whereas no effect was evident in the other three p110-sensitive cell lines tested MDA-MB-468, NCI-H2085 and NIH:OVCAR-3 (data not shown). 
In parallel with this experiment I treated the p110β-sensitive cancer cell lines with MG-132, an inhibitor of proteasome-dependent protein degradation. Since one of the major effects of IRS-1 phosphorylation by S6K1 is its commitment to proteasome degradation, I reasoned that by inhibiting such mechanism I could observe an increase in IRS-1 protein in the p110β-sensitive cell lines. The results of this experiment are shown in Figure 5.4‑6, and indicate that only in MDA-MB-468 it was possible to observe an effective increase of IRS-1 protein upon MG-132.


Figure 5.4‑5. Treatment with Rapamycin in PC-3 increases IRS-1 protein expression
PC-3 cells were treated with Rapamycin (or DMSO as control) for the indicated time, followed by evaluation of IRS-1 expression by Western blotting. The IRS-1 bands were quantified and normalized with those corresponding to tubulin to generate the graph on the right side.
This experiment has been performed twice.

Finally, the phosphorylation status of IRS-1 in the p110β-sensitive PC-3 cells (compared to control MCF-7) growing in the presence of serum was analyzed. The aim was to assess whether in these cells IRS-1 could be highly phosphorylated on residues known to be S6K substrates (amongst others) and involved in the negative regulation of IRS-1. The hypothesis was that high IRS-1 phosphorylation (compared to a p110β-resistant cell line such as MCF-7) could explain why in PC-3 cells IRS-1 protein is expressed but it appears not to recruit p85 (Figure 5.4‑3). As already discussed in § 1.3.1, the phosphorylation of specific serine residues can result in IRS-1 degradation or functional downregulation, by impairing IRS-1 ability to recruit and activate downstream signalling molecules such as the p85 subunit of PI3K. One of the negative regulatory serine residues on IRS-1 known to be phosphorylated by S6K is Ser1101  ADDIN EN.CITE (Tremblay, et al., 2007). I therefore evaluated IRS-1 phosphorylation on this Ser residue in PC-3 and MCF-7 cells exponentially growing in serum-containing culture medium (Figure 5.4‑7), both in TCL and in IRS-1 IPs. No significant difference could be observed between MCF-7 and PC-3 cells in terms of IRS-11101 phosphorylation, excluding that the defective recruitment of p85 by IRS-1 in PC-3 cells could be attributed to increased IRS-1 phosphorylation on Ser1101.
In conclusion, the hypothesis that IRS-1 downregulation in the p110β-sensitive cancer cell lines is due to the overactive signalling of the Akt/S6K1, caused by the inactivation of PTEN, could not be documented in all cell lines investigated. The possibility exists that the experimental condition used to perform such experiments may not have been the optimal to reveal the increase in IRS-1 protein expression (following either Rapamycin or MG-132 treatment) in all the tested cell lines. 


Figure 5.4‑6. Effect on IRS-1 protein expression of inhibition of proteasome-mediated protein degradation by MG-132 
The indicated cancer cell lines were kept in complete culture media with the addition of MG-132 (10 M) or DMSO (control) for 16 h, followed by Western blot analysis. This experiment has been performed twice.  


Figure 5.4‑7. Analysis of IRS-1 phosphorylation in MCF-7 and PC-3 
The cells were kept in complete culture media and total protein extracts suitable for Western blotting and immunoprecipitation were obtained as described elsewhere. The TCL and IRS-1 IP samples  were loaded together on a gel and probed with the indicated antibodies. 
This experiment has been performed once.

5.5	STABLE TRANSFECTION OF NCI-H2085 AND NIH:OVCAR-3 CANCER CELL LINES WITH AN EXPRESSION VECTOR FOR HUMAN IRS-1

5.5.1	Analysis of IRS mRNA expression in p110-sensitive cancer cell lines 
The proposed hypothesis that the lack of IRS-1 protein expression in the p110-sensitive cancer cell lines is caused by the chronic negative activity of the Akt/mTOR/S6K negative feedback loop, based on the findings presented in § 5.4.1 and §5.4.2, predicts that these cells might be able to express the IRS-1 gene, but that the synthesized IRS-1 protein is degraded. In the case of PC-3 cell line, IRS-1 protein is expressed but it seems not able to functionally recruit p85 (Figure 5.4‑3). 
To verify whether the p110-sensitive cell lines express IRS-1 mRNA, an RT-PCR analysis was performed on MDA-MB-468, NCI-H2085 and NIH:OVCAR-3, using the huIRS-1F1 and huIRS-1R1 primers. The results, shown in Figure 5.5‑1, document that these cancer cell lines express IRS-1 mRNA. 
The oligonucleotide primers used to perform the experiment shown in this figure amplified a fragment of ~310bp, in line with the published results obtained with the same primers  ADDIN EN.CITE (Huang, et al., 2002). These results were confirmed using a different pair of oligonucleotide primers that amplify a different region (IRS1-F2 and IRS1-R1; Figure 5.5‑4). 


Figure 5.5‑1. p110-sensitive cell lines express IRS-1 mRNA
A. A RT-PCR analysis was performed on the indicated cancer cell lines using the RNeasy kit and procedure as described in the Materials and Methods. The total mRNA was extracted from the cell lines growing in complete culture media. The two primers used to amplify the region corresponding to IRS-1 cDNA were huIRS-1F1 and huIRS-1R1 (§ 2.9.3). This photograph depicts the resulting bands corresponding to the expected size of the amplified fragment of IRS-1 cDNA.
B. BLAST alignment of DNA sequence obtained for the PCR fragment amplified in the cancer cell lines, with the human IRS-1 DNA sequence. The query sequence shown in this figure corresponds to MCF-7 IRS-1 cDNA.
 

5.5.2	Characterization of the IRS-1/pcDNA3 plasmid
To test the hypothesis of a correlation between the lack of IRS-1 protein expression and p110 sensitivity, I aimed to stably overexpress IRS-1 in some p110-sensitive cancer cell lines. The scope of this experiment was to test if, by reintroducing IRS-1 in the p110-sensitive cell lines, these would become resistant to p110 inhibition.
Of the four p110-sensitive lines available to us, I chose to use the p110-sensitive NCI-H2085 and NIH:OVCAR-3 cell lines because the former is PTEN-negative (lack of PTEN expression) and the latter is PTEN-positive (PTEN protein can be revealed by Western blot). In this way, I wanted to test whether the expression of PTEN had any influence on the overexpression of IRS-1. MDA-MB-468 was not used because it has been already reported that reintroduction of IRS-1 in this cell line is not sufficient to activate downstream pathways (i.e. PI3K and MAPK) or to enable responsiveness to IGF-1  ADDIN EN.CITE (Jackson & Yee, 1999). The PC-3 cell line, on the other hand, does express IRS-1 (see Figure 5.4‑3), although it seems not able to function properly and recruit p85, therefore this cell line was not chosen for IRS-1 overexpression experiments.











Figure 5.5‑2. Alignment between the IRS-1 cDNA sequence cloned into the pcDNA3 vector and the cDNA sequence of the IRS-1 sequence in the NCBI online database
This figure shows the alignment between a portion of the IRS-1 cDNA cloned into pcDNA3 plasmid and the complete cDNA sequence of human IRS-1. The alignment analysis indicated a region of 92% identity (0% gaps) between the two sequences, covering the first 225 bp (~25%) of the portion of IRS-1 cDNA cloned into pcDNA3 that was sequenced (total length of the sequenced cDNA: 884 bp). 

5.5.3	Transient transfection of NIH 3T3 cells  








 Figure 5.5‑3. Transient transfection of NIH 3T3 cells with IRS-1/pcDNA3
NIH 3T3 were transiently transfected with the indicated vectors. The transfection procedure lasted for 48 h followed by direct cell harvesting and lysis. The total protein extracts were used to run a Western blot and blotted for IRS-1 and IRS-2 proteins. MCF-7 total protein extract was also used here as positive control. Untransfected NIH 3T3 cells (ctrl.) or cells subjected to the transfection procedure but in the absence of any vector (mock) were used as negative controls.
This experiment has been performed twice.

5.5.4	Stable transfection of NCI-H2085 and NIH:OVCAR-3 cell lines 
I obtained three separate pools of both NCI-H2085 and NIH:OVCAR-3 cells transfected with the IRS-1/pcDNA3 vector (which encodes for a selection marker conferring resistance against G418, Figure 2‑1) and that were stably resistant to the selection agent G418 (data not shown). 
First, the expression of the IRS-1 mRNA was evaluated in the transfected cells with the hope to observe enhanced expression over the basal IRS-1 mRNA expression in these cells (Figure 5.5‑1). 
Figure 5.5‑4 documents that transfected p110-sensitive cancer cell lines expressed IRS-1 mRNA, but there was no indication for enhancement compared to mock- or pcDNA3-transfected cells. However, this PCR analysis was not quantitative, and therefore no firm conclusion could be achieved whether the cells transfected with IRS-1/pcDNA3 plasmid expressed more IRS-1 mRNA than the control cells. 
The expression of IRS-1 protein was then evaluated in the transfected cells (Figure 5.5‑5). Although these cells showed long-term resistance to G418 they did not express the IRS-1 protein. The expression of IRS-2 protein in both NCI-H2085 and NIH:OVCAR-3 cell lines was also unaffected by transfection.
As expected, p110 sensitivity of NCI-H2085 cells stably transfected with IRS-1/pcDNA3 vector was unaffected (Figure 5.5‑6). 
Two possible scenarios could explain these results:
1.	It was not possible to overexpress IRS-1 in NCI-H2085 and NIH:OVCAR-3 cancer cell lines because the same molecular mechanisms that prevent the expression of the endogenous IRS-1 protein are active to inhibit the translation or the protein stability of the exogenous IRS-1. One would still hope to have seen an increased IRS-1 mRNA expression in the transfected cells, but that may not have been possible due to the non-quantitative nature of the RT-PCR. 








Figure 5.5‑4. Analysis of IRS-1 cDNA expression in NCI-H2085 and NIH:OVCAR-3 cancer cell lines transfected with the IRS-1/pcDNA3 vector










Figure 5.5‑5. NCI-H2085 and NIH:OVCAR-3 cancer cells stably transfected with IRS-1/pcDNA3 do not express IRS-1 protein
Pools of NCI-H2085 and NIH:OVCAR-3 cancer cells resistant to G418 were screened for the expression of IRS-1 protein. TCL of MCF-7 cells was used as a positive control. The samples were probed with antibodies recognizing IRS-1, IRS-2 and vinculin (used to assess that the same amounts of protein extracts were loaded on the three lanes).




Figure 5.5‑6. NCI-H2085 transfected with IRS-1/pcDNA3 vector remain sensitive to TGX-221
NCI-H2085 cells stably resistant to G418 and transfected with either pcDNA3 or IRS-1/pcDNA3 vectors were used to perform a cell growth and proliferation MTS assay, by treating them either with LY294002 or TGX-221 at the indicated concentrations. The MTS signals expressed here are related to cells transfected with pcDNA3 vector and treated with DMSO (control). The assay was performed on cells growing either upon serum deprivation or in the presence of 5% serum. The cell growth and proliferation rate was measured after 96 h of growth in the presence of the indicated inhibitors.

5.6	MANIPULATION OF IRS-1 AND IRS-2 GENE EXPRESSION THROUGH RNAi

5.6.1	Introduction  
To further investigate the role of IRS-1 and IRS-2 in p110 sensitivity, I next proceeded to manipulate endogenous expression of these two proteins by RNAi in IRS-1/-2 positive cell lines. I speculated that, if lack of IRS-1 and/or IRS-2 expression and proper function were crucial to determine p110 sensitivity, experimental downregulation of the expression of these two proteins could render p110-resistant cell lines sensitive to TGX-221 treatment. Pre-designed commercially available siRNAs targeting IRS-1 and IRS-2 genes were used to knockdown IRS-1 and IRS-2, with a negative control scrambled sequence siRNA known not to target any coding sequence within the human genome.

5.6.2	Validation of the IRS-1 and IRS-2 knockdown approach  






 Figure 5.6‑1. Screening of four different siRNA targeting IRS-1 mRNA
A.	Four different siRNAs designed to target human IRS-1 mRNA (#1 to #4) were transfected in MCF-7 cells at the recommended concentration (100 nM). Following 72 h of growth in complete media, TCLs were harvested and lysed, and total cellular lysates were analysed through Western Blot. Vinculin blotting was used to assess protein loading on the gel. Mock-transfected (i.e. in the absence of any siRNA) cells were used as controls.  
B.	Two different siRNAs targeting IRS-1 (#1 and #2) along with the control (i.e. scrambled sequence) siRNA were used in this experiment at the indicated concentrations. All siRNAs were transfected as described earlier, and mock-transfected cells were used as controls.







Figure 5.6‑2. Knockdown of IRS-1 and IRS-2 proteins by RNAi
A. MCF-7 cells were transfected with scrambled-sequence siRNA (control siRNA), IRS-1 targeting siRNA (#2) and two IRS-2 targeting siRNA (#1 and #2) that had already shown good knockdown activity in pilot experiments (data not shown). The final concentration used for all these siRNAs in this experiment was 100 nM. TCLs were obtained and analyzed as described in the legend to Figure 5.6‑1, except that in this experiment tubulin was used to assess equal loading on the gel. 
B. MCF-7 cells were transfected with scrambled-sequence siRNA (ctrl) or a mix of the siRNAs targeting IRS-1 and IRS-2 (both #2) that had been selected based on pilot experiments (data not shown). The experimental conditions are similar to those described for the figure above, except that the IRS-1 siRNA was used at 50nM and the control siRNA at 150nM (the concentration of the IRS-2 siRNA was maintained at 100nM). Along with the transfection of siRNAs, the cells were subjected to the incubation with TGX-221 (final concentration: 0.3 M) and PTX (100 ng/ml). The cells were harvested and lysed after 72 h of growth upon serum deprivation and the continuous presence of both the transfection reagents and the tested drugs (TGX-221 and PTX).
This experiment has been performed twice.

5.6.3	Effect of double knockdown of IRS-1 and IRS-2 on TGX-221 sensitivity of MCF-7 cells   
MCF-7, a TGX-221-resistant human cancer cell line, was transfected with the IRS-1 #2 and IRS-2 #2 siRNAs described above to achieve transient knockdown of both IRS-1 and IRS-2. The final dilution of the two siRNAs was optimized to achieve optimal target protein knockdown at the lowest concentration possible and to minimize aspecific inhibitory effects on cell proliferation (data not shown). Therefore the siRNA targeting IRS-1 was used at 50 nM, whereas the siRNA targeting IRS-2 was used at the recommended concentration of 100 nM. The control siRNA was used at 150nM. In parallel with siRNA transfection, the cells were treated with TGX-221 and LY294002 either in serum-free or 5% FCS culture media, followed by MTS assay 72 h later. As in previous experiments, LY294002 was used to compare the relative potency of p110-specific versus pan-PI3K inhibition.
If sensitivity to p110 inhibition depended at least in part on the expression of IRS-1 and IRS-2, knockdown of these two proteins should make a TGX-221-resistant cell line such as MCF-7 sensitive to this drug. Because knockdown of the two IRS proteins was expected to partially inhibit cell proliferation per se, I compared the reduction of cell proliferation achieved with RNAi with or without TGX-221 treatment. The results obtained are shown in Figure 5.6‑3.


Figure 5.6‑3. MTS assay cell proliferation analysis of MCF-7 cells treated with TGX-221 upon IRS-1 and IRS-2 knockdown
MCF-7 human breast cancer cells were transfected using control scrambled sequence (      ) or siRNAs targeting IRS-1 and IRS-2 mRNA (     ). The final concentration of siRNA directed against IRS-1 and IRS-2 were 50 nM and 100 nM respectively, whereas scrambled control siRNA was 150 nM. Along with transfection, cells were treated with either DMSO (control), LY294002 (5 M) or TGX-221 (0.3 M). Cell proliferation rate was quantified after growing the cells for 72 h either in presence of 5% FCS (A) or in serum starvation (B) using MTS assay, and normalized to the proliferation of control-treated (DMSO) cells. The experiment was repeated three times to confirm the observations described.

These results suggest that the transfected cells responded differently to TGX-221 and LY294002 depending on the presence of serum in the culture media. Upon serum starvation or in the presence of serum, IRS-1 and IRS-2 knockdown alone led to 50% decrease in cell proliferation, in agreement with the important role of these proteins to relay pro-growth signals coming from the serum and autocrine/paracrine stimuli. This effect was specific since transfection of control siRNA (black columns) did not reduce cell proliferation. 
In the presence of serum (Figure 5.6‑3A), addition of TGX-221 to cells with IRS-1/-2 knockdown did not further reduce cell proliferation, whereas LY294002 was able to further decrease it to less than 30% of control.
In contrast, in the absence of serum, treatment with TGX-221 unexpectedly reduced the negative impact of double IRS-1/-2 RNAi on cell growth, from 50% to 15% (Figure 5.6‑3B). In other words, the inhibition of p110β offset most of the anti-proliferative effects induced by IRS-1/IRS-2 knockdown (compare the two white columns corresponding to control-treated and TGX-221-treated cells, all of them transfected with anti IRS-1/-2 siRNAs). This result was statistically significant (p<0.001) and was repeated in three independent experiments. On the other hand, treating the cells with LY294002 did not lead to any change of cell proliferation level. These results suggest that: 
1)	treatment of the cells with TGX-221, but not LY294002, in the absence of serum relieves the inhibitory effect of double IRS-1/-2 knockdown. The treatment with the pan-PI3K inhibitor does not mimic the effect of the p110-specific inhibitor, thus implying a specific role for this PI3K isoform. 
2)	The pan-PI3K inhibitor LY294002 does not have an additive effect on double IRS knockdown upon serum starvation. This could be due to the fact that LY294002 inhibits both pro- and anti-proliferative effects attributable to PI3K, resulting in a net neutral effect.
The preliminary results shown in Figure 5.6‑2B exclude that the surprising effects observed upon double IRS-1/IRS-2 knockdown and TGX-221 treatment were due to TGX-221 interfering on the transfection or RNAi-dependent IRS-1/-2 knockdown efficiency. Indeed, IRS-1 and IRS-2 protein expression levels did not appear to be influenced upon drug treatment, as neither TGX-221 nor PTX treatment reduced the knockdown efficiency in transfected MCF-7 cells. Therefore the observed increase of cell proliferation and growth upon p110 inhibition can be related to a specific role of p110 activity.
5.6.4	Effect of PTX treatment on double knockdown of IRS-1 and IRS-2 in MCF-7 cells    
Since p110β is known to be active downstream GPCRs, I aimed to test whether other inhibitors of GPCR signalling (such as PTX) would replicate the findings obtained using TGX-221. For this reason I chose to treat MCF-7 cells with PTX alone or in conjunction with TGX-221 upon double IRS-1/-2 knockdown (Figure 5.6‑4).
As expected, PTX treatment also partially inhibited the growth and proliferation of control siRNA-transfected cells by 20% (white columns), most likely due to an impact of GPCR signalling. The treatment with PTX alone partially mimicked the increase in cell growth and proliferation induced by TGX-221, although to a lesser extent. Upon treatment with both drugs an intermediate effect was observed.


Figure 5.6‑4. Proliferation response of transfected MCF-7 cells in the presence of TGX-221 and/or PTX treatment
MCF-7 cells were treated as described for the experiment shown in Figure 5.6‑3 (white colums: control siRNA; black columns: anti-IRS-1/-2 siRNAs). PTX was used at 100 ng/ml, TGX-221 at 0.3 M and LY294002 at 5 M. A group of cells received DMSO only. The white columns correspond to the cells transfected with the control siRNA, whereas the black columns correspond to the cells transfected with siRNA targeting both IRS-1 and IRS-2.
The MTS signals were normalized to the control-treated cells (i.e. with DMSO only).
This experiment has been performed twice. 

5.6.5	RNAi-induced IRS-1 knockdown in MCF10-A cells 
The results described in the previous sections, obtained in MCF-7 cells, were unexpected and surprising. The inhibition of p110 by TGX-221 (or the broader downregulation of GPCR-dependent signalling by PTX) paradoxically reversed the inhibition of MCF-7 growth and proliferation following the transfection with siRNAs targeting both IRS-1 and IRS-2. To assess the generality of these observations, the experiments were repeated using a non-cancerous cell line closely related to MCF-7, i.e. the immortalized breast epithelial MCF10-A line. MCF-7 bears an activating oncogenic mutation of the PIK3CA gene (Table 4‑1) that could potentially explain the paradoxical effects observed during the RNAi experiments using this cell line (Figure 5.6‑3 and Figure 5.6‑4). One could hypothesize that oncogenic p110 does not require the presence of the IRS proteins to be properly recruited and activated at the plasma membrane level, thus invalidating the assumption that the knockdown of IRS-1 would make a p110-sensitive cell line (MCF-7 in this case) sensitive to TGX-221. For a similar reason the other p110-sensitive cancer cell line that was available, the colon carcinoma HCT-116, may not represent a suitable alternative to MCF-7 cells, as it does also carries oncogenic active p110 (Table 4‑1). In contrast, the immortalized, but non-transformed cell line MCF10-A does not present p110α mutations, potentially being more sensitive to the downregulation of IRSs docking proteins.  
To begin with, the knockdown efficiency of IRS-1 and IRS-2 in MCF10-A was assessed as previously done for MCF-7 cells. The results shown in Figure 5.6‑5 are representative of several optimization experiments and indicate that effective and selective IRS-1 downregulation was obtainable, whereas for IRS-2 isoform a similar result could not be achieved in MCF10-A cells (data not shown). For this reason the experiments described used anti-IRS-1 siRNA only, thus being different from the experimental approach used with MCF-7 cells (that included the transfection of both anti-IRS-1 and anti-IRS-2 siRNAs). 
Once the transient transfection protocol was optimized, MCF10-A cells were subjected to RNAi-induced knockdown of IRS-1 protein followed by drug treatment, similar to the experiment shown in Figure 5.6‑4. The results are shown in Figure 5.6‑6 and suggest that the treatment of the IRS-1 siRNA-transfected MCF10-A cells with TGX-221 (with or without concomitant PTX treatment) did also increase the cell growth and proliferation, in agreement with the results obtained with MCF-7 cells. The fact that control-transfected MCF10-A cells (white columns) did not respond to neither PTX nor TGX-221 treatment confirm that this cell line, similarly to MCF-7, was a suitable model to test whether the downregulation of IRS would induce the sensitivity to p110β inhibition.
The increase of cell growth and proliferation was more pronounced upon TGX-221 and PTX co-treatment, with cell growth and proliferation rate being similar to cells transfected with control siRNA (white column). 
One significant difference between the results obtained in MCF-7 and MCF10-A was the effect of PTX on the IRS siRNA-transfected cells. In MCF-7 cells (Figure 5.6‑4), PTX treatment reproduced the effect of TGX-221 by increasing the cell growth and proliferation rate, whereas in MCF10-A (Figure 5.6‑6) PTX failed to replicate this effect, but instead further reduced the cell growth and proliferation rate. Co-treatment with TGX-221, nonetheless, reversed such inhibition to an even greater extent than TGX-221 alone. The reason of such differences between MCF-7 and MCF10-A cells is likely to reside in the differences between these two cell lines in terms of intracellular signalling circuitries, e.g. due to the fact that MCF-7 is a fully transformed cancer cell line.









Figure 5.6‑5. Transient transfection of MCF10-A cells with siRNA tageting IRS-1 




Figure 5.6‑6. Treatment of MCF10-A cells transfected with anti-IRS-1 siRNA with TGX-221, LY294002 and PTX
MCF10-A cells were transfected with control siRNA or with siRNA targeting IRS-1 using the same conditions described for Figure 5.6‑3. The transfected cells were treated with DMSO only, TGX-221 (0.3 M), LY294002 (5 M) and PTX (100 ng/ml). The cell proliferation rate was assessed after 72 h of growth in complete culture media using MTS assay. The MTS signals were normalized to that of DMSO-treated (control) cells. The difference between the cells transfected with anti-IRS-1 siRNA and treated with TGX-221 versus control was statistically significant (**; p<0.01). The experiment was performed in the complete culture media (i.e. 10% FCS) because the transfection process in MCF10-A cells caused high unspecific toxicity either upon reduced serum concentration (5% FCS) or serum deprivation (data not shown), thus causing unreliable experimental readouts.
5.6.6	The experiment has been performed twice.
5.6.7	Analysis of the effect of p110β inhibition in IRS-1 and IRS-2 KO MEF cells  
An additional cellular model that was used to test whether the lack of IRS proteins could determine an increased sensitivity to p110β inhibition were the MEF cells derived from IRS-1 and IRS-2 KO murine models (provided by White M., Boston). These cells were obtained from embryos of the IRS-1 and IRS-2 KO mice and were immortalized following the 3T3 protocol  ADDIN EN.CITE (Araki, et al., 1994; Tamemoto, et al., 1994; Withers, et al., 1998). 
The response of these MEFs to TGX-221 and LY294002 and, for WT and IRS-1 KO cells in the presence of serum, to PTX was tested both in the presence of serum and upon serum deprivation, at various time points (Figure 5.6‑7).















Figure 5.6‑7. Analysis of the response of IRS-1 and IRS-2 KO MEF cells to p110 inhibition
A. MEF cells derived from IRS-1 KO and IRS-2 KO mice, along with control WT cells, were checked for expression of IRS-1 and IRS-2 proteins by Western blotting. 
B. The MEF cells were tested for their growth and proliferation sensitivity to p110 inhibition in a series of MTS assay experiments. They were treated for 48-96 h (with or without FCS in the media) with LY294002, TGX-221 and PTX (except the IRS-2 KO MEFs) at the indicated concentration. The cell growth and proliferation rates were assessed by MTS assay. 










The experimental work described in this thesis focused on the in vitro investigation of specific properties of p110 signalling. Several cellular models have been used for the experiments presented here, ranging from human cancer cell lines to murine fibroblasts. We found that in NIH 3T3 fibroblast cells, p110 can be recruited downstream a prototypical RTK receptor, PDGFR, upon activation by its cognate ligand (PDGF). However, no clear and conclusive evidence of an increased recruitment of p110 and p110 upon co-stimulation of cells with PDGF plus LPA was obtained. A partial inhibitory effect of p110 inhibition on the recruitment of p110 to active PDGFR was also observed, potentially implying a role for p110 as an integrator of GPCR- and RTK-dependent cell signalling activity, but this reduction was not statistically significant. Nonetheless, pre-treatment of cells with inhibitors of Ras or GPCR signalling reduced the recruitment of p110 to active PDGFR. These data may suggest that receptor transactivation or the cooperation with GPCR signalling pathway is required to achieve the full recruitment of p110 downstream PDGFR. These results are further discussed in § 6.1.
I also investigated p85/p110 binding in a subset of cancer cell lines. Here I show that the interaction between the p85 and the p110 subunits forming the functional PI3K heterodimer is a random event in cancer cells, regulated by the relative abundance of each isoform, and that it does not correlate with the sensitivity to p110 inhibition (discussed in § 6.2). 
I then analyzed the mechanism underlying the sensitivity of some cancer cell lines to growth-inhibition by p110-selective drugs. This was done in a panel of human cancer cell lines. A subset of these was found to be growth-inhibited upon TGX-221 (a p110-selective inhibitor) treatment (discussed in § 6.3). During the following investigation of the molecular determinants of this phenotype, the p110-sensitive cell lines were found to lack functional IRS-1 expression and to show a chronic upregulation of the Akt/S6K signalling pathway, likely due to pre-existent PTEN inactivation (§ 6.4). I proposed that IRS-1 downregulation in these cells (due to various mechanisms, including the impact of the Akt/S6K negative feedback loop or inactivating gene mutations) would lead to p110 taking the role as the main class IA signalling isoform, due to its capacity to signal downstream GPCR. During the RNAi-based experiments in some p110-resistant cell lines aimed to verify this model, an unexpected positive role of p110 inhibition on cell growth and proliferation emerged. These findings are in line with those obtained upon long-term treatment of some p110-sensitive cancer cell lines. Overall a novel positive role of p110 inhibition on cell growth and proliferation has emerged from this work (discussed in § 6.5). This phenomenon is not completely explained to date and will require further investigation to elucidate the underlying molecular mechanisms. Some potential experiments that could shed further light on my observations are discussed at the end of the chapter.

6.1	p110 IS RECRUITED TO THE ACTIVE PDGFR 
An important role for p110 downstream of GPCRs has recently been reported (Guillermet-Guibert, et al., 2008), but the possibility that p110 can also be active downstream some RTKs can not be fully excluded. Indeed, it has been suggested that in NIH 3T3 murine fibroblasts p110 is recruited to and activated by the PDGFR, although it is not the main PI3K isoform to relay downstream stimulatory signals  ADDIN EN.CITE (Roche, et al., 1998). This evidence was obtained by microinjecting the cells with selective antibodies raised against p110 and p110. Furthermore, it has been proposed that p110 (and p110α) in MEF cells shows a dynamic pattern of recruitment and activation downstream membrane receptors, with p110activity peaking at early (up to 1 h) and late (8 h) time points after serum stimulation  ADDIN EN.CITE (Marques, et al., 2008). Finally, published data suggest that p110 can be in vitro synergistically activated by G subunits and phosphotyrosyl peptide based on the amino acid sequence of IRS-1  ADDIN EN.CITE (Katada, et al., 1999; Kurosu, et al., 1997; Maier, et al., 1999).
Based on this information, the recruitment of p110 to active PDGFR was investigated in NIH 3T3 cells. The research described here aimed to evaluate whether p110β was effectively recruited to active PDGFR and the effect of the concomitant GPCR-derived signalling input (using the GPCR ligand LPA to stimulate the cells). The recruitment of p110α to active PDGFR was also monitored, because this PI3K isoform is known to be one of the main actors in the signal transduction downstream PDGFR, and RTKs in general  ADDIN EN.CITE (Foukas, et al., 2006; Knight, et al., 2006). 
The inherent dynamicity of the biological systems, coupled with the semi-quantitative nature of some of the techniques used in this investigation (i.e. the co-IP and Western blotting analysis of multiprotein complexes) contributed to the variability of the results obtained. For this reason internal loading controls were used and the bands obtained were quantified and analysed for statistical significance using suitable software. Moreover, several findings reported here suggest a subtle and modest impact of PI3K inhibition, and particularly of p110, on protein interaction and downstream signalling thereby complicating their interpretation. Ideally, the co-IP strategy reported here should have been integrated with the reverse approach, i.e. by immunoprecipitating the individual p110 and p110 isoforms and then blotting for PDGFR upon different stimuli and conditions, to confirm the observations relative to the recruitment dynamics. This approach has indeed been attempted but because of technical difficulties no reliable results were obtained (data not shown). 
1)	Nonetheless, the results reported here can be summarized as follows:
2)	p110β can be effectively recruited to active PDGFR.
3)	Compared with PDGF alone, the co-stimulation of the cells with PDGF plus LPA does not have a major impact on the recruitment of p110α and p110 to active PDGFR.
4)	Treatment with small-molecule inhibitors of Ras- or GPCR-dependent signalling reduces the recruitment of p110β to active PDGFR upon stimulation of NIH 3T3 cells with PDGF.  
5)	LPA-induced phosphorylation of Akt/PKB and S6K is inhibited by TGX-221, in line with the results obtained by Guillermet-Guibert, et al., 2008.  
Taken together, these findings show that p110 is recruited to the PDGFR. It remains unclear which function, if any, does p110 play in this context. One of the molecular mechanisms that could have a role in the recruitment of p110 is the transactivation of PDGFR by GPCR receptors (introduced in § 1.4.2). 
 One of the first reported examples of GPCR-RTK transactivation involved the activation of EGFR upon treatment with several GPCR agonists, including LPA, as discussed in § 1.4.2  ADDIN EN.CITE (Daub, et al., 1996). The suggested mechanism involved the GPCR activation of matrix metalloproteinases residing at the cell surface and the consequent release of EGF from the extracellular matrix, followed by binding and activation of EGFR. Regarding PDGFR transactivation, the proposed mechanism was different and involved the activation of PLD following GPCR activation  ADDIN EN.CITE (Wang, et al., 2003). Other mechanisms of GPCR-induced transactivation involve cytoplasmic Tyr kinases such as Src and Pyk2, or second messengers like H2O2, as presented in § 1.4.2 (Wetzker & Bohmer, 2003). Further molecular events that may occur are (in parallel with transactivation) the positive allosterical effects of active G subunit, as has been suggested in literature  ADDIN EN.CITE (Kurosu, et al., 1997) and the clustering of ligand-activated RTKs and GPCRs in limited regions of the plasma membrane, thus favouring the aggregation of downstream proteins. In conclusion p110 (and possibly p110) recruitment to PDGFR could be promoted by receptor transactivation, and one may investigate a possible role of p110 in the transactivation mechanism itself. As an example, one could monitor the phosphorylation (over time) of PDGFR upon stimulation with LPA alone and TGX-221 (or PTX) treatment.










Figure 6.1‑1.  p110 and p110 show distinct activation kinetics
These figures are taken from  ADDIN EN.CITE (Marques, et al., 2008) and display the results on the activation dynamics of overexpressed p110α and p110β in NIH 3T3 cells stimuated with serum. The plot on the left depicts the results of a time-course experiment aimed at measuring the production of PIP3 attributable to p110α and p110β upon stimulation with serum. The NIH 3T3 cells were transfected with tagged p110 and p110 proteins, serum-starved and stimulated with serum for the indicated time. The cells were harvested and lysed and the lipid kinase activity of the two p110 isoforms was evalued with a PIP2 kinase in vitro assay. The results for each isoform were normalized to the highest measured level of lipid kinase activity (the peak), that for p110 and p110 corresponded to 1 h and 8 h post-serum addition, respectively. The graph on the right summarizes the experiments aimed at investigating the impact of the treatment of NIH 3T3 cells with herbamycin, an inhibitor of RTK signalling, and lovastatin, that inhibits Ras-dependent co-stimulation, on the lipid kinase activity of p110α and p110β. NIH 3T3 cells transfected with tagged p110 and p110 proteins were pre-incubated with either of the two drugs and then serum-stimulated for 7 min or 1 h. The bars represent the measured values of lipid kinase activity measured for each p110 isoform in the various experimental conditions tested.

The results published by Marques, et al., 2008 (Figure 6.1‑1, left plot) suggest that p110α and p110β lipid kinase activity follows a double-peak kinetics, as p110α activation is higher than p110β at early time points (i.e. up to 1 h post-serum stimulation), and the recruitment of both p110 isoforms peaks again about 7-8 h post-serum stimulation, with a minor peak of p110 activity at 4 h.




Figure 6.1‑2. PDGF induces two peaks of PIP3 production (30 min and 4 h) in human hepatoma cells stimulated with PDGF
This plot shows the results of PIP3 production monitoring in human HepG2 hepatoma cells treated with PDGF for increasing periods of time. The cells were labelled with [32P] orthophosphate and, following PDGF treatment, harvested and lysed. The radiolabeled phosphoinositides were then analysed by HPLC and the amount of PIP2 and PIP3 was determined and normalyzed to the amount of PI-4-P.
This image has been taken from Jones, et al., 1999.

The experiment shown in Figure 5.1‑3 was therefore conducted to verify whether the dynamics of p110β recruitment to active PDGFR was in line with these published data and to assess if the recruitment of p110 to active PDGFR presented a peak at later time points. Indeed, my results suggest that p110α recruitment is more sustained and reaches a peak earlier (5-10 min post-stimulus) than p110β (15-30 min) at early time points (i.e. within 1 h post-PDGF plus LPA stimulation). At later time points (i.e. up to 6 h) no further peak of the recruitment of p110α or p110β was observed, although a minor increase of co-immunoprecipitated PDGFR and p110 (less evident for p110) was observed at 4 h post-stimulus. This secondary peak was transient (i.e. it tended to disappear at 6 h post-stimulus) and could be related to the dynamics of PI3K activity and PIP3 production described in Figure 6.1‑1 and Figure 6.1‑2, although this analysis should be further extended to longer time points (and complemented with a measurement of PIP3 production level) for a correct comparison with the data of Marques, et al., 2008 (i.e. up to 14 h post serum addition). Moreover, these authors claim that the peak of p110 activity observed at 8 h post-serum stimulation may be related to a p110 pool that resides in the nucleus and that can affect the nuclear mechanisms of cell cycle progression and cell proliferation. In this scenario the lack of p110 recruitment to active PDGFR (occurring at the plasma membrane) could not be observable. In line with this hypothesis, the late PIP3 peak reported in HepG2 cells (Figure 6.1‑2) has been associated to DNA synthesis and cell cycle progression through S-G2 phases (Jones, et al., 1999). In conclusion, a direct comparison between the data presented here and those by Marques, et al., 2008 cannot be made, because i) the experiment I performed did not cover all the temporal range (i.e. up to 14 h stimulation with serum) of the published results and ii) it was focused on p110s recruitment to PDGFR at the plasma membrane, and not on their activation in other cellular compartments such as the nucleus.

6.2	THE BINDING BETWEEN CLASS I PI3K REGULATORY AND CATALYTIC SUBUNITS IS NOT A REGULATED EVENT
It has been shown that the regulatory and the catalytic subunits of class IA PI3K mainly occur in heterodimers (Geering, et al., 2007a). In cell-based overexpression studies, each p85 isoform can bind to any p110 (Vanhaesebroeck, et al., 1997b). However, it is not clear if there is a preference of the different p85 isoforms for the various p110s in physiological systems. 
In this work the binding between class IA catalytic and regulatory subunits (p85 and p85, the two main isoforms) has been investigated by co-immunoprecipitation and Western blotting analysis (§ 5.3). The methodology used here was aimed to reach a conclusion as quantitative as possible within the technical possibilities of the analytical technique that has been used, that is Western blot. Such technique is semi-quantitative at best, but it is possible to use side-by-side comparison of semi-quantitative data to obtain meaningful conclusions. As an example, for each cell line both the TCL and the co-IP samples were loaded on the same gel and blotted with the same antibody. The resulting bands were then optically quantified and the ratio between the IP samples and the TCL was calculated. This approach took into account the possible differences between the antibodies that have been used throughout the experiment in terms of epitope specificity and binding efficiency, as the same antibodies were used to blot both the TCL lanes and those loaded with the co-IP samples (being on the same membrane). As the data analysis was conducted focusing on the ratios between different signal intensities (by comparing p85 and p85) and not on their absolute values, the possible bias due to different exposure duration, antibodies quality or any other technical issues were taken into account in the data elaboration process when comparing different cell lines.
The results presented here do not support the hypothesis that, in human cancer cell lines, there is any preference of p85 or p85 for a specific p110 isoform, nor that there is a link between the interaction of p110 with p85α or p85β and the anti-proliferative response to TGX-221. Despite the comprehensive analysis of the seven cancer cell lines did not evidence any statistically significant p85/p110 binding preference, the results on some cell lines taken individually (e.g. HCT-116, PC-3) could suggest the opposite, although to reach statistical significance this experiment should be repeated. In retrospect, one could have chosen to focus the research only on these cancer cell lines, but in doing so it would have been difficult to conclude on the possible differences between the p110-resistant and the p110-sensitive cell lines. The rationale behind the choice of screening an ample array of cell lines was therefore to investigate the p85/p110 binding and at the same time the possible correlation with p110 sensitivity.    
    
6.3	ANALYSIS OF THE RESPONSE OF A PANEL OF HUMAN CANCER CELL LINES TO p110 INHIBITION
6.3.1	Introduction
Data from our laboratory and others show that the PI3K isoforms perform different and non-redundant functions both in cell and organism physiology. Parameters that contribute to the functional specificity of each isoform include the selective activation downstream different membrane receptors and the relative expression levels in different tissues and organs  ADDIN EN.CITE (Graupera, et al., 2008; Guillermet-Guibert, et al., 2008; Okkenhaug, et al., 2002). The specific role of each PI3K isoform in cellular signalling is currently under investigation through the generation of genetically engineered mouse models lacking the expression of one or more PI3K isoforms (knock-out genetic strategy), or expressing PI3K isoforms in a kinase-inactive state (knock-in strategy) and the use of isoform-selective drugs that have now become available (Vanhaesebroeck, et al., 2005). Such studies are interesting in light of the possible clinical applications of manipulating the activity of PI3K enzymes in pathological contexts such as autoimmune diseases, diabetes and cancer  ADDIN EN.CITE (Knight & Shokat, 2007; Marone, et al., 2008). The determination of the isoform-specific roles of PI3K isoforms is crucial not only to design the pharmacological intervention with the best chance of therapeutic success, but also to anticipate and possibly minimize any possible undesirable side effects. Such understanding is of valuable importance in the early phases of drug development for isoform-specific, small-molecule inhibitors of PI3K and is currently an important aspect of the research effort of the pharmacological industry. Currently, several clinical trials involving both pan-PI3K (Semafore, Exelexis, Genentech) and p110-selective inhibitors (Calistoga) are in progress, with potential clinical application in the fields of oncology, inflammatory and autoimmune diseases. Recent studies define p110 as an important new target for antithrombotic therapy  ADDIN EN.CITE (Jackson, et al., 2005) and clinical trials are planned to test p110-selective inhibitors as inhibitors of blood clotting during the extracorporeal blood circulation for surgery applications (Straub, et al., 2008). 

6.3.2	Identification of p110-sensitive cancer cell lines 
To investigate the role of p110 in cancer, our collaborators at AZ performed a screening on more than 100 human cancer cell lines treated with p110 inhibitors. The preliminary data they obtained indicated that about ten cancer cell lines were sensitive to p110 inhibition in terms of intracellular signalling, cell growth and proliferation or both. Eight of these cell lines were used for this thesis. I conducted the analysis of p110 inhibition through a series of MTS assays, which evidenced a reduction of up to 60% of cell growth and proliferation in the p110-sensitive cell lines (Table 5.2‑1). These values were similar to the effect of pan-PI3K inhibition obtained by treating the cells with LY294002 and overall confirmed the information obtained by AZ, with two noteworthy exceptions. The brain cancer cell line U87-MG showed an intermediate response to p110 inhibition that did not allow its clear classification as p110β-resistant or p110β-sensitive cell line. Nonetheless, U87-MG cells showed no expression of IRS-1 (and therefore defective recruitment of p85; Figure 5.4‑1), a feature shared with the other p110β-sensitive cancer cell lines further discussed below. The other exception, the melanoma A2058, was resistant to both TGX-221 and LY294002 (was therefore “PI3K-resistant) and is discussed in detail in § 6.3.3.
The subsequent investigation of the possible molecular determinants of p110 sensitivity led to the following results: i) the Akt/mTOR/S6K pathway is chronically active in some p110-sensitive cancer cell lines, likely due to defective PTEN expression (this part is further discussed in § 6.4), and ii) the p110-sensitive cancer cell lines lack IRS-1 expression or functional recruitment of p85 to IRS. These two characteristics are in line with the hypothesis outlined in § 4.3.2, that anticipated in the p110-sensitive cells a defective RTK-dependent signalling activity, possibly due to IRS downregulation (either through the inhibition of its expression or functionality) by overactive negative feedback activity. A second proposed hypothesis (§ 4.3.2) envisioned that p110-sensitive cells could express higher levels of p110 compared to controls, thereby making these cells more susceptible to p110 inhibition, but the evidence presented in this work (Figure 5.2‑8) did not support this hypothesis. 
To verify the correlation between p110 sensitivity and the lack of IRS-1 expression or activity, two complementary approaches were chosen: i) the reintroduction of IRS-1 in some p110-sensitive cancer cell lines by transfection and ii) the transient knockdown of IRS-1 in p110-resistant cells through RNAi. I also analysed the response of IRSs KO MEFs to p110 inhibition. For different reasons, these approaches did not lead to conclusive results. It was not possible to re-express IRS-1 in the p110-sensitive cancer cells by stably trasfecting them with an IRS-1/pcDNA3 vector, either because of chronic downregulation of the newly synthesized IRS-1 or because the selection of stable pools of transfected cells led to the propagation of cells that did not express IRS-1, despite being resistant to the selection agent G418 (§ 5.5). The IRS KO MEFs did not show increased sensitivity to p110 or GPCR inhibion. Finally, RNAi-induced downregulation of IRSs in the p110-resistant MCF-7 and MCF10-A cells succeeded, but surprisingly TGX-221 treatment had a positive effect on their growth and proliferation. Some hypotheses to explain this unexpected finding are discussed in § 6.5. Similar results were also obtained for some p110-sensitive cell lines upon long-term (168 h) TGX-221 treatment, suggesting that the positive effects of p110 inhibition on cell growth and proliferation were not an artifact caused by IRSs knockdown. 

6.3.3	A2058 melanoma cells: a cell line that is fully dependent on p110 PI3K?
The human melanoma A2058 cancer cell line differed from all the other cell lines tested because it showed resistance to LY294002 and thus, also to TGX-221 (Table 5.2‑3 and Figure 5.2‑2). Interestingly, A2058 does not express IRS-1 (and IRS-2 protein is almost undetectable, Figure 5.4‑2). 
These results suggest that in A2058 cells the class IA PI3K isoforms, which are inhibited by LY294002 at the concentration used throughout this work (i.e. 5 M), do not play a relevant role in stimulating cell growth and proliferation. It is important to note that, based on published IC50 values for the class I PI3K isoforms, 5 M LY294002 may not be sufficient to achieve p110 inhibition  ADDIN EN.CITE (Knight, et al., 2006) (Table 2‑1). Interestingly, it has been reported that p110 in A2058 cells plays an important and isoform-specific role in the transduction of pro-motility signalling originating from the LPA receptor (a prototypical GPCR) leading to the activation of the Cdc42/PAK1/FAK pathway and, ultimately, to cytoskeleton rearrangements and cell movement  ADDIN EN.CITE (Jung, et al., 2004). Moreover, this LPA-induced downstream effect is inhibited by PTX treatment and is therefore strictly GPCR-dependent. Furthermore, it has also been shown in A2058 cells that the effects of another strong chemotactic molecule, the glycoprotein autotaxin (isolated in A2058 cells and acting as an autocrine motility factor), can be inhibited by LY294002 or PTX treatment and that both these inhibitors strongly decrease the p110γ-dependent, but not the p85-associated (i.e. due to the class IA isoforms p110α, p110β or p110δ) lipid kinase activity  ADDIN EN.CITE (Lee, et al., 2002). 
Overall, these findings suggest that p110β and its role downstream GPCR are not crucial for signal transduction in A2058 cells. The interpretation of the data related to this cell line is difficult because the effect of pan-PI3K inhibition upon LY294002 treatment could not be used as a reference parameter for p110β inhibition, as it has been done for the other cancer cell lines. In agreement with this, the lack of IRS-1 expression (and therefore of p85 recruitment) in A2058 cells argues against a role for the p85-coupled p110 isoforms to relay PI3K signalling. For these reasons it is tempting to speculate that p110γ could play the main role as PI3K isoform in A2058 cells, not just as transducer of pro-motility signals but also controlling cell growth and proliferation. In this scenario the isoform-selective inhibition of p110γ, the use of higher LY294002 concentration (that results in p110γ inhibition, see Table 2‑1) or treatment with PTX could have led to a measurable inhibitory effect on A2058 cells in the MTS experiments. One could therefore test these approaches to verify whether p110 is the main class I signalling isoform in A2058.

6.4	CHRONIC ACTIVATION OF THE Akt/S6K PATHWAY AND IRS-1 DOWNREGULATION IN THE p110-SENSITIVE CELL LINES
A large part of this work was aimed at investigating the molecular mechanisms that could underlie the sensitivity to p110 isoform-specific inhibitors in a panel of human cancer cell lines. Here, I have shown that all p110-sensitive cell lines have a defect in recruitment of the p85 regulatory subunit of class I PI3K to the IRS-1 docking protein. This defect is due to reduced or null expression of IRS-1 in MDA-MB-468, NCI-H2085 and NIH:OVCAR-3 cell lines or its functional inactivation i.e. no binding to p85 in PC-3 cells, possibly due to phosphorylation of inhibitory sites. 
It has been proposed that the two isoforms of IRS (IRS-1 and IRS-2) play different roles in the regulation of cancer cell behaviour. In particular, IRS-1 has been described as the main isoform to be recruited downstream IGF-1 and insulin receptors, whereas IRS-2 would be mainly involved in the regulation of cell motility and metastasis  ADDIN EN.CITE (Jackson, et al., 1998; Jackson, et al., 2001). Nonetheless, a co-operative action of both IRS-1 and IRS-2 isoforms to stimulate cell growth and proliferation has not been excluded.
The activity of IRS-1 as well as its protein stability is controlled by direct phosphorylation of several serine residues known to be phosphorylated by active S6K protein (Shah & Hunter, 2006). I proposed that both the lack of expression and the inactivation of IRS-1 shown in the cancer cell lines could be caused by chronic Akt/mTOR/S6K negative feedback loop signalling leading to IRS-1 phosphorylation. This could be due to PTEN loss, which has been shown to induce stable Akt/PKB phosphorylation and upregulation of downstream signaling pathway  ADDIN EN.CITE (Di Cristofano & Pandolfi, 2000; Weng, et al., 2001). In other words, chronic activity of S6K could be directly caused, or partly sustained among other factors, by the lack of the PTEN lipid phosphatase function to counteract PI3K-mediated Akt/PKB activation, thereby leading to prolonged downstream activation of mTOR and S6K and ultimately switch from p110 to p110 as the main actively signalling class IA PI3K (a model presented in § 4.3.2). Indeed, three out of four TGX-221-sensitive cancer cell lines lack functional PTEN, and the evidence presented in this work suggests that p110β-sensitive cells have a high P-Akt and P-S6K level both in presence of serum and, most importantly upon serum starvation, indicating that the Akt/mTOR/S6K signalling pathway is chronically active. However, inhibition of mTOR-directed negative feedback signalling by Rapamycin treatment did not cause a measurable (within the sensitivity of the Western blotting technique) recovery of IRS-1 protein expression in all the tested cell lines, nor did it the inhibition of proteasome-dependent protein degradation by treating the cells with MG-132. A limited (~1.5 fold) increase in IRS-1 protein upon Rapamycin treatment was detectable in PC-3 cells that already express a detectable level of IRS-1 in the basal state (Figure 5.2‑8), suggesting that the inhibition of S6K negative feedback signalling may contrast IRS-1 downregulation only if basal IRS-1 gene expression is already taking place at a sufficient level, but not in the case of very low (as in NCI-H2085) or total absence of IRS-1 protein expression (MDA-MB-468, NIH:OVCAR-3). 
In conclusion, the treatment with Rapamycin and MG-132 induced IRS-1 re-expression in only a subset of the p110-sensitive cancer cell lines. Since all these cell lines appear to express endogenous IRS-1 mRNA (§ 5.5.1), one possible explanation is that nonsense point mutations (i.e. mutations that result in the appearance of premature stop codons) present in the IRS-1 mRNA sequence may prevent endogenous IRS-1 protein expression in some p110β-sensitive cell lines even if the conditions that cause its downregulation (i.e. S6K negative feedback signalling, proteasome degradation) are removed. 























Figure 6.4‑1. Scheme of the known serine phosphorylation sites on IRS-1
This scheme depicts the IRS-1 serine phosphorylation sites currently known. Most of these sites are involved in the negative regulation of IRS-1 functionality or protein stability, and are phosphorylated by an array of signalling proteins that respond to several extracellular stimuli, including insulin and IGF-1,  that trigger both the PI3K /mTOR/S6K and the Erk1/2 MAPK pathways. 
Black, blue, and red circles represent, respectively, a suggested negative, positive, or negative/positive regulatory phosphorylation site.
This figure is taken from Boura-Halfon et al., 2009.

6.5	POSITIVE EFFECTS OF p110 INHIBITION ON CELL GROWTH AND PROLIFERATION
6.5.1	Inhibition of p110 reverses the effect of IRS knockdown in both MCF-7 and MCF10-A cell lines
To further test whether the sensitivity to p110 inhibition is linked to the lack of functional IRS, I set out to experimentally mimic the loss of IRS-1 expression found in TGX-221-sensitive cancer cell lines. 
These studies were initially carried out in MCF-7 cells, which are resistant to p110 inhibition, both in the presence of serum or upon serum starvation. I first measured the effect of TGX-221 treatment on MCF-7 cells transfected with IRS-1 siRNA only, which per se caused a ~20% reduction of cell growth and proliferation (data not shown). I tested different experimental conditions to increase this effect (data not shown), but I could not achieve further reduction of the cell proliferation rate without observing aspecific effects due to the transfection process itself (measured as the effect of control-siRNA transfection). Treatment with TGX-221 (in the presence of serum or upon serum starvation) did not have an impact on cellular growth and proliferation. In conclusion, these preliminary experiments suggested that the knockdown of IRS-1 protein only did not make MCF-7 cell line sensitive to p110 inhibition. However, I speculated that a 20% inhibition of cell growth and proliferation could be not sufficient to overcome the resistance of these cells to p110 inhibition and that downregulation of both IRS-1 and IRS-2 isoforms was necessary. 
MCF-7 cells were then simultaneously transfected with siRNAs targeting IRS-1 and IRS-2 isoforms, and this led to ~50% reduction of cell growth and proliferation. Surprisingly, when the experiment was performed upon serum starvation, treatment with p110 inhibitor did not further reduce cell growth and proliferation, but instead overcame the growth inhibition. Moreover, the transfected MCF-7 cells also showed enhanced growth and proliferation upon PTX treatment, further pointing to a role for p110β (active in the GPCR-dependent cell signalling) in the reversal of the inhibitory effect caused by IRS-1 and IRS-2 knockdown. These results were not replicated in MCF-7 cells when RNAi and TGX-221 treatment occurred in the presence of serum. In this case p110β inhibition did not have any effect on cell growth and proliferation rate (Figure 5.6‑3A). 
Essentially similar conclusions were drawn from the experiments in MCF10-A cells, which are immortalized but untransformed human breast epithelial cells. In the presence of serum, treatment with TGX-221 reversed the reduction of cell growth and proliferation induced by the transient knockdown of IRS-1 (it was not possible to set up the optimal conditions for the concomitant downregulation of IRS-2 isoform). This experiment could not be replicated upon serum starvation because of the elevated toxicity caused by concomitant RNAi approach and serum deprivation stress. In the presence of serum, treatment of anti-IRS-1 siRNA-trasfected cells with PTX alone did not have a positive effect in this case, but combined TGX-221 and PTX treatment strongly reversed IRS-1 knockdown-induced inhibition of cell growth and proliferation (Figure 5.6‑6).
The RNAi experiments described here were performed using one specific couple of anti-IRS-1 and anti-IRS-2 siRNAs (both labelled as #2) that were selected in the preliminary screening shown in Figure 5.6‑1 and Figure 5.6‑2. To confirm these findings and to rule out any unspecific RNAi-induced effect, one could test another couple of siRNAs that showed high efficacy in downregulating their target (e.g. IRS-1 siRNA #3 and IRS-2 siRNA #1). A further experimental control would be the reintroduction of IRS-1 protein (and IRS-2 in the appropriate case, i.e. MCF-7 cells subjected to double IRS-1/-2 knockdown) in siRNA-treated cells, to assess whether IRS reintroduction rescues the phenotype induced by RNAi (i.e. reduction of cell growth and proliferation), by means of transient transfection of the IRS-1/pcDNA3 vector. IRS-2 re-expression could be achieved by using the IRS-2/pCMV vector that is available in our laboratory. This vector was used for some preliminary PCR screening work (similar to that described for IRS-1/pcDNA3, see Figure 5.5‑2) that confirmed the coding sequence cloned in the vector corresponded to that of human IRS-2 (data not shown). By following this approach, one would assume that transient re-expression of IRS proteins in p110-resistant cells such as MCF-7 and MCF10-A is possible (as is IRS-1 overexpression in NIH 3T3 cells, see Figure 5.5‑3), although a mayor technical issue could lie in the proper temporal execution of RNAi treatment followed by transfection with IRS-coding vectors, to avoid that the former procedure does not prevent the prompt re-expression of IRS proteins.  
The reason for the differential response of the siRNA-treated MCF-7 cells to TGX-221 treatment in the presence or absence of serum is not clear to date. One possibility is that the effects of TGX-221 in MCF-7 are not evident in the presence of serum because this compound has a high binding affinity with the protein fraction of the serum (AZ, personal communication), resulting in a lowering of the amount of drug available for p110 inhibition in the cells (that may be instead sufficient to achieve an effect in MCF10-A). To overcome this problem it would be useful to test other small-molecule inhibitors of p110 that have been developed by several pharmaceutical companies, including AZ. Moreover, the capacity of boiled serum to protect the cancer cell lines from the TGX-221 inhibitory effects should be also tested, to assess whether the denaturation of the proteic fraction of the serum added to culture media has any effect on the response to TGX-221. Conversely a non-proteic factor, which is not destroyed by heat treatment, could still confer resistance to TGX-221. Examples of putative, non-protein protective factors that act at a functional level (i.e. they do not directly sequester TGX-221 through molecular binding) are androgen and estrogens hormones. Indeed, a connection between IRS-1 and the steroidal hormone system has been documented, as IRS-1 expression in breast cancer cell lines is positively controlled by estrogen receptor (ER) activity  ADDIN EN.CITE (Bartucci, et al., 2001; Morelli, et al., 2003; Surmacz & Bartucci, 2004) and has been found to stimulate the cellular response to androgen hormones (Lanzino, et al., 2008). Generally speaking, IRS proteins play a role as a link between the androgen/estrogens and the insulin/IGF-1 signalling pathway. 
It has been reported that MDA-MB-468 cells do not express estrogens receptor (are thus ER-) whereas MCF-7 and NIH:OVCAR-3 are ER+  ADDIN EN.CITE (Jackson & Yee, 1999; Kang, et al., 2001; Lee, et al., 1999). The results presented in this work do not suggest that the exposure to serum increases IRS-1 expression in the analysed cancer cell lines. Nonetheless, it would be interesting to test the capacity of androgen or estrogen hormones to act as protective factors upon TGX-221 treatment if added to the growth media, with or without the addition of charcoal-stripped serum (i.e. deprived of the steroid hormones that are normally found in the serum).
Finally the possible effects of phenol red, a common pH indicator present in all the culture media used for this work and known as a weak estrogen receptor ligand (Berthois, et al., 1986), should be taken into account. Repeating some cell growth and proliferation experiments using phenol red-free cell culture media could help to clarify this point.

6.5.2	Further evidence for a positive effect of p110 inhibition on cell growth and proliferation 
- Long term (7 days) treatment with TGX-221. The data on TGX-221 treatment of the cancer cell lines presented in this work were mainly derived from the cell treatment for up to 96 h. For most model cancer cell lines used in this study, the response to drug treatment upon 168 h (i.e. 7 days) of continuous presence of both LY294002 and TGX-221 in the culture media (both upon serum starvation and 5% FCS) was also tested (Figure 5.2‑4 and Table 5.2‑2). In line with the p110-sensitivity observed at shorter (up to 96 h) time points, in the presence of serum the p110β-sensitive cell line NCI-H2085 was greatly inhibited (60-70% cell growth and proliferation reduction) by TGX-221, whereas NIH:OVCAR-3 cell line showed clear sensitivity to p110β inhibition (60% reduction) upon serum starvation. 
Interestingly, in the opposite case (i.e. NCI-H2085 upon serum starvation and NIH:OVCAR-3 in the presence of serum) the response of these cell lines to long-term inhibition was very different and opposite to the shorter-time treatment. Indeed, NCI-H2085 cells (that were p110-sensitive at shorter time points) showed very low sensitivity to p110β inhibition, while the cell growth and proliferation rate of NIH:OVCAR-3 cells (p110-sensitive at shorter time points) greatly increased (up to 50% compared to control, Figure 5.2‑4 lower panel). The reason for the discrepancies between the different cell lines are yet to be clarified, and they are likely to be due to the differencies in the specific intracellular signalling networks that operate in the various cancer cell lines. As an example, NIH:OVCAR-3 expresses functional PTEN whereas NCI-H2085 do not, and that may have an influence on the chronic signalling activity of PI3K upon serum deprivation. 
Finally, these results confirmed the definition of the A2058 melanoma cell line (based on the 48-96 h treatment experiments, Figure 5.2‑2) as a “pan-PI3K resistant” cancer cell line, as it was not inhibited by LY294002 or TGX-221 even over long-term treatment.
- p110 inhibition in MDA-MB-231 cells. Further experimental evidence for an increase in cell growth and proliferation upon TGX-221 treatment in different cell lines, both cancerous and primary murine fibroblasts, has been obtained during this project or has been communicated by collaborators. As an example, one human breast carcinoma cell line screened in search of an alternative for MCF-7 cell line to be used for the IRSs RNAi experiments, namely MDA-MB-231, showed a marked increase of cell growth and proliferation upon TGX-221 treatment, particularly at lower doses (i.e. 0.05-0.1 M) (Figure 5.2‑5). In line with this finding, positive effects of p110 inhibition on Akt/PKB signalling (data not shown) have also been sporadically observed during the experimental work reported in this thesis, mostly when the p110 inhibitors (TGX-221 and TGX-115) were used at lower doses.   
MDA-MB-231 cell line was not chosen for the IRSs RNAi experiments because, similarly to A2058 cell line, it was resistant to LY294002 treatment (i.e. “pan-PI3K resistant), therefore not suitable for a comparison analysis of the effect of TGX-221 versus LY294002 treatment. 

6.5.3	Conclusion
Taking together, the results obtained in the IRSs RNAi experiments on MCF-7 and MCF10-A cells, the analysis of the response of the IRS-1 and IRS-2 KO MEFs to p110β inhibition and the attempted overexpression of IRS-1 in the p110β-sensitive cancer cells, it has not been possible to experimentally confirm the correlation between the lack of IRS-1 expression (or it functional inactivation) and the sensitivity to p110β inhibition observed in a panel of human cancer cell lines. Nonetheless, during the course of the investigation, an unexpected and previously unreported positive effect of p110β inhibition on cell growth and proliferation, that appears to be dependent on the specific experimental conditions tested, has emerged. Such effect may not be restricted to p110β isoform, but is of great interest for the understanding of the signalling properties of this PI3K isoform. 
At the moment, we have no clear explanation for these findings. A possibility is that p110β inhibition causes a feedback response in the cell circuitry that “over-compensates” the lack of p110β-dependent signalling, thereby leading to a net positive downstream output that ultimately increases the cell growth and proliferation. Interestingly, the positive effects of TGX-221 treatment reported here have been mainly observed when the inhibitor was used at lower doses or upon long-term treatment (when presumably the drug concentration in the culture media tends to decrease due to degradation). This effect is similar to a phenomenon that has already been described in the scientific literature, including the toxicology and pharmacology field and has been named “hormesis” (Calabrese, 2006). This concept describes the inherent capacity of a biological system to respond positively (e.g. increasing the signalling activity of a pathway or the cell growth and proliferation rate) to low-doses exposures to a toxic or damaging physical, biological or chemical agent (such as TGX-221) that at medium-high exposure doses may exert a negative or inhibitory response. The molecular mechanisms involved in hormesis in general, and specifically in the phenomena described in this thesis are currently unknown.   
An alternative model is that p110activity, under certain circumstances, exerts an inhibitory action in cells, which would be relieved by treatment with TGX-221. Such an apparent anti-proliferative role of p110 is unexplained at the moment and will be further investigated. One hypothesis is that p110 is involved in signal termination possibly through internalization and degradation of RTKs, including those that can bypass the lack of IRS-1/IRS-2 docking proteins to convey pro-proliferative stimuli (e.g. EGFR, GPCR). p110 is known to interact with Rab5, a member of the Ras-like small GTPase protein family, that is implicated in the regulation of both RTK and GPCR receptor internalization and degradation  ADDIN EN.CITE (Bhattacharya, et al., 2004; Chamberlain, et al., 2004; Kurosu & Katada, 2001; Seachrist & Ferguson, 2003). In particular, as p85 exerts a GAP activity on Rab5, the impairment of its Rab5-GAP function in NIH 3T3 cells results in a reduced rate of PDGFR degradation  ADDIN EN.CITE (Chamberlain, et al., 2004). Moreover, recent evidence points to a model of p85-Rab5 interaction that crucially regulates the dynamics of recycling and degradation of the internalized active PDGFR, as the overexpression of a mutant form of p85 lacking RabGAP activity in NIH 3T3 cells leads to increased internalization and accumulation of active PDGFR in the early endosome  ADDIN EN.CITE (Chamberlain, et al.). This pool of active PDGFR stuck in the early endosome is likely to exert physiological functions through the downstream activation of PI3K and MAPK pathways, as it has been shown in HepG2 human carcinoma cells treated with inhibitors of vescicular trafficking  ADDIN EN.CITE (Wang, et al., 2004). 
In the context of GPCRs, particularly interesting because of the preferential activation downstream this class of receptors shown by p110β, several receptors are internalized when they form a stable complex with -arrestin, which is a cytosolic protein involved in the uncoupling of the receptor from the heterotrimeric G protein, thereby terminating the signalling output of the GPCR. The binding of -arrestin primes the GPCR for the clathrin-dependent internalization, and the stability of this complex appears to regulate, at least in part, whether the receptors are freed from the bound -arrestin in early endosomes and recycled back to the cell surface as fully functional receptors, retained in early endosomes or targeted for degradation in lysosomes (Bhattacharya, et al., 2004) (Figure 6.5‑1).
One hypothesis could be that p110β plays a role in this context by linking the activation of Rab proteins during the clathrin-mediated receptor internalization and the downstream activation of Akt/PKB signalling pathway in the early-endosome phase of intracellular receptor trafficking. In this scenario, inhibition of p110 activity would lead to the prolonged presence of active RTK and GPCRs at the plasma membrane or as actively signalling receptors in the endosomal compartment, where they may still retain the capacity to trigger downstream signalling, thus resulting in enhanced cell growth and proliferation. 
An alternative hypothesis is that the inhibition of p110 could increase the amount of lipid substrates available for p110. This would occur either because inhibited p110 does not consume the available lipid substrates or because inhibition of p110 negatively regulates the activity or the plasma membrane localization of PTEN lipid phosphatase, which is known to interact with p110 (discussed below). 
It is also worth noting that the positive effect of p110 inhibition has been observed in siRNA-transfected MCF-7 cells only upon growing in serum-free media, suggesting that p110 could become more relevant in conditions where the cells rely more on autocrine-paracrine extracellular proliferative stimuli like the steroidal hormones, known to be widely used by cancerous cells in vitro to sustain their growth and proliferation  ADDIN EN.CITE (Siriwardana, et al., 2006). An alternative speculation would be that p110inhibition has an effect only when the cells lack the support of the steroid hormones provided with the serum. Interestingly, three out of four p110-sensitive cell lines (MDA-MB-468, NIH-OVCAR-3 and PC-3) derive from tissues that are physiological targets of steroidal hormones such as mammary gland, ovaries and prostate.
To further support this interpretation one could check the response of siRNA-transfected MCF-7 to TGX-221 when grown in serum-free culture supplemented with estrogens, to test whether their presence is sufficient to contrast the effects of p110 inhibition.   


Figure 6.5‑1. Rab5 binds to and regulates the GPCR internalization and intracellular trafficking
Rab5 regulates the endocytosis and the intracellular trafficking of several GPCR. Following ligand binding and receptor activation, the signal arising from the active GPCR is shut off by the ligation of -arrestin (Arr), a cytoplasmic protein, to the GPCR that causes ligand detachment and receptor uncoupling from the heterotrimeric G protein. Rab5 is also recruited to the GPCR and its activation triggers the formation of clathrin-coated membrane invaginations that inglobate the GPCR, resulting in the formation of endocytic vescicles. These vescicles (still bound to Rab5) then migrate towards the endosomal compartment and ultimately the intracellular GPCR can be either recycled and return to the plasma membrane or it can be targeted for protein degradation in the lysosomal compartment. This complex mechanism is regulated by several components of the Rab small GTPase family. Rab7 mediates the targeting of the GPCR to lysosomes for degradation, whereas Rab4 and Rab11 regulate the rapid or slow recycling of receptors from early endosomes.
This image has been taken from Bhattacharya et al., 2004.


6.5.4	Raf inhibition: an example of positive effects on cancer cell growth induced by a small-molecule inhibitor
The counterintuitive concept that, upon certain conditions an inhibitor can have positive effects on cancer cell growth and proliferation has begun to receive experimental support in a series of very recent publications. Indeed, a positive effect on cancer growth of small-molecule inhibitors of BRaf (one of the three known isoforms of Raf) in the context of melanoma has been described  ADDIN EN.CITE (Cichowski & Janne; Hatzivassiliou, et al.; Heidorn, et al.; Kwong & Chin; Poulikakos, et al.). The preliminary observations of the authors were made in human metastatic melanoma patients carrying an oncogenically active form of BRaf. About 20% of those that received an experimental BRaf inhibitor developed hyperproliferative skin lesions in areas of their skin already presenting actinic keratosis, that is thought to be caused by Ras (a small GTPase placed immediately upstream Raf in the MAPK signalling pathway) activation. Subsequent experiments  in melanoma cell lines and murine models confirmed the growth-inducing effects of BRaf inhibitors when Ras was oncogenically mutated and active. 












Figure 6.5‑2. The effects of RAF inhibitors in mutant and wild-type cells
a. Triggering of the MAPK signalling pathway stimulates cell growth, but its overactivation is associated with cancer. Ras signals when it is in its GTP-bound state.
b. Mutant BRaf (bearing the point mutation V600E) is a known oncogenic version of BRaf signalling in this pathway. In tumor cells that present this mutation Ras signalling is low, and the downstream MEK/Erk pathway is predominantly activated by dimers of phosphorylated (blue blocks) mutant BRaf proteins.
c. When a Raf inhibitor (used at high doses) binds to Raf kinase domain (green block) the MEK/Erk signalling activity in cancer cells harbouring the BRaf V600E mutant (but wild-type Ras) is inhibited, thus causing cell death and tumor suppression.
 d. In cancer cells presenting oncogenically active Ras (but wild-type BRaf), Raf inhibitors (particularly when used at lower doses) block the phosphorylation of Raf monomers (both BRaf and CRaf isoforms, green blocks), forming homo- or etero-dimeric complexes such as BRaf-BRaf or BRaf-CRaf. The same event occurs when BRaf is catalitically inactive (knock-out) and therefore it cannot phosphorylate (grey).
Overall, the formation of these Raf complexes causes the upregulation of CRaf signalling activity, fuelled by the upstream stimulation from mutant Ras. This model may explain the appearance of skin lesions (keratocarcinomas) in melanoma patients treated with experimental Raf inhibitors.  
This figure is taken from Cichowski and Janne, 2010.  
In the context of the work presented here, one could speculate that the same principle of cross-activation between the different PI3K isoforms explains the observations discussed so far. In this hypothetical scenario the binding of TGX-221 to p110β catalytic domain would trigger its interaction with other PI3K isoforms and particularly p110α, leading to pathway stimulation and, ultimately, increased cell growth and proliferation. One possible mechanism in the MCF-7 cells subjected to RNAi against IRS proteins could be that p110β takes the role of IRS-1 to recruit p110α at the plasma membrane, downstream active RTKs (such as IR/IGFR) or other receptors that do not require IRS proteins like PDGFR, thus allowing p110α activation and ultimately circumventing the block due to IRS downregulation. This way, p110β inhibition would reinstate the cell growth and proliferation of MCF-7 and MCF10-A cells transfected with anti-IRSs siRNA to the level of control-trasfected cells (Figure 5.6‑3). To test this, one could first test whether p110 and p110 interact with each other and then evaluate the effect of TGX-221 treatment, in particular in the IRS-depleted MCF-7 cells and in the IRS KO MEFs, or analyze the interaction between the two p110 isoforms in p110 KI MEFs by comparing with WT cells. 
An alternative hypothesis is based on the recent observation that PTEN specifically interacts with p85-p110β dimers and, even more interestingly, it is the unphosphorylated form of PTEN, the most active in antagonizing PI3K activation and downstream signalling activation, to be primarily involved in this interaction (Rabinovsky, et al., 2009). The binding of TGX-221 to p110 could influence this interaction and consequently modulate PTEN protein phosphatase activity. In this case, though, the hypothetical effect of TGX-221 treatment would be the opposite, i.e. upon p110β inhibition the activity of PTEN would decrease thus increasing the signalling output generated by the other PI3K isoforms (e.g. active p110α recruited downstream receptors that do not require IRSs such as EGFR, PDGFR and others). 
The phosphorylation of PTEN on specific serine residues in its C-terminal region is known to play an important role in the regulation of its stability and activity. In particular, such phosphorylation decreases PTEN phosphatase activity although it prolongs the protein stability  ADDIN EN.CITE (Vazquez, et al., 2000). Therefore, a different level of phosphorylation of PTEN upon treatment with TGX-221 may be the mechanism whereby, upon IRSs knockdown, the inhibition of p110β would result in increased cell growth and proliferation. This could happen because the prolonged inhibition of p110 by treatment with TGX-221 may have an indirect influence on PTEN phosphorylation status and consequently on its enzymatic activity and protein stability. p110 may even directly phosphorylate PTEN, as it is known that the class I PI3K catalytic isoforms possess a protein kinase potential along with the well known lipid kinase ability, which is likely to be part of an intrinsic regulatory feedback mechanism (p110 subunits can inhibit through phosphorylation the p85 subunits they are coupled with, thereby decreasing their own activity level)  ADDIN EN.CITE (Dhand, et al., 1994).      
Finally, the positive effects of TGX-221 may also be due to the fact that inhibited p110β does not trigger PTEN activity, as the mechanism for the control of PTEN function may be designed so that p110β activation is the signal of an ongoing PI3K signalling event. In this scenario, in the absence of p110β activation the functionality of PTEN would be strongly decreased, therefore leading to net PI3K signalling output increase.

6.6	FUTURE EXPERIMENTS 
The work described in this thesis has uncovered some previously unrecognized properties of p110 signalling that mainly for time constraints have not been addressed exhaustively. In particular, the paradoxical positive effects of p110 inhibition reported here require a deeper investigation of the underlying molecular mechanism. Some hypotheses aimed at explaining this striking new role of p110 have been presented in the previous paragraphs, along with the experimental approaches that may be followed to address the question. The priority experiments are described again here for clarity.  
6.6.1	Testing the effect of p110 inhibition on cell cycle progression and apoptosis
The MTS assay that has been used in this work to test the effect of drug treatment on cell growth and proliferation does not give a clear indication regarding the possible drug-induced blockage of cell cycle progression or induction of apoptosis. For this reason one could perform other established in vitro tests to evaluate whether treatment with TGX-221 effectively blocks the cell cycle progression or induces apoptosis in the p110-sensitive cancer cell lines. Examples are the incorporation of propidium iodide (PI) assay and the use of commercially available kits that measure the apoptosis induction. In the first case, following treatment with the desired drugs PI is added to the cells. PI is a fluorescent intercalating agent that binds to nucleic acids, thus allowing the quantitative determination of the cellular DNA content. By staining the cells with PI one can then evaluate the proportion of cells in the pre- and post-S phase (i.e. the phase of genomic DNA replication) of the cell cycle, and detect DNA degradation that is a marker of cell death (due to necrosis or apoptosis). Apoptosis can also be detected by using kits that detect DNA fragmentation or accumulation of marker proteins on the cell surface (e.g. annexin).  
 
6.6.2	Analysis of the possible regulation of PTEN and p110α activity by p110 
Our research group has recently published that PTEN lipid phosphatase activity is regulated by p110δ through a complex negative feedback mechanism. Only the isoform-selective inhibition of p110 led to a reduction of PTEN lipid phosphatase activity, with no effect of inhibition of p110 or in cells expressing a genetically inactivated form of p110  ADDIN EN.CITE (Papakonstanti, et al., 2007; Papakonstanti, et al., 2008). The mechanism proposed to explain these findings suggests a role for active p110 as a positive regulator of RhoA (a member of the Ras homolog gene family) in turn leading to the inhibition of PTEN activity. It is nonetheless conceivable that in different cellular context other class I PI3K isoforms play a similar regulatory role over PTEN. In particular, p110β may acquire this capacity in cells that express little or no p110δ, such as the cancer cell lines described in this work.  In such scenario, p110β inhibition may similarly result in PTEN downregulation with the consequent net increase in the PIP3 output (mainly due to p110α activity) and therefore in the signalling downstream PI3K, thus explaining the positive net effect of TGX-221 treatment on cell growth and proliferation that has been observed in several instances. p110 may regulate PTEN by phosphorylating selective residues that are known to regulate its lipid phosphatase activity. One could therefore investigate, in cellular models where cell growth and proliferation increased upon TGX-221 treatment (e.g. IRSs siRNA-transfected MCF-7 cells), the phosphorylation level of PTEN, the possible p110β-PTEN interaction and whether TGX-221 treatment can influence it. 
Similarly, the possible binding between p110β and p110α (and the effect of TGX-221 treatment) could also be assessed in the IRSs siRNA-transfected MCF-7 cells and in the IRS KO MEFs. It would also be interesting to do so in p110 KI MEFs, as genetic inactivation of p110 mimicks the treatment with small-molecule inhibitors such as TGX-221. 

6.6.3	Role of p110 in the regulation of receptor turnover 
p110 is involved in signal termination possibly through internalization and degradation of RTKs, including those that can bypass the lack of IRS-1/IRS-2 docking proteins to convey pro-proliferative stimuli (e.g. EGFR, PDGFR). Moreover, p110β may also play a role in the internalization and cellular trafficking of GPCRs, both because of its role in signalling downstream this class of receptors and because of its interaction with Rab5, that has a main role in the clathrin-dependent GPCR internalization and trafficking in the early endosomal compartment (Seachrist & Ferguson, 2003). The inhibition of p110 activity would lead to the prolonged presence of active RTK receptors at the plasma membrane or in endosomes, thus resulting in enhanced cell growth and proliferation. 
It would therefore be interesting to investigate the dynamics of the receptor turnover upon p110β inhibition by using immunofluorescence techniques and FACS analysis, to assess the impact of the treatment with p110β inhibitors on receptor internalization following stimulation of the cells with their specific ligands (e.g. PDGFR, GPCRs like the LPA receptor). 

6.6.4	Inhibition of RTK-dependent signalling in p110-resistant cancer cell lines 
The hypothesis presented in this work that the sensitivity to p110 inhibition observed in some cancer cell lines is caused by the absence of IRS proteins expression (or functionality) could not be proven. Other components of the cellular signalling machinery may be reduced or absent in the p110-sensitive cancer cell lines, thus contributing to their phenotype. As an example, PDGFR itself can also be downregulated upon chronic Akt/mTOR/S6K negative feedback signalling (that is turned on in the p110-sensitive cancer cell lines)  ADDIN EN.CITE (Zhang, et al., 2007a). 
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